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CHAPTER 1
ABSTRACT
1.1 English abstract
OvarCaN carcCNoLaGCIIs @uNdreds of t@ousaNds ofwoLeN aNNuaIIy. ?Cg@ grade
serous carcCNoLa Cs t@e Lost coLLoN subtype. HCGe ot@er tuLors, @Cg@ grade
serous ovarCaN carcCNoLa successfuIIy evades eIeLCNatCoN by t@e CLLuNe sysA
teL A for exaLpIe, a proACNflaLLatory actCvatCoN state of Lacrop@ages Cs supA
presed. UNICGe ot@er caNcer types, Ct spreads Not oNIy vCa bIood aNd t@e IyLA
p@atCc systeL, but vCa perCtoNeaI fluCd aNd growt@ aIoNg t@e oLeNtuL. Bt Cs
ofteN acoLpaNCed by a LaICgNaNt accuLuIatCoN of perCtoNeaI fluCd, caIIed asA
cCtes CN w@Cc@ tuLor ceIIs aNd @ost (CLLuNe) ceIIs, suc@ as Lacrop@ages, float
aNd CNteract.
PrCor to t@e pubICcatCoNs suLLarCzed CN t@Cs cuLuIatCve dCssertatCoN, No deA
taCIed Lap of t@ese CNteractCoNs @ad beeN pubICs@ed. We coLpCIed a detaCIed
pCcture of LedCators aNd receptors based oN geNe expressCoN data froLLacroA
p@ages aNd tuLor ceIIs @arvested froL t@e ascCtes of patCeNts uNdergoCNg prCA
Lary surgery. T@oug@ t@e Lap Cs of ICLCted accuracy due to t@e addCtCoNaI IayA
ers of reguIatCoN betweeN geNe expressCoN aNd actuaI effector LoIecuIe reIease,
Ct reveaIed caNdCdates w@Cc@ were tested for t@eCr assocCatCoN wCt@ reIapse free
survCvaI. ALoNg t@e stroNgIy (NegatCveIy) assocCated LedCators were arac@CA
doNCc acCd aNd Cts derCvatCves as weII as cytoGCNes suc@ as BHA6 aNd BHA10.
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1.1 English abstract
To dCscerN t@e tuLor CNflueNce oN Lacrop@ages, tuLor assocCated LacroA
p@ages aNd LoNocyte derCved (C.e. cuItured) Lacrop@ages were coLpared.
T@ey s@owed Iarge dCffereNces CN t@eCr geNe expressCoN patterNs aNd actCvaA
tCoN state. T@e experCLeNt @owever couId Not dCstCNguCs@ betweeN tuLor aNd
ceII cuIture CNduced effects. T@erefore a Lore approprCate coNtroI, perCtoNeaI
Lacrop@ages froLNoNALaICgNaNt dCseases, was soug@t. T@ese perCtoNeaILacroA
p@ages turNed out to be very sCLCIar to tuLor assocCated Lacrop@ages CN bot@
geNe expressCoN aNd actCvatCoN state, suggestCNg t@at t@e tuLor ascCtes eNvCroNA
LeNt does Not CNduce, but rat@er suppresses, a c@aNge CN actCvatCoN state. T@e
oNIy dCscerNCbIe dCffereNce was a cIuster of coAreguIated geNes reIated to extra
ceIIuIar LatrCx reorgaNCzatCoN, w@Cc@ @CNts t@at Lacrop@ages LCg@t pIay a roIe
CN estabICs@CNg Letastases wCt@CN t@e coeIoL.
A secoNd focus of t@Cs t@esCs Cs t@e roIe of t@e NucIear receptor PPARβ/δ CN
tuLor assocCated Lacrop@ages. We fouNd PPARβ/δ to be CNduced durCNg t@e
dCffereNtCatCoN of LoNocytes CNto Lacrop@ages aNd ascCtes to coNtaCN PPARβ/δ
ICgaNds, e.g. arac@CdoNCc acCd. PPARβ/δ sCgNaICNg was accordCNgIy actCvated
aNd reNdered tuLor assocCated Lacrop@ages uNrespoNsCve to furt@er stCLuIaA
tCoN by (syNt@etCc) PPARβ/δ agoNCsts but susceptCbIe to CNverse agoNCsts. UsCNg
in vitro dCffereNtCated Lacrop@ages aNd ex vivo tuLor assocCated Lacrop@ages
we couId s@ow t@at PPARβ/δ CNduces a dCstCNct actCvatCoN state CNLacrop@ages
aNd were abIe to c@aracterCze Cts target geNe NetworG CN great detaCI.
vCC
1.2 Deutsche Zusammenfassung / German abstract
1.2 Deutsche Zusammenfassung / German abstract
ECerstocGGarzCNoL tötet Eä@rICc@ @uNdertauseNde FraueN. DabeC Cst @oc@gradCA
ges seröses FarzCNoL der aL @äufigsteN vorGoLLeNde Subtyp. WCe aNdere
TuLoreN eNtzCe@t sCc@ das @oc@gradCge seröseOvarCaIGarzCNoL erfoIgreCc@ der
EICLCNatCoN durc@ das BLLuNsysteL A zuL BeCspCeI wCrd eCN eNtzüNduNgsförA
derNder AGtCvCeruNgszustaNd voN KaGrop@ageN uNterdrücGt. BL GegeNsatz
zu aNdereN FrebsarteN verbreCtet es sCc@ NCc@t Nur über BIut uNd das IyLp@aA
tCsc@e SysteL, soNderN auc@ über PerCtoNeaIflüssCgGeCt uNdWac@stuL eNtIaNg
des OLeNtuLs. Es wCrd oft voN eCNer bösartCgeN ANsaLLIuNg voN PerCtoNeaIA
flüssCgGeCt begIeCtet, weIc@e AszCtes geNaNNt wCrd, uNd CN der TuLorzeIIeN uNd
WCrtszeIIeN, beCspCeIsweCse KaGrop@ageN uNd aNdere BLLuNzeIIeN, sc@wCLA
LeN uNd CNteragCereN.
Vor deN CN dCeser GuLuIatCveNDCssertatCoN zusaLLeNgefassteN PubICGatCoA
NeN gab es GeCNe detaCIICerte C@araGterCsCeruNg dCeser BNteraGtCoNeN. Auf der
GruNdIage voN GeNexpressCoNsdateN aus KaGrop@ageN uNd TuLorzeIIeN, dCe
aus deLAszCtes voN ersLaIs operCerteN PatCeNteNCNNeN gewoNNeNwurdeN, @aA
beN. @abeN eCNe Farte voNKedCatoreN uNd RezeptoreN auf ersteIIt. Obwo@I zuA
sätzICc@e ReguICeruNgssc@Cc@teN zwCsc@eN GeNexpressCoN uNd tatsäc@ICc@e EfA
feGtorLoIeGüIfreCsetzuNg dCe GeNauCgGeCt begreNzeN GoNNteN wCr FaNdCdateN
CdeNtCfizCereN uNd auf C@re AssozCatCoN LCt GraNG@eCtsfreCeL ÜberIebeN testeN.
UNter deN starG (NegatCv) assozCCerteN KedCatoreN wareN Arac@CdoNsäure uNd
dereN DerCvate sowCe ZytoGCNe wCe BHA6 uNd BHA10.
UL deN ECNfluss des TuLors auf KaGrop@ageN zu uNtersuc@eN wurdeN
tuLorAassozCCerte KaGrop@ageN uNd LoNozyteNAabgeIeCtete (GuItCvCerte) KaA
Grop@ageN vergICc@eN. SCe zeCgteN große UNtersc@Cede CN C@reN GeNexpressCA
oNsLusterN uNd C@reL AGtCvCeruNgszustaNd. Das ExperCLeNt Cst Eedoc@ NCc@t
geeCgNet uL zwCsc@eN zwCsc@eN TuLor uNd ZeIIGuItur CNduzCerteN VeräNdeA
ruNgeN zu uNtersc@eCdeN. BN FoIge wurdeN da@er perCtoNeaIe KaGrop@ageN
aus beNCgNeNFraNG@eCteN uNtersuc@t. DCese perCtoNeaIeNKaGrop@ageN erwCeA
seN sCc@ aIs se@r ä@NICc@ zu tuLorAassozCCerteN KaGrop@ageN CN GeNexpressCA
oN uNd AGtCvCeruNgszustaNd, was darauf @CNdeutet, dass AszCtes GeCNe VeräNA
deruNgeN des AGtCvCeruNgszustaNds ausIösst, soNderN eCNe soIc@e e@er uNterA
vCCC
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drücGt. Der eCNzCge erGeNNbare UNtersc@Ced war eCN CIuster voN coAreguICerteN
GeNeN dereN ProduGte dCe extrazeIIuIäreKatrCx beeCNflusseN GöNNeN, was sugA
gerCert, dass KaGrop@ageN beC der EtabICeruNg voN KetastaseN CL ZöIoL eCNe
RoIIe spCeIeN GöNNteN.
  ECN zweCter Sc@werpuNGt dCeser ArbeCt Cst dCe RoIIe des FerNrezeptors
PPARβ/δ CN tuLorAassozCCerteNKaGrop@ageN.WCr @abeN festgesteIIt, dass PPARβ/δ
wä@reNd der DCffereNzCeruNg voNKoNozyteN zuKaGrop@ageN CNduzCert wCrd
uNd dass AszCtes PPARβ/δAHCgaNdeN, wCe z.B. Arac@CdoNsäure eNt@äIt. ENtA
sprec@eNd wareN PPARβ/δ ZCeIgeNe CN tuLorAassozCerte KaGrop@ageN exprCA
LCert uNduNeLpfäNgICc@ fürweCtere StCLuIatCoNdurc@ (syNt@etCsc@e) PPARβ/δ
AAgoNCsteN, aber respoNsCv für CNverse AgoNCsteN. UNter VerweNduNg in vi-
tro dCffereNzCerter KaGrop@ageN uNd ex vivo tuLorAassozCerter KaGrop@ageN
GoNNteNwCr dCe ZCeIgeNe voNPPARβ/δ c@araGterCsCereNuNd zeCgeN, dass PPARβ/δ
eCNeN bCsIaNg uNbesc@rCebeNeN AGtCvCeruNgszustaNd CN KaGrop@ageN CNduA
zCert.
Cx
CHAPTER 2
BMTRODUCTBOM
2.1 Ovarian carcinoma
OvarCaN carcCNoLa (OvCa) GCIIed 42,704 woLeN CN t@e EuropeaN UNCoN CN 2012
[52]. WCt@Lore t@aN 65,000 New cases aNNuaIIy, t@e estCLate ICfetCLe rCsG CN t@e
saLe regCoN Cs 1.8%. CoLpared to ot@er caNcers, t@e patCeNts progNosCs Cs bIeaG,
wCt@ survCvaI rates at two, five aNd teN years of 65%, 44% aNd 36%, respectCveIy
[6].
OvCa Lay be dCvCded CNto two groups, desCgNated type B aNd type BB carcCA
NoLa. Type B Cs geNeraIIy IowAgrade aNd sIow growCNg, w@CIe type BB CNcIudes
aggressCve @Cg@ grade carcCNoLas. Type B @as weIIAestabICs@ed precursor IeA
sCoNs, w@CIe No precursor for type BB @as beeN dCscovered oN t@e ovary CtseIf
[53] (see beIow).
?Cg@ grade serous ovarCaN carcCNoLa (?GSOC), t@e focus of t@Cs worG, Cs
t@e Lost coLLoN aLoNg t@e eCg@t LaEor cIassCficatCoNs of ovarCaN tuLors [52].
ALoNg t@e gyNecoIogCcaI LaICgNaNcCes, ?GSOC Cs t@e oNe wCt@ t@e @Cg@est
LortaICty rate. DCagNosCs ofteN occurs at advaNced stages of t@e dCsease, w@eN
ot@er regCoNs of t@e abdoLeN (FBGO [78] stage BBB) or t@ose outsCde t@e perCA
toNeaI cavCty (stage BV) @ave beeN CNvaded [77].
T@e ceIIuIar orCgCN of ?GSOC @as IoNg beeN uNcIear [53]. ReceNt researc@
poCNts to a faIIopCaN orCgCN, w@ere IesCoNs CN t@e fiLbrCae deveIop CNto serous
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2.2 Tumor associated macrophages
tubaI CNtraepCt@eICaI carcCNoLa (STBC) w@Cc@ acts as a precursor to ?GSOC.
T@Cs wouId CLpIy t@at t@e ?GSOC t@eLseIves are aIreadyLetastases [52, 102].
?GSOC typCcaIIy LetastasCzes earIy, spreadCNg vCa bIood, t@e IyLp@atCc
systeL, IateraI growt@ aNd perCtoNeaI fluCd wCt@CN t@e abdoLCNaI cavCty [53].
AN accuLuIatCoN of suc@ fluCd, caIIed ascCtes, Cs a fuNctCoNaIIy proAtuLorCgeNCc
eNvCroNLeNt coNtaCNCNg caNcer ceIIs [53], tuLorAproLotCNg growt@ factors [48],
extraceIIuIar vesCcIes [74] aNd CLLuNe ceIIs [82, O6].
2.2 Tumor associated macrophages
ALoNg t@e @aIILarGs of caNcer are t@e successfuI evasCoN of t@e CNNate aNd
adaptCve CLLuNe systeL aNd t@e estabICs@LeNt of a tuLorAproLotCNg CNflaLA
Latory eNvCroNLeNt [38]. TuLors CNflueNce t@eCr CNfiItratCNg Lacrop@age popA
uIatCoN (“tuLor assocCated Lacrop@ages” or TAKs) by aIterCNg Lacrop@age
actCvatCoN.
?CstorCcaIIy, proACNflaLLatory aNd aNtCACNflaLLatory actCvatedLacrop@ages
@ave beeN IabeIed as K1 aNd K2, respectCveIy. T@Cs cIassCficatCoN, orCgCNaIIy
proposed byKCIIs et aI. [62] (CNMus musculus), was based oN t@e productCoN of
eCt@er NCtrCc oxCde, a cytotoxCc coLpouNd, or trop@Cc poIyaLCNes. Hater worGs
@ave Ied to a Lore NuaNced vCew, pIacCNg dCffereNtIy in vitro stCLuIated LacroA
p@ages oN a coNtCNuuL betweeN K1 aNd K2 (K2a, K2b aNd K2c) [57].
T@e in vivo sCtuatCoN @owever Cs Lore coLpIex A Lacrop@ages are exposed
to a coLbCNatCoN of K1A aNd K2ACNducCNg sCgNaIs (see [5O] for a receNt reA
vCew). A receNt @Cg@At@roug@put traNscrCptCoNaI in vitro study [110] s@owed
t@at Lacrop@age actCvatCoN Cs Not a spectruL wCt@ two dCstCNct eNd poCNts.
To accurateIy c@aracterCze Lacrop@age popuIatCoNs, Ct Cs t@us Necessary to deA
scrCbe t@eL CN Lore detaCI, for exaLpIe by t@eCr CNput sCgNaIs (as suggested for
in vitro experCLeNts by Kurray et aI. [65]) or by t@e LeasureLeNt of a Iarge
NuLber of LarGers.
TAKs accordCNgIy s@ow a LCxed traNscrCptCoNaI aNd p@eNotypCcaI actCvaA
tCoN (see page 28). T@ey serve a proAtuLorCgeNCc roIe, eN@aNcCNg tuLor growt@
aNd progressCoN by aCdCNg CN proICferatCoN, CNvasCoN, aNgCogeNesCs, CLLuNe
suppressCoN aNd CNtravasatCoN [16, 28, 7O]. T@ere Cs a cIear correIatCoN betweeN
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2.3 Peroxisome proliferator-activated receptor β/δ
t@e preseNce of CD1631@Cg@ TAKs CN ascCtes aNd earIy reIapse [82], coNsCsteNt
wCt@ t@e CNverse correIatCoN betweeN Lacrop@age deNsCty wCt@CN tuLors aNd
cICNCcaI outcoLe CN ot@er caNcers [16].
BN LCce Ct @as beeN proposed t@at t@ere are two sources of Lacrop@ages;
(B) tCssue resCdeNt Lacrop@ages derCved froL t@e yoIG sac aNd (BB) CNfiItratCNg
Lacrop@ages derCved froL perCp@eraI bIood LoNocytes, w@Cc@ derCve froL
@eLatopoCetCc steL ceIIs CN t@e boNe Larrow [30]. Kore receNt data suggests
t@at t@ere Cs aN addCtCoNaI Lacrop@age source: eLbryoNaI @eLatopoCetCc steL
ceIIs, aNd t@at t@e source of Lacrop@ages Cs tCssue specCfic [O2]. Kost of our
GNowIedge of Lacrop@age orCgCN Cs derCved froL Louse LodeIs, but LoNoA
cytopeNCa2 patCeNts stCII @arbor tCssueAresCdeNt Lacrop@ages [104], suggestCNg
t@at t@e dCc@otoLy (or trCc@otoLy) ofLacrop@age sources Cs coNserved CNLaLA
LaIs.
TAKs, perCtoNeaI aNd LoNocyteAderCved Lacrop@ages are t@e subEect of aII
pubICcatCoNs CN t@Cs cuLuIatCve dCssertatCoN.
2.3 Peroxisome proliferator-activated receptor β/δ
PPARβ/δ3 Cs a LeLber of t@e NucIear @orLoNe receptor superfaLCIy of traNA
scrCptCoN factors [46].
?uLaN PPARD Cs expressed CN vCrtuaIIy aII tCssues4 [101], aNd @as beeN asA
socCated wCt@LoduIatCNg a wCde raNge of fuNctCoNs, suc@ as LetaboICsL (espeA
cCaIIy fatty acCd oxCdatCoN aNd gIucose @oLeostasCs), wouNd @eaICNg, ceII proA
ICferatCoN aNd CLLuNe reguIatCoN [22]. PPARβ/δ aIso pIays a roIe CN a NuLber
of CIINesses suc@ as psorCasCs [86], ?uNtCNgtoN’s dCsease [1O], bCpoIar dCsorders
[114], aNd possCbIy CN cardCovascuIar dCseases [22]. Bts roIe CN caNcer Cs uNcIear
A coNflCctCNg reports CN t@e ICterature suggest two @ypot@esCs: oN t@e oNe @aNd
aN overexpressCoN CN tuLors proLotCNg aNtCAapoptotCc actCvCtCes aNd ceII proA
1 CIuster of DCffereNtCatCoN faLCIy LeLber
2 A deficCeNcy of LoNocytes.
3 PeroxCsoLe proICferatorAactCvated receptor faLCIy LeLber
4 see http://www.proteinatlas.org/ENSG00000112033-PPARD/tissue
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ICferatCoN; aNd oN t@e ot@er @aNd a proLotCoN of terLCNaI dCffereNtCatCoN aNd
CN@CbCtCoN of proACNflaLLatory sCgNaICNg w@Cc@ abates tuLorCgeNesCs [75].
C@eLCcaIIy CNduced sGCN carcCNogeNCs Cs eN@aNced CN PPARβ/δANuII LCce
but Not CN LCce IacGCNg PPARβ/δ oNIy CN basaI GeratCNocytes [63], suggestCNg
a fuNctCoN CN ot@er ceII types wCt@CN t@e sGCN caNcer tuLor stroLa. Targeted
dCsruptCoN of t@e PPARD geNe CN coIoN eNdot@eICaI ceIIs greatIy reduced t@e
CNcCdeNce of c@eLCcaIIy CNduced coIoN tuLors CN aNot@er Louse LodeI [117],
possCbIy vCa reduced expressCoN of VEGF.
AII eNdogeNous PPARβ/δ ICgaNds so far CdeNtCfied, suc@ as arac@CdoNCc acCd
(AA), ICNoIeCc acCd (HA) [103] aNd 15A?ydroxyeCcosatetraeNoCc acCd (15A?ETE)
[67] are ICpCds aNd @ave aN agoNCstCc effect A t@ey CNduce target geNe expresA
sCoN1. PPARs bCNd to PPAR respoNse eIeLeNts (PPREs) toget@er wCt@ Cts @etA
erodCLerCc partNer RXR2 [7]. T@e agoNCst CNduced CNcrease CN target geNe traNA
scrCptCoN Cs LedCated by t@e recruCtLeNt of coAactCvators [105].
SyNt@etCc A NoN fattyAacCd A ICgaNds deveIoped CN receNt years caN eICcCt agoA
NCstCc, aNtagoNCstCc aNd CNverse agoNCstCc effects. T@e agoNCsts (e.g. GW501516
[71] or H165,041 [42] CNduce traNscrCptCoN beyoNd t@e effect of eNdogeNous ICgA
aNds; aNtagoNCsts (e.g. GSF0660 [35]) coLpete wCt@ eNdogeNous ICgaNds aNd
t@ereby reduce target geNe traNscrCptCoN aNd CNverse agoNCsts (e.g. ST247 [68])
recruCt coArepressors coAfactors IeadCNg to a stroNg traNscrCptCoNaI repressCoN.
PPARβ/δ’s roIe CN dCsease aNd Cts druggabCICty LaGe Ct aN CNterestCNg poteNA
tCaI target. A Iarge NuLber of poteNtCaI ICgaNds @as beeN tested CN sufficCeNt
detaCI to buCId predCctCve bCNdCNg LodeIs [44]. T@e agoNCstCc ICgaNd GW501516
@as beeN evaIuated CN two cICNCcaI p@ase BB studCes for t@e treatLeNt of dysICpCA
deLCa, but t@eworG @as beeN abaNdoNed becauseGW501516 appears to CNduce
caNcer CN severaI orgaNs of LCce aNd rats [8O]. KBXA8025 @as beeN evaIuated for
t@e treatLeNt of dysICpCdeLCa CN 166 patCeNts aNdwas abIe to affect presuLabIy
beNeficCaI c@aNges CN ICpoproteCN partCcIe coNceNtratCoN w@eN coAadLCNCstrated
wCt@ atorvastatCN [14].
1 T@ere Cs soLe evCdeNce t@at ProstagIaNdCN B2 (PGB2) caN act as a PPARβ/δ agoNCst [33], but a
LassCve CNductCoN CN PGB2 syNt@esCs dCd Not Iead to aN actCvatCoN of PPARβ/δ CN 3T3AderCved
ceIIs, aNd t@e orCgCNaI experCLeNtaI setup couId Not be reproduced CN aNot@er Iab [24].
2 RetCNoCdAXAreceptor
4
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PPARβ/δ Cs Necessary for CN t@e aNtCACNflaLLatory actCvatCoN ofLacrop@ages
CN adCpose tCssue aNd ICver [12] aNd we couId c@aracterCze aN effect of PPARβ/δ
ICgaNds oNLacrop@age actCvatCoN (see c@apter 3.2). AscCtes coNtaCNs fatty acCds
[11], soLe of w@Cc@ we fouNd to be PPARβ/δ ICgaNds (see c@apter 3.3).
2.4 Issues with primary cell transcriptome analysis
and sample isolation
W@eN CsoIatCNg prCLary ceIIs froL coLpIex, LuItCAceIIuIar euGaryotes oNe usuA
aIIy procures a LCxture of ceII types. For soICd tCssues, Iaser dCssectCoN provCdes
a Iow t@roug@Aput Let@od to seIect aNd extract (dead) ceIIs by Lorp@oIogy or
staCNed surface LarGers. For ceIIs CN fluCds suc@ as bIood or ascCtes, fluoresA
ceNce actCvated ceII sortCNg (FACS) or LagNetCc actCvated ceII sortCNg (KACS)
aIIow aNtCbody based seIectCoN of ICvCNg ceIIs CN great NuLbers. SoICd tCssues
caN be separated by t@e saLeLet@ods after dCssoIutCoN of ceIIAceII coNtacts aNd
t@e extra ceIIuIar LatrCx. Kacrop@ages ad@ere to staNdard ceII cuIture dCs@es
Luc@ Lore quCcGIy t@aN ot@er ceIIs, aIIowCNg for ad@ereNce seIectCoN 1.
T@e Let@ods dCffer CN appICcabCICty, cost, processCNg tCLe aNd output purCty,
IeavCNg No cIear wCNNer. AII Let@ods trCgger sCgNaI cascades aNd subsequeNt
traNscrCptoLCc aNd surface LarGer c@aNges, t@e LagNCtude of w@Cc@ CNcreases
wCt@ processCNg tCLe. FACS aIIows t@e user to trade of specCficCty for seNsCtCvCty,
but Cs t@eLost expeNsCve aNd tCLe coNsuLCNg of t@e t@reeLet@ods. Ad@ereNce
seIectCoN Cs oNIy avaCIabIe for Lacrop@ages. KACS caN be appICed to a Iarger
NuLber of ceIIs t@aN FACS, but Ct Cs CN esseNce aN eNrCc@LeNt, Not a seIectCoN,
Let@od aNd as suc@ Ieaves a (varCabIe) NuLber of ot@er ceIIs CN t@e resuItCNg
suspeNsCoN.
T@e IacG of ceIIuIar purCty Ieads to obvCous probIeLsw@eN tryCNg to dCscerN
dCffereNces betweeN ceII types. KaNy aIgorCt@LCcLet@ods to quaNtCfy ceII LCxA
ture coNteNts froL traNscrCptoLe data (’decoNvoIutCoN’) @ave beeN estabICs@ed
1 For coLpIeteNess, Ct s@ouId be LeNtCoNed t@at Lacrop@ages caN aIso be derCved froL peA
rCp@eraI bIoodLoNocytes by sCLpIe ad@esCoN. KoNocyte derCvedLacrop@ages are dCffereNt
froL prCLary tCssue Lacrop@ages, as we s@ow CN sectCoN 3.4, page 26.
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for LCcro arrays (see [111] for a revCew), but fewer Let@ods were avaCIabIe for
RMAseq data sets. B @ave deveIoped suc@ a Let@od for t@e worG descrCbed CN
t@Cs dCssertatCoN.
2.5 Aims of this dissertation
T@Cs dCssertatCoN
• c@aracterCzes aNd coLpares t@e traNscrCptoLes of @Cg@ grade serous ovarA
CaN carcCNoLa ascCtes tuLor aNd Lacrop@age ceIIs (see pages 8 aNd 26)
• studCes t@e effect of artCficCaI PPARβ/δ ICgaNds oN t@e actCvatCoN state of
LoNocyteAderCved Lacrop@ages (see page 16)
• descrCbes t@e effect of eNdogeNous PPARβ/δ ICgaNds oN tuLor assocCated
Lacrop@ages (see page 22).
• CNcIudes a NoveILet@od for t@e decoNvoIutCoN of RMAseq data froL popA
uIatCoNs of LCxed prCLary ceIIs (see page 74).
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3.1 A transcriptome based global map of signaling
pathways in the ovarian cancermicro-environment
associated with clinical outcome1
3.1.1 Results
3.1.1.1 Correction of RNAseq data for contaminating cells
BN t@Cs worG [81], tuLor ceII (TU), tuLor assocCtated Lacrop@age (TAK) aNd
tuLor assocCtated T ceII (TAT) were CsoIated froL 28 patCeNts wCt@ ?GSOC.
RMA sequeNcCNg (RMAseq) was perforLed oN 21 TU, 18 TAK aNd 5 TAT saLA
pIes aNd aICgNed to t@e @uLaN geNoLe usCNg STAR [20]. To correct TU aNd
TAK saLpIes for coNtaLCNatCNg ceIIs of t@e ot@er GCNds teN prevCousIy pubA
ICs@ed aIgorCt@Ls for traNscrCptoLe decoNvoIutCoN were evaIuated. Kost were
fouNd out to @ave restrCctCoNs LaGCNg t@eL uNsuCtabIe for our settCNg. DeKCx
[4], DsectCoN [111] aNd PSEA [47] @ad oNIy beeN estabICs@ed oNLCcroarray data.
CoNtaLDE [O1] requCred at Ieast two cIeaN saLpIes of eac@ GCNd. ESTBKATE
[113] does Not estCLate a perceNtage but aN “BLLuNoScore” uNsuCtabIe to corA
rectCoN. UMDO [107] requCres No cIeaN saLpIes, but requCres two saLpIes geNA
erated froL t@e saLe LCxtures (C.e., two LCxed saLpIes per patCeNt, at dCfferA
CNg LCxture perceNtages). TEKT [54] worGs oN traNscrCpt IeveI A aN aNaIysCs
uNsuCtabIe to bot@ our sCNgIe eNded 50 bp dataset aNd t@e ceIIAceII NetworG CNA
vestCgated CN t@Cs study. BsoPure [80] assuLes t@at t@e two ceII types beCNg
decoNvoIuted are cIoseIy reIated w@Cc@ caNNot be assuLed for TUs aNd TAKs.
Two aIgorCt@Ls, CBBERSORT [70] aNd DecoNRMASeq [31] appeared to be
suCtabIe aNd were tested aIoNgsCde a custoL decoNvoIutCoN aNd correctCoN aIA
gorCt@L we deveIoped.
BN brCef, our aIgorCt@L first seIects ceII type specCfic geNes froL (exterNaIIy
defiNed) cIeaN refereNce saLpIes, uses t@eCr appareNt expressCoN to estCLate a
1 PubICs@ed CN S. ReCNartz et aI. “A traNscrCptoLeAbased gIobaI Lap of sCgNaICNg pat@ways CN
t@e ovarCaN caNcer LCcroeNvCroNLeNt assocCated wCt@ cICNCcaI outcoLe.” BN: Genome biology
(2016). doi: 10.1186/s13059-016-0956-6, see page 51 for fuII text.
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coNtaLCNatCoN perceNtage aNd subtracts t@e ICNearIy scaIed refereNce saLpIe.
See AddCtCoNaI FCIe 1, “DescrCptCoN of aIgorCt@L”, page 74 for detaCIs.
ONIy our aIgorCt@L offers aN autoLated Let@od to seIect LarGer geNes (or
“ceII type sCgNatures” CN CBBERSORT parIaNce). RuNNCNg aII t@ree CN a sCLuIaA
tCoN settCNg approxCLatCNg our coNdCtCoNs1, usCNg t@e exact saLe LCxtures aNd
t@e saLe NuLber of adA@oc seIected LarGer geNes for eac@ aIgorCt@L s@owed
t@at oNIy our aIgorCt@L was abIe to expIoCt t@e CNforLatCoN CN@ereNt CN t@e in
silico LCxtures (AddCtCoNaI FCIe 1 FCgure 2, page 7O). T@Cs was CNdepeNdeNt of
t@e dataset used for sCLuIatCoN (AddCtCoNaI FCIe 1, FCgure 3, page 80). We couId
aIso s@ow t@at our aIgorCt@L Cs of use across bot@ LCxtures of cIoseIy reIated
ceII types (suc@ as CD4+ aNd CD8+ TAceIIs froL t@e GSE60424 dataset, FCgure
1A, page 55, AddCtCoNaI FCIe 1, TabIe 1, page 75) aNd of very dCffereNt ceII types
(Datasets GTex aNd EAKTABA2836, AddCtCoNaI FCIe 1, TabIe 2 aNd 3, page 77,
FCgure 2, page 7O aNd FCgure 3, page 80).
We appICed our aIgorCt@L to our actuaI saLpIes aNddCscovered Iess t@aN 2%
coNtaLCNatCoN (per coNtaLCNatCNg ceII type) CN Lost of t@e CD45+AKACS purCA
fiedTU saLpIes (FCgure 1B, page 55), but @Cg@er coNtaLCNatCoN CN t@eCD14+AKACS
purCfied TAK saLpIes (10 saLpIes wCt@ Lore t@aN 2% coNtaLCNatCoN, FCgure
1C, page 55). T@ree saLpIes s@owed coNtaLCNatCoN of Lore t@aN >25% aNd
were excIuded froL furt@er aNaIysCs. SCNce eveN a sCNgIeAdCgCt coNtaLCNatCoN
caN add @uNdreds of TraNscrCpts per KCIICoN (TPK) uNCts for specCfic geNes, we
appICed a correctCoN to t@e reLaCNCNg saLpIes. T@e correctCoN dCd succeed CN
reLovCNg Lacrop@age LarGers froL tuLor saLpIes, as caN be seeN CN FCgure
1D, page 55 (Note t@at CD163 Cs Not aLoNg t@e LarGers used to deterLCNe coNA
taLCNatCoN perceNtage). Bt dCd Not affect tuLor LarGers suc@ as PAX82 (FCgure
1D, page 55) or uNreIated geNes, except CN faCrIy coNtaLCNated saLpIes (>10%)
w@ere Ct Iead to a sICg@t CNcrease CN TPK due to t@e reNorLaICzatCoN to oNe
LCIICoN. T@e correctCoN of TAKs was sCLCIarIy successfuI (Not s@owN).
BN suLLary, we were abIe to estabICs@ a Let@od to correct our dataset for
coNtaLCNatCoN wCt@ ot@er ceII types in silico.
1 W@Cc@ were arguabIy uNfavourabIe wCt@ oNIy oNe saLpIe of eac@ cIass avaCIabIe to IearN
froL.
2 PaCred box geNe/proteCN 8
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3.1.1.2 Protein mediators and their receptors
We were CNterested CN ceIIAceII sCgNaICNg betweeN TUs aNd TAKs.
A LaEor cIass of sCgNaICNg LoIecuIes are cytoGCNes aNd growt@ factors A
w@Cc@ we defiNe broadIy to be proteCN LedCators. UsCNg t@e geNe oNtoIogy
(GO) aNNotatCoN, t@e ENseLbI [26] @uLaN geNoLe aNNotatCoN, aNd a ICteraA
ture searc@, we asseLbIed a dataset of 502 cytoGCNe aNd 28O cytoGCNe receptors
geNes, of w@Cc@ 15O aNd 173, respectCveIy, were expressed CN at Ieast 65% of our
TU aNd/or TAK saLpIes. We estCLated coNfideNce CNtervaIs oN t@e ratCo of
TU vs. TAK expressCoN based oN a bootstrappCNg Let@od1 (FCgure 2A aNd 2B
respectCveIy, page 56).
SeIected geNes were aNaIyzed by reverse traNscrCptCoN quaNtCtatCve poIyA
Lerase c@aCN reactCoN (RTAqPCR) CN a Iarger NuLber of patCeNts2 (FCgure 3A,
page 57), w@Cc@ geNeraIIy coNfirLed t@e RMAseq data. ExpressCoN of BHA83 aNd
S100A8/AO4 asweII as ceII surface expressCoN of HBFR5 aNd TGFBR36 coNfirLed
t@e RMAseq resuIts (FCgure 3C, page 57). Mo sCgNCficaNt expressCoN dCffereNce
was fouNd for S100A14, aIt@oug@ t@e rCboNucIeCc acCd (RMA) IeveIs dCffered
100AfoId (FCgure 3C, page 57). Mo sCgNaI for BHA4, BHA12Ap707, BHA13 or GKACSF8
was detected CN ascCtes by EHBSA (FCgure 3D, page 57), as predCcted by IowLesA
seNger RMA (LRMA) IeveIs (Not s@owN). BHA6 aNd VEGFCO were preseNt CN
@Cg@er aLouNts t@aN expected froL LRMA IeveIs. We fouNd t@at attac@LeNt
of tuLor ceIIs in vitro Ieads to aN CNductCoN of t@e traNscrCptCoN of bot@ IL6 aNd
VEGFC, suggestCNg t@at @Cg@ IeveIs of t@e correspoNdCNg proteCNs were derCved
froL soICd tuLor tCssue rat@er t@aN froL ceIIs floatCNg CN ascCtes (FCgure 3E,
page 57).
1 BootstrappCNg estCLates t@e accuracy of saLpIe estCLates usCNg raNdoL subsaLpICNg (wCt@
repIaceLeNt).
2 Mot aII patCeNts provCde eNoug@ RMA for sequeNcCNg, but RTAqPCR requCres Iess LaterCaI.
3 BNterIeuGCN faLCIy LeLber
4 S100 caIcCuL bCNdCNg proteCN faLCIy LeLber
5 HeuGLCa CN@CbCtory factor receptor
6 TGFβ receptor 3
7 BNterIeuGCN 12; actCve @eterodCLer (p70)
8 GraNuIocyte Lacrop@age coIoNyAstCLuIatCNg factor
O VascuIar eNdot@eICaI growt@ factor C
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ALoNg t@e sCgNaICNg NetworGs CdeNtCfied by t@Cs approac@ (FCgure 4, page
58) were STAT31 aNd TGFβ2 ceNtered NetworGs, WMT3 sCgNaIICNg, pat@ways
drCveN by S100 proteCNs, seLap@orCN aNd ep@rCN sCgNaICNg asweII as c@eLoGCNe
LedCated pat@ways.
3.1.1.3 Lipid-mediators, their producing enzymes and receptors
ANot@er LaEor cIass of sCgNaICNgLoIecuIes are ICpCds. UsCNg t@e saLeLet@ods
as above, a set of geNes codCNg for ICpCd LedCator producCNg eNzyLe aNd t@e
correspoNdCNg receptors was buCId aNd appICed to our dataset (FCgure 5A, 5B,
page 61). RTAqPCR resuIts geNeraIIy supported t@e RMAseq data, bot@ oN uNA
Latc@ed aNdLatc@ed saLpIes (FCgure 5C, 5D, page 61). AscCtes coNceNtratCoNs
of AA aNd Iysop@osp@atCdCc acCds (HPA) were CN t@e LCcroLoIar raNge, w@CIe
prostagIaNdCN E2, 6AGetoAprostagIaNdCN F1A, IeuGotrCNe B4 (HTB4), 5A?ydroxyA
eCcosatetraeNoCc acCd (5A?ETE) aNd 15A?ETE were preseNt CN NaNoLoIar coNA
ceNtratCoNs (FCgure 5E, page 61). AII Leasured ICpCds varCed by at Ieast oNe
order of LagNCtude betweeN patCeNts.
3.1.1.4 Lipid-mediator concentrations and gene expression associated with
differences in clinical outcome
To estabICs@ a bCoIogCcaI roIe of t@e CdeNtCfied sCgNaICNg pat@ways, we tested
cytoGCNe aNd ICpCd LedCator coNceNtratCoNs CN ascCtes for t@eCr assocCatCoN wCt@
reIapseAfreeAsurvCvaI (RFS) usCNgFapIaNAKeCer pIots [45] aNd t@e IogAraNG tests
[56]. We fouNd BH10, BHA6, PHA2G74, AA aNd HTB4 to be CNverseIy assocCated
wCt@ RFS (C.e. patCeNts wCt@ Iow ascCtes IeveIs of t@ese substaNces @ad a proA
IoNged survCvaI tCLe, FCgure 7AAG, page 64). Mo posCtCve assocCatCoN was obA
served for aNy of t@e CNvestCgated LoIecuIes (FCgure 7A, page 64).
UsCNg a pubICs@eddataset assocCatCNgLCcroarray expressCoNdatawCt@OvCa
RFS [34] (N=1018), we tested geNes predoLCNaNtIy expressed CN tuLor ceIIs by
FapIaNAKeCer aNd IogAraNG tests. We focused oN tuLor specCfic geNes sCNce No
1 SCgNaI traNsducer aNd actCvator of traNscrCptCoN faLCIy LeLber
2 TuLor growt@ factor β faLCIy faLCIy LeLber
3 WNt sCgNaICNg pat@way
4 HCpoproteCNAassocCated p@osp@oICpase A2
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CNforLatCoN about t@e preseNce of ot@er ceII popuIatCoNs CN t@e tuLor saLpIes
was avaCIabIe. T@e two Lost proLCNeNt resuIts were a favorabIe assocCatCoN of
WMT receptor frCzzIed 4 (FZD41) aNd NDP2 expressCoN; aNd aN adverse assoA
cCatCoN of PTGIS3 aNd TGFβ3 wCt@ cICNCcaI outcoLe (bot@ p J 0.001, FCgure OA,
OB, OD, OF, OG, page 66).
3.1.2 Discussion
UsCNg traNscrCptCoNaI data froL 20 ?GSOC TU aNd 16 TAK saLpIes, we CdeNA
tCfied aNd c@aracterCzed severaI ceIIAceII sCgNaICNg NetworGs LedCatCNg coLLuA
NCcatCoN betweeN t@ese ceII types (FCgure 4, page 58 aNd FCgure 6, page 62). BN
t@e foIIowCNg sectCoNs t@e pat@ways s@owCNg t@e stroNgest ICNG to cICNCcaI outA
coLe wCII be dCscussed.
3.1.2.1 STAT3 inducing signaling
T@e actCvatCoN of t@e traNscrCptCoN factor STAT3 @as a detrCLeNtaI fuNctCoN CN
OvCa [87]. STAT3 CNducCNg cytoGCNes were Lade bot@ by TUs (e.g. HBF4) aNd
TAKs (e.g. BH10, BHA6). Bot@ ceII types couId receCve BHA6 sCgNaICNg, t@oug@
TAKs @ad a stroNger expressCoN of t@e receptor geNes (FCgure 4A, page 58). T@e
expressCoN of HBF receptor CN tuLor ceIIs poCNts to a roIe beyoNd Lacrop@age
actCvatCoN [21] of t@Cs pat@way. BHA6 proteCN coNceNtratCoN CN ascCtes (FCgure
3D, page 57) was @Cg@er t@aN oNe wouId expect froL t@e geNe expressCoN IeveI
CN TAKs, suggestCNg a dCffereNt ceII popuIatCoN as t@e LaEor BHA6 source. In
vitro experCLeNts coLparCNg floatCNg aNd attac@ed OvCa tuLor ceIIs s@owed
aN CNcrease of IL6 expressCoN (FCgure 3E, page 57). Bt Cs t@erefore possCbIe t@at
t@e soICd tuLor ceIIs A as opposed to t@e floatCNg popuIatCoN aNaIyzed CN t@Cs
worG A are t@e LaEor source for BHA6. CoNsCsteNt wCt@ prevCous studCes [82, 100,
17], Iow IeveIs of BHA6 aNd BH10 CN ascCtes were assocCated wCt@ a IoNger RFS
CNtervaI (FCgure 7B, C, page 64).
1 FrCzzIed faLCIy LeLber
2 MorrCe dCsease proteCN
3 ProstagIaNdCNAB2 syNt@ase
4 HeuGeLCa CN@CbCtory factor
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3.1.2.2 TGF
T@e TGFβ faLCIy LeLbers TGFβ1, 2 aNd 3 were assocCated wCt@ earICer reIapse
(FCgure 7G, page 64, FCgure OA, D, page 66). TGFβ1 was LaCNIy produced by
TAKs, w@CIe t@e TGFβ2 aNdTGFβ3were produced byTUs (FCgure 4B, page 58).
KuItCpIe studCes @ave assocCated TGFβ faLCIyLeLberswCt@OvCaprogressCoN
[23, 58, 83], aNd our resuIts are CN agreeLeNt wCt@ GNowN fuNctCoNs of TGFβ
ICgaNds [72, 108]. T@e TGFβ super faLCIy LeLbers BKP21 aNd BKP4 @ave
beeN prevCousIy descrCbed CN t@e coNtext of OvCa [61]. T@ey were descrCbed as
beCNg produced by LeseNc@yLaI steL ceIIs w@Cc@ fits wCt@ t@e extreLeIy Iow
expressCoN IeveIs we observed CN bot@ TAKs aNd TUs.
3.1.2.3 Frizzled
We fouNd evCdeNce t@at bot@ t@e caNoNCcaI aNd t@e NoNAcaNoNCcaI WMT sCgA
NaICNg pat@ways were operatCoNaI CN bot@ TAKs aNd TUs (FCg 4C, page 58).
CaNoNCcaI WMT sCgNaICNg depeNds oN FZ aNd HRP2 proteCN faLCIy LeLbers
aNd stCLuIates βAcateNCN3 sCgNaICNg. MoNAcaNoNCcaIWMTsCgNaICNg occurswCt@A
out t@e CNvoIveLeNt of HRP coreceptors aNd trCggers a caIcCNeurCN depeNdeNt
pat@way. Bot@ ceII types expressed overIappCNg sets of FZ aNd LRP faLCIy
LeLbers. FCve of t@e seveN WMT ICgaNd eNcodCNg geNes observed were exA
pressed predoLCNaNtIy by tuLor ceIIs, CNcIudCNgWNT7A4 aNdWNT11, w@Cc@
were bot@ assocCated wCt@ a Lore rapCd reIapse (FCg OA).
For optCLaI caNoNCcaI WMT sCgNaICNg RSPO5 faLCIy LeLbers aNd t@eCr reA
ceptor HGR56 are Necessary [50], but NeCt@er were expressed CN our saLpIes.
We fouNd evCdeNce of autocrCNe NorrCN (aN aIterNatCve FZD4 ICgaNd [43])
sCgNaICNg. MDP, Cts receptor FZD4 aNd a sCgNaI aLpICfyCNg coLpoNeNt of t@e
receptor coLpIex (TSPAM127 [43]) were fouNd to be expressed CN TU (t@oug@
1 BoNe Lorp@ogeNetCc proteCN faLCIy LeLber
2 ICpoproteCN receptorAreIated proteCNs
3 SubuNCt of t@e cad@erCN coLpIex
4 WNt sCgNaICNg pat@way faLCIy LeLber
5 RAspoNdCN
6 HeucCNeArCc@ repeatAcoNtaCNCNg GAproteCN coupIed receptor 5
7 TetraspaNCN 12
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NDPwas oNIy expressed CN a subset of saLpIes). AII t@reewere assocCatedwCt@
a deIayed reIapse, w@Cc@ Cs surprCsCNg sCNce NorrCN aIso @as t@e abCICty to CNduce
βAcateNCN, w@Cc@ Cs geNeraIIy t@oug@t to be proAtuLorCgeNCc; aNd because t@ey
were receNtIy ICNGed to coIoN caNcer aNgCogeNesCs [76]. T@Cs suggests a prevCA
ousIy uNGNowN fuNctCoN of MDP sCgNaICNg.
3.1.2.4 Semaphorins and ephrins
AutocrCNe aNd paracrCNe sCgNaICNg vCa seLap@orCNs aNd ep@rCNs was evCdeNt
CN our RMAseq data. At Ieast 13 seLap@orCNs, sCx of t@eCr receptors, sCx ep@rCN
LeLbers aNd seveN of t@eCr receptors were expressed CN tuLor ceIIs aNd TAKs
(FCg 4E, page 58). BN dCffereNt caNcers, bot@ proA aNd aNtCAtuLorCgeNCc roIes
@ave beeN descrCbed for t@e seLap@orCN receptor PHXMB11 [O4], w@Cc@ @ere
was expressed excIusCveIy CN tuLor ceIIs. BN t@e coNtext of OvCa, we fouNd
five seLap@orCNs aNd four ep@rCN receptors to be assocCated wCt@ earIy reIapse
(NoNe were assocCated wCt@ a protectCve status).
3.1.2.5 Arachidonic acid and its metabolites
We fouNd @Cg@ coNceNtratCoNs of AA CN ascCtes to be assocCated wCt@ earIy reA
Iapse (FCgure 7F, page 64). T@Cs assocCatCoN was CNcreased CN coLbCNatCoN wCt@
@Cg@ BH10, BHA6 or TGFβ IeveIs (FCgure 8, page 65), aII of w@Cc@ were aIso ICNGed
to earICer reIapse by t@eLseIves (FCgure 7, page 64). SCNce t@e IeveI of AA aNd
t@e above cytoGCNes were CNdepeNdeNt (FCgure 8D, page 65), Ct caN be presuLed
t@at t@eCr syNt@esCs Cs as weII.
As for AA derCvatCves, we observed aN adverse ICNG betweeN HTB4 ascCtes
IeveIs aNd RFS (FCgure 6A, page 62, 7A aNd 7G, page 64) as weII as for t@e geNes
PTGIS aNd PTGER32, w@Cc@ eNcode for PGB2 syNt@ase aNd PGE2 receptor (FCgA
ure 6A, page 62). T@e receptors for PGB2, PGE2 aNd 15A?ETE were predoLCA
NaNtIy expressed oN TAKs, uNICGe t@e HTB4 receptor, w@Cc@ was expressed oN
bot@ TAKs aNd TUs. Bt Cs teLptCNg to specuIate t@at t@ese AA derCvatCves aIso
LedCate t@e AAARFS assocCatCoN descrCbed above, but Ct curreNtIy caNNot be
1 PIexCN B1
2 ProstagIaNdCN EP3 receptor
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excIuded t@at NoNALetaboICzed AA was a coNtrCbutor. T@oug@ PPARβ/δ Cs agA
oNCzed by AA aNd AAAderCvates [O0] (see sectCoN 3.3, page 22), t@e Lost abuNA
daNt agoNCstCc poIyuNsaturated fatty acCd (PUFA) ICNoIeCc acCd was Not ICNGed
to survCvaI at aII (FCgure 7A, page 64), LaGCNg Ct uNICGeIy t@at AA Cs actCNg vCa
PPARβ/δ.
3.1.2.6 Conclusion
BN t@Cs study, we @ave deveIoped a decoNvoIutCoN (or LCxture correctCoN) aIA
gorCt@L t@at aIIowed successfuI correctCoN of our datasets. We coNstructed a
sCgNaICNg Lap betweeN OvCa ascCtes tuLor ceIIs aNd tuLor assocCated LacroA
p@ages, based oN RMAseq data aNd t@e LaxCL t@at geNe expressCoN Cs reIated
to proteCN expressCoN.
We CdeNtCfied aNd c@aracterCzed, wCt@ respect to t@e ceIIuIar orCgCN of t@eCr
coLpoNeNts, severaI GNowN (STAT3, TGFβ, WMT) aNd prevCousIy uNdescrCbed
(MDP, AA) sCgNaICNg pat@ways assocCated wCt@ reIapse free survCvaI, as weII as
pat@ways t@at do Not appear to affect caNcer recurreNce.
3.1.3 My contribution
KycoNtrCbutCoNwas t@e aNaIysCs aNd vCsuaICzatCoN of aII RMAseq aNdRTAqPCR
data (FCgures 1B, 1C, 1D, 1E, 2A, 2B, 3A, 3E, 5A, 5B, 5C, 5D, TabIes 1 aNd S1,
SuppIeLeNtaI Datasets1 S1, S2, S3, S4, S5, S6, S7, S8, SO), t@e draftCNg of t@e CNA
spected geNe sets (cytoGCNes aNd t@eCr receptors (Datasets S2, S4), ICpCd sCgNaIA
CNg assocCated eNzyLes, accessory proteCNs (Dataset S6) aNd receptors (Dataset
SO) (AddCtCoNaI FCIe 3 A DescrCptCoN of t@e creatCoN of t@e geNe sets used), aNd t@e
deveIopLeNt, CLpIeLeNtatCoN aNd evaIuatCoN of t@e decoNvoIutCoN aIgorCt@L
(FCgure 1A, AddCtCoNaI FCIe 1 descrCptCoN aNd evaIuatCoN of t@e aIgorCt@L, AdA
dCtCoNaI FCIe 6 A source code). B aIso partCcCpated CN t@e coNceptCoN aNd wrCtCNg
of t@e LaNuscrCpt. B s@are first aut@ors@Cp CN t@Cs worG wCt@ oNe ot@er aut@or.
1 SuppIeLeNtaI FCgures, datasets, suppIeLeNtaI Datasets aNd AddCtCoNaI fiIes (except for AdA
dCtCoNaI FCIe 1) are Not CNcIuded CN t@Cs dCssertatCoN, but avaCIabIe froL t@e EourNaI’s websCte
at @ttps://geNoLebCoIogy.bCoLedceNtraI.coL/artCcIes/10.1186/s1305OA016A0O56A6
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3.2 The transcriptional PPARβ/δ network in human
macrophages defines a unique agonist-induced
activation state1
3.2.1 Results
3.2.1.1 PPARβ/δ is present and functional inmonocyte-derivedmacrophages
PPAR ICgaNds @ave IoNg beeN assocCated wCt@ aN aNtCACNflaLLatory roIe CN varA
Cous dCsease LodeIs [O5]. UNtCI our worG pubICs@ed CN Ad@CGary et aI. [2], t@e
PPARβ/δ depeNdeNt sCgNaICNg NetworG CN prCLary Lacrop@ages @ad beeN uNA
c@aracterCzed oN bot@ a traNscrCptCoNaI aNd cCstroNCc IeveI.
To estabICs@ aN in vitro LodeI we verCfied aN CNtact PPARβ/δ sCgNaICNg NetA
worG CN LoNocyteAderCvedLacrop@ages (KDKs) as foIIows: DurCNg t@e ad@eA
sCoN CNduced LaturatCoN of bIood LoNocytes CNto KDKs, PPARDLRMA aNd
PPARβ/δ proteCN IeveIs rose for 5 to 6 days before graduaIIy decICNCNg agaCN,
wCt@ t@e LRMA precedCNg t@e proteCN (FCgure 1A, 1B, page 8O). PPARβ/δ tarA
get geNe CNductCoN vCa syNt@etCc agoNCsts (aNd repressCoN vCa syNt@etCc CNverse
agoNCsts) foIIowed t@e saLe patterN (FCgure 1C, page 8O). UsCNg C@BP foIIowed
by quaNtCtatCve poIyLerase c@aCN reactCoN (C@BPAqPCR) bot@ PPARβ/δ aNd Cts
obICgatory desoxyrCboNucIeCc acCd (DMA)AbCNdCNg partNer RXR couId be s@owN
to be preseNt CN t@e reguIatory regCoN of t@e PPARβ/δ target geNe PDK42 eveN
before dCffereNtCatCoN (FCgure 1D, page 8O). TaGeN toget@er, t@ese facts CNdCcate
t@at KDKs are a suCtabIe LodeI to study Lacrop@age PPARβ/δ sCgNaICNg.
3.2.1.2 Canonical and inverse PPARβ/δ target genes
C@BP foIIowedby sequeNcCNg (C@BPseq) aNaIysedusCNgBowtCe 2 [4O] aNdKACS
[116] CdeNtCfied 1,175 PPARβ/δ aNd 27,255 RXRbCNdCNg sCtes3 after faIse posCtCve
1 PubICs@ed CN T. Ad@CGary et aI. “T@e traNscrCptCoNaI PPAR/ NetworG CN @uLaN LacroA
p@ages defiNes a uNCque agoNCstACNduced actCvatCoN state.” BN: Nucleic acids research (2015).
doi: 10.1093/nar/gkv331, see page 84 for fuII text.
2 Pyruvate de@ydrogeNase GCNease 4
3 T@e Iarge dCscrepaNcy CN t@e NuLber of bCNdCNg sCtes Lay be expIaCNed by a @Cg@er affiNCty
aNtCbody aNd t@e fact t@at RXR forLs aIterNatCve DMAbCNdCNg coLpIexeswCt@ ot@er NucIear
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fiIterCNg. T@e c@aNges CN traNscrCptCoN effected by agoNCst aNd CNverse agoNCst
treatLeNt were profiIed by RMAseq aNd aNaIysed wCt@ STAR [20] (FCgure 2A,
2B, page O0).
AgoNCst reguIated geNes were assocCated wCt@ CLLuNe reIated fuNctCoNs
suc@ as “ad@esCoN of CLLuNe ceIIs” aNd “CNflaLLatCoN” (FCgures 2C, 2D, page
O0). UpstreaL reguIator aNaIysCs (FCgure 2E, page O0) s@owed cIear dCffereNces
betweeN agoNCst CNduced (C.e. caNoNCcaI) geNes, w@Cc@ correspoNd to GNowN
PPARα aNd PPARγ ICgaNds (@Cg@ actCvatCoN zAscore), aNd CNverse target geNes
(Iow actCvatCoN zAscore), w@Cc@ are targets of coLLoN proACNflaLLatory reguA
Iators suc@ as ICpopoIysacc@arCde (HPS), TMFα1, BFMγ2, BHA1β, STAT3 aNdTHR43.
AssocCatCoN of bCNdCNg sCtes wCt@ geNes wCt@CN 50 Gbp aNd aN overIap aNaIA
ysCs wCt@ geNes CNduced CN KDKs by agoNCst H165,041 s@owed t@at about @aIf
(46.3%, or 132 geNes) of t@e Iatter @ad a PPARβ/δ bCNdCNg sCte. AILost aII
(O8.5%) of t@ese sCtes aIso s@owed RXR occupaNcy (FCgure 3A, page O1). MCNe
out of teN upstreaL reguIators of t@ese 132 geNes were eCt@er PPAR ICgaNds or
t@e PPAR coAactCvator PPARGC1A4 (FCgure 3D, page O1). BN coNtrast, aLoNg
t@e agoNCst repressed geNes oNIy a sLaII subset (O%) s@owed a PPARβ/δ or
RXR bCNdCNg sCte (FCgure 4A, page O3). CytoGCNe sCgNaICNg pat@ways suc@ as
e.g. STAT1, STAT3, BH10, BHA4 aNd BHA1β were CdeNtCfied as upstreaL reguIaA
tors for t@e agoNCst repressed geNes (FCgure 4C, page O3). CoLparCsoN to pubA
ICs@ed C@BPseq sCtes (CN ot@er ceII types) reveaIed a sCgNCficaNt overIapwCt@ MFA
κBAp655, BCH66 aNd HPSACNduced EP3007 bouNd sCtes. MFAκBAp65, EP300 aNd
STAT3 @ave beeN descrCbed as CNvoIved CN cross taIGCNg pat@ways [40]. T@Cs
suggests a LodeI were agoNCst CNduced geNes are dCrect (cCsA) PPARβ/δ target
geNes aNd (IargeIy) t@e saLe aLoNg ceII types8 w@CIe agoNCst repressed target
geNes are CNdCrect (traNsA) aNd ceII type specCfic.
receptors [2O].
1 TuLor NecrosCs factor α
2 BNterferoN γ
3 ToIIAICGe receptor 4
4 PPARγ coactCvator 1 aIp@a
5 MFAκB subuNCt p65
6 BAceII IyLp@oLa 6
7 E1A bCNdCNg proteCN p300
8 sCNce t@ey appear CN target ICsts of PPARβ/δ ICgaNds w@Cc@ were coLpCIed CN ot@er ceII types
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3.2.1.3 Morphologically and functional consequences of PPARβ/δ activation
Korp@oIogCcaIIy, KDKs treated wCt@ agoNCst durCNg dCffereNtCatCoN reseLbIe
BHA4 treated ceIIs (“K2”Ap@eNotype), w@CIe CNverse agoNCst oNes appear Lore
sCLCIar to HPS treated (“K1”Ap@eNotype) ceIIs (FCgure 6, page O5).
FuNctCoNaI NetworGs buCIt froL expressCoN data (FCgure 5, page O4) usCNg
BPA (BNgeNuCty® SysteLs, www.CNgeNuCty.coL) predCcted aN CNcreased TAceII
actCvatCoN by agoNCst treated KDKs. T@Cs @ypot@esCs was tested CN coAcuIture
experCLeNts. ResuIts were supportCve, wCt@ H165,041 pretreatLeNt of KDKs
IeadCNg to Lore BFMγ+CD8+ ceIIs CN five out of sCx doNors (FCgure 7A, page
O6). T@Cs effect LCg@t be LedCated by IDO11, aN CNverse PPARβ/δ target geNe
w@ose RMA aNd proteCN IeveIs were decreased uNder agoNCst treatLeNt (FCgure
7B, 7C, page O6). BDO1 produces GyNureNCNe, a suppressor of TAceII actCvatCoN
[64]. FyNureNCNe IeveIs dropped upoN agoNCst treatLeNt (FCgure 7D, page O6),
provCdCNg a possCbIe expIaNatCoN.
3.2.1.4 Comparison with other macrophage states
To better c@aracterCze t@e PPARβ/δAagoNCst CNduced Lacrop@age p@eNotype,
we coLpared t@e traNscrCptCoNaI ICgaNd respoNse to 4O sCgNatures derCved by
stCLuIatCNg KDKs wCt@ 28 stCLuIC (pIus baseICNe) [110] (FCgure 8A, page O8).
FCve of t@e 4O sCgNatures were eNrCc@ed CN our PPARβ/δAKDK target geNe set
based oN a @ypergeoLetrCcaI overIap test. For t@ese five LoduIes, t@e agreeA
LeNt betweeNdCrectCoN of stCLuIC respoNse (respectCve to baseICNe) aNdH165,041
respoNse was dCscretCzed aNd pIoted as a @eat Lap (FCgure 8B, page O8). T@Cs
cIearIy s@ows t@at t@e agoNCst respoNse was outsCde of t@e cIassCcaI K1/K2
cIassCficatCoN, sCNce LoduIe 15 aNd 43 were reguIated CN t@e saLe dCrectCoN by
H165,041 aNd t@e K2ApoIarCzCNg stCLuIus BHA4, but LoduIe 16 was reguIated
dCscrepaNtIy. T@e saLe arguLeNt caN be Lade for BHA13, aNot@er K2AstCLuIus.
1 BNdoIeaLCNeApyrroIe 2,3AdCoxygeNase 1
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3.2.1.5 Cell type dependent regulation of PPARβ/δ target genes
BNtrCgued by t@e appareNt dCstCNctCoN of dCrect aNd CNdCrect target geNes sugA
gested by C@BPseq aNd upstreaL reguIator aNaIysCs (see page 17) we coLpared
t@e actuaI bCNdCNg sCte IocatCoNs wCt@ prevCousIy pubICs@ed data froL a @uA
LaN LyofibrobIasts ceII ICNe [1] (WPKYA1 ceIIs) aNd a breast caNcer ceII ICNe [3]
(KDAAKBA231).
T@Cs s@owed a cIear overIap of PPARβ/δ bCNdCNg sCte assocCated target geNes1
(N=12O) (FCgure OA, page OO). T@ese ceII type CNdepeNdeNt target geNes were
@Cg@Iy eNrCc@ed for t@e aNNotatCoNs “eNergyproductCoN” aNd “ICpCdLetaboICsL”.
BN coNtrast, CNverse target geNes A C.e. t@ose respoNdCNg to agoNCst treatLeNt
wCt@ a repressCoN of t@eCr traNscrCptCoNaI actCvCty CNdepeNdeNt of t@e preseNce
of a PPARβ/δ bCNdCNg sCte CN t@eCr vCcCNCty A s@owed No (N=0) overIap betweeN
t@e t@ree ceII types (FCgure OB, page OO).
T@Cs toget@er wCt@ t@e Iarge NuLber of CNverse target geNes (N=2O2A447, FCgA
ure OB, page OO) suggests t@at t@e ceII type specCfic respoNse to PPARβ/δ agoA
NCsts Cs LedCated by ot@er traNscrCptCoN factors dowNstreaL of PPARβ/δ.
3.2.2 Discussion
Our studywas aCLed to CdeNtCfy t@eLec@aNCsLs be@CNd t@e aNtCACNflaLLatory
effects of PPARβ/δ agoNCsts. To t@Cs eNd we estabICs@ed KDKs as a LodeI sysA
teL aNd c@aracterCzed t@eL by C@BPseq aNd RMAseq.
BesCdes a set of fatty acCd oxCdatCoN aNd ICpCd LetaboICsL target geNes repA
reseNtCNg t@e caNoNCcaI, ceII type CNdepeNdeNt fuNctCoN of PPARβ/δ, we @ave
CdeNtCfied two cIasses of CLLuNoreguIatCoN assocCated geNes: (C) dCrect aNd CNA
duced targets aNd (CC) CNdCrect aNd repressed targets.
Bot@ groups were oNIy respoNsCve CN KDKs (aNd (LurCNe) boNe LarrowA
derCvedLacrop@ages (BKDKs)), t@us ceII type specCfic, aNdLost ICGeIy PPARβ/δ
specCfic as weII – tested geNes t@at were respoNsCve CN wCId type BKDKs were
Not respoNsCve CN ceIIs froL PPARβ/δANuII LCce (FCgure 2F, page O0).
1 C.e. t@ose @avCNg a C@BPseq CdeNtCfied PPARβ/δ bCNdCNg sCte CN t@eCr proLotor regCoN
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T@e Lec@aNCsL of t@e traNsreguIatCoN of a Iarge part of group (CC) CNdCrect
target geNes Cs ICGeIy vCa MFAκB1 aNd STAT1, sCNce t@e group s@owed Iarge overA
Iaps wCt@ geNes coNtroIIed by t@ese pat@ways.
BN agreeLeNt wCt@ t@Cs @ypot@esCs, MFAκB actCvatCoN CN@CbCtor KG1322 dCA
LCNCs@ed PPARβ/δ agoNCst effects oN severaI MFAκB target geNes (froL group
(CC)) (FCgure 4E, page O3).
T@e set of CLLuNeAreguIatory target geNes suggested a prCLarCIy aNtCACNflaLLatory
effect (e.g. vCa IL8, IFNγ, CCL33 wCt@ soLe CLLuNoAstCLuIatory secoNdary
effects (e.g. vCa IL-10, IL13). BN accordaNce wCt@ t@Cs, bCoCNforLatCc aNaIysCs
reveaIed a dCstCNct actCvatCoN state for PPARβ/δ agoNCsts w@Cc@ coLbCNes aNtCA
CNflaLLatory, CLLuNe stCLuIatory, aNd ICpCdAtrCggered actCvatCoN states outA
sCde of t@e K1AK2 axCs.
SeveraI Gey coLpoNeNts of t@e MAHP CNflaLLosoLe [60] were CdeNtCfied
as PPARβ/δ target geNes, estabICs@CNg a secoNd PPARβ/δAdepeNdeNt CLLuNoA
reguIatory axCs.
A t@Crd axCs Cs t@e repressCoN of CD300E, a proACNflaLLatory subtype by
PPARβ/δ agoNCst toget@er wCt@ aN CNductCoN of CD300A, w@Cc@ suggests aN
CLLuNoAsuppressCve actCvCty vCa CD300 LeLbers [O].
BN suLLary, we @ave c@aracterCzed t@e PPARβ/δ sCgNaICNg NetworG CN a
Lacrop@age LodeI wCt@ specCaI regard to poteNtCaI LedCators of (aNtCA) CNflaLA
Latory effects. W@CIe t@Cs produced a usefuILap for furt@er experCLeNts, fiNdA
CNg aN approprCate settCNg LCLCcGCNg t@e p@ysCoIogCcaI eNvCroNLeNt reLaCNs
aN opeN (aNd LaEor) c@aIIeNge.
3.2.3 My contribution
Ky coNtrCbutCoNs CNcIuded t@e aNaIysCs of C@BPseq aNd RMAseq data, t@e coLA
parCsoN wCt@ pubICs@ed C@BPseq datasets of NoNAPPARβ/δ factors, t@e coLparA
CsoN to pubICs@ed stCLuIusAspecCfic KDK traNscrCptoLes aNd t@e coLparCsoN
wCt@ pubICs@ed PPARβ/δ bCNdCNg sCtes. T@Cs Ied to figures 2B, 2C, 2D, 3A, 3C,
1 MucIear factor κAICg@tAc@aCNAeN@aNcer of actCvated B ceIIs
2 w@Cc@ aIso fuNctCoNs as a proteasoLe CN@CbCtor
3 C@eLoGCNe (cAC LotCf) ICgaNd 3, aIso GNowN as Lacrop@age CNflaLLatory proteCN 1AaIp@a
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3B, 4A, 4B, 4D, 8, OA aNd OB. B assCsted CN aII statCstCcaI aNaIyses aNd s@are first
aut@orAs@Cp wCt@ two ot@er aut@ors.
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3.3 Deregulation of PPARβ/δ target genes in tumor-
associated macrophages by fatty acid ligands in
the ovarian cancer micro-environment1
3.3.1 Results
?avCNg estabICs@ed t@e PPARβ/δ CLLuNoAreguIatory respoNse CN aN in vitro
systeL (KDKs, see sectCoN 3.2), we focused our CNvestCgatCoN oNto Cts effects
CN t@e (ascCtes) tuLor eNvCroNLeNt aNd tuLor derCved in vitro systeLs.
BNCtCaIIy, we coLpared t@e (gIobaI) traNscrCptCoNaI aNdp@eNotypCc respoNses
of TAKs (cuItCvated CN ascCtes) aNd KDKs (cuItCvated CN RPKBA1640 + 10% feA
taI caIf seruL (FCS)) to t@e PPARβ/δ agoNCst H165,041. KDKs were c@oseN as
a refereNce because TAKs were beICeved to derCve froL CNvadCNg bIood LoNoA
cytes (See sectCoN 3.4.2.2). TraNscrCptCoNaIIy, TAKs were refractory to PPARβ/δ
agoNCsts across LaNy geNes (FCgure 2B, 2C, page 106), but s@owed aN CNcreased
(aNd dosage depeNdeNt) respoNse to CNverse agoNCst treatLeNt w@eN coLpared
wCt@ KDKs (FCgure 2B, page 106, FCgure 6E, page 112). T@ere was No dCfferA
eNce CN PPARβ/δ c@roLatCN CLLuNoprecCpCtatCoN (C@BP) eNrCc@LeNt (FCgure
2A, page 106), IeadCNg to t@e @ypot@esCs t@at t@ere was a sCgNCficaNt aLouNt of
PPARβ/δ agoNCst(s) CN ascCtes w@Cc@ causes t@e refractory p@eNotype.
T@e refractory effect oN PPARβ/δ target geNes CN TAKs CNCtCaIIy persCsted
w@eN TAKs were Gept CN RPKBA1640 + 10% FCS for 24 @ (FCgure 2D, page 106),
but was atteNuated after 4 d (FCgure 7C, page 113). Kacrop@ages caN accuLuA
Iate ICpCd dropIets [106], aNd t@e atteNuatCoN coAoccurred wCt@ a decrease of
ICpCd dropIets CN TAKs (FCgure 7A, 7C, page 113). HCpCd dropIet accuLuIatCoN
CNKDKswas CNducCbIe by exposCNg t@e ceIIs to HA at a IeveI coLparabIe to t@at
CN ascCtes. T@e dropIets persCsted for at Ieast 4 d CN RPKBA1640 after reLovaI of
t@e HA stCLuIus (FCgure 7D, 7E, page 113) aNd CNterfered wCt@ CNducCbCICty by
syNt@etCc ICgaNds (coLpare FCgure 7F wCt@ t@e CNductCoN CN KDKs CN FCgure
7C, page 113).
1 PubICs@ed CN T. Sc@uLaNN et aI. “DereguIatCoN of PPAR/ target geNes CN tuLorAassocCated
Lacrop@ages by fatty acCd ICgaNds CN t@e ovarCaN caNcer LCcroeNvCroNLeNt”. BN: Oncotarget
(2015). doi: 10.18632/oncotarget.3826, see page 103 for fuII text.
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We defiNed a set of PPARβ/δ target geNes CN KDKs by coLparCNg agoNCst
aNd CNverse agoNCst treated ceIIs froLfive @eaIt@y doNors vCa RMAseq. Of t@ese
1O5 geNes, 54 s@owed CNcreased expressCoN CN fres@Iy CsoIated (ex vivo) TAKs
coLpared to KDKs (FCgure 3A, page 10O), wCt@ a Iarge overIap (N=21) to aN
TAK vs. KDK coLparCsoN (FCgure 3B, page 10O). AIso, a LaEorCty of t@eL
(32 of 54) were refractory to H165,041 treatLeNt (FCgure 3C, page 10O). T@Cs
was coNfirLed for seIected geNes CN RTAqPCR aNd WesterN bIot experCLeNts
usCNg saLpIes froL addCtCoNaI doNors (FCgure 3D, 3E, page 10O). Bt s@ouId
be Noted t@at aNot@er Iarge fractCoN of t@e KDKAPPARβ/δAtarget geNes (N=4O)
was expressed at Iower IeveIs CN fres@Iy CsoIated TAKs (cyaN dots CN FCgure
3A, page 10O), possCbIy because t@ey were repressed by ot@er sCgNaICNg pat@A
ways trCggered by t@e tuLor eNvCroNLeNt. ONe of t@e Lost CNduced geNes
CN TAKs Cs ANGPTL41, w@Cc@ eNcodes for a secreted proteCN t@at @as prevCA
ousIy beeN assocCated wCt@ caNcer ceII CNvasCoN aNd LetastasCs CN breast caNcer
[3]. AMGPTH4 couId be detected CN t@e ascCtes at NaNograL/LI coNceNtratCoNs
(FCgure 3F, page 10O) aNd @Cg@ AMGPTH4 expressCoN s@owed a weaG assocCaA
tCoNwCt@ s@orteNedRFS CN a?GSOCLCcroarray dataset froLT@eCaNcerGeNe
AtIas (TCGA) [6O] (FCgure 3G, page 10O).
To testwet@er a soIubIeLedCatorwas respoNsCbIe for t@e CNcreased PPARβ/δ
target geNe expressCoN CN TAKs, KDKs were cuItured CN ceII free ascCtes saLA
pIes. ExpressCoN of aII five Leasured target geNes was CNdeed CNduced by asA
cCtes (FCgure 5A, page 111) aNd couId Not be furt@er CNduced by coAtreatLeNt
wCt@ H165,041 (FCgure 5B, page 111). BNductCoN of a IucCferase reporter by ascCtes
was depeNdaNt oN t@e preseNce of a PPRE (FCgure 5C, page 111), stroNgIy @CNtA
CNg at a PPARAfaLCIy LeLber beCNg CNvoIved. CeII free ascCtes CNduced t@e tarA
get geNes PDK4 aNd ANGPTL4 CN LurCNe boNe LarrowAderCved Lacrop@ages
of wCId type LCce, but Not CN ceIIs froL a PPARD deIetCoN LutaNt (FCgure 5D,
page 111).
SCNce aII GNowN eNdogeNous PPARβ/δ agoNCsts are fatty acCds, aN aNaIyA
sCs of O7 fatty acCd LoIecuIes CN 38 dCffereNt ascCtes saLpIes was perforLed
by ICquCd c@roLatograp@y Lass spectoLetry Lass spectoLetry (HCAKS/KS).
SeveraI GNowN PPARβ/δ agoNCsts were preseNt CN coNceNtratCoNs t@at exceed
1 ANgCopoCetCNAICGe 4
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t@eCr @aIf LaxCLaI effectCve coNceNtratCoN (EC50) by t@ree orders of LagNCtude
(FCgure 6A, page 112). A seIectCoN of t@e poIyuNsaturated fatty acCds preseNt
CN ascCtes (HA, AA, docosa@exaeNoCc acCd (D?A), eCcosapeNtaeNoCc acCd aNd
αAICNoIeNCc acCd (AHA)) were added to KDK cuItures (at a coNceNtratCoN of
20 µK, w@Cc@ Cs coLparabIe to t@at fouNd CN ascCtes (FCgure 6A, page 112)). HA,
AA aNd D?A Ied to aN CNductCoN (>10x) of t@e PPARβ/δ target geNe PDK4 afA
ter 24 @ (FCgure 6B, page 112). BNductCoN by HA (or a NuLber of Cts derCvatCves)
was rapCd (3 @), dosage depeNdeNt (FCgure 6C, page 112) aNd Not restrCcted to
PDK4: ANGPTL4, CD300A, CPT1A1, LRP52, PLIN23, aNd SLC25A204 were aIso
CNduced (FCgure 6D, page 112). T@e prevCousIy descrCbed PPARβ/δ agoNCsts
15A?ETE [66] aNd prostacycICN5 were preseNt at coNceNtratCoNs two orders of
LagNCtude beIow t@eCr respectCve EC50 (FCgure 6F, page 112).
3.3.2 Discussion
We @ave, for t@e first tCLe, c@aracterCzed t@e prevCousIy descrCbed @Cg@ fatty
acCd coNteNt CN ascCtes [11, 112] vCa ICpCdoLCc aNaIysCs. T@e IeveI of GNowN
PPARβ/δ agoNCstCc PUFAs exceeded t@eCr respectCve EC50 by orders of LagA
NCtude. T@e observed PPARβ/δ target geNe expressCoN CN TAKs, t@e IacG of
respoNse to syNt@etCc PPARβ/δ agoNCst aNd t@e stroNg respoNse to PPARβ/δ CNA
verse agoNCst are CN agreeLeNt wCt@ t@ese PUFAs actCNg as boNaAfide PPARβ/δ
agoNCsts CN ascCtes. W@CIe bIood pIasLa aIso coNtaCNs Iarge coNceNtratCoNs of
PUFAs [27], PPARβ/δ CtseIf was expressed CN bIood LoNocytes at a very Iow
IeveI (FCgure 2A, page 106, aNd [2] FCgures 1A, 1B, page 88), precIudCNg tarA
get geNe CNductCoN. T@e PUFA effect oN PPARβ/δ target geNes was sustaCNed
for severaI days w@eN t@e PUFAs were No IoNger preseNt CN t@e surrouNdCNg
LedCuL, possCbIy due to t@eCr storage CN ICpCd dropIets (FCgure 7, page 113)6.
1 CarNCtCNe paILCtoyItraNsferase B
2 ICpoproteCN receptorAreIated proteCNs faLCIy LeLber
3 PerCICpCN 2
4 soIute carrCer faLCIy 25 LeLber 20 (carNCtCNe/acyIcarNCtCNe traNsIocase)
5 ProstacycICN IeveIs were Leasured by Cts stabIe degradatCoN product 6AGetoAprostagIaNdCN
F1α
6 KDK were Gept CN seruLAfree LedCuL for 7 days durCNg dCffereNtCatCoN aNd presuLabIy
coNsuLed aII bIood PUFAs t@at LoNocytes LCg@t @ave accuLuIated durCNg t@Cs tCLe.
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ALoNg t@e dereguIated PPARβ/δ target geNes are ANGPTL4, w@Cc@ Cs a
GNowN tuLor LetastasCs aNd CNvasCoN proLoter [3, 73]; CD300A aNd FOS1,
w@Cc@ act CN Lacrop@age poIarCzatCoN [O8, 3O]; aNd LRP5, aN actCvator of WMT
sCgNaICNg [O7]. T@e LassCve CNductCoN of PDK4 suggests t@at t@e TAKs LCg@t
be s@Cfted to aLore gIycoIytCc LetaboICsL [115], CLprovCNg survCvaI CN @ypoxCc
coNdCtCoNs.
BNverse PPARβ/δ agoNCsts are capabIe of repressCNg target geNe expressCoN
eveN CN t@e preseNce of eNdogeNous agoNCsts at ascCtes IeveIs, suggestCNg t@at
t@ey couId poteNtCaIIy be used to CNterfere wCt@ t@e tuLor proLotCNg effects of
ascCtes vCa PPARβ/δ target geNes.
3.3.3 My contribution
Ky coNtrCbutCoNs were t@e aNaIysCs of C@BPseq (FCgure 2E, 2F) aNd RMAseq
(FCgure 2B, 2C, 3A, 3B, 3C, TabIe 1) data. B aL a coAaut@or of t@Cs LaNuscrCpt.
1 Fos protoAoNcogeNe, APA1 traNscrCptCoN factor subuNCt
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3.4 The transcriptional signature of human ovarian
carcinomamacrophages is associatedwith extra-
cellular matrix reorganization1
3.4.1 Results
Sc@uLaNN et aI [O0] estabICs@ed t@at cuItured, LoNocyteAderCved Lacrop@ages
@ad a quCte dCffereNt Lorp@oIogCcaI aNd traNscrCptCoNaI p@eNotype froL ex vivo
tuLor assocCtated Lacrop@ages (see sectCoN: 3.3). BN our quest to uNderstaNd
t@e roIe of tuLor assocCated Lacrop@ages CN ascCtes, we t@erefore IooGed for
a Iess artCficCaI NoNAcaNcer refereNce aNd fouNd Ct CN perCtoNeaI Lacrop@ages
(pKP?s) froL patCeNts wCt@ NoNALaICgNaNt afflCctCoNs, suc@ as uterCNe LyA
oLatosCs, ovarCaN cysts or eNdoLetrCosCs. UsCNg oNIy prCLary ceIIs ex vivo aIA
Iowed us to avoCd ceII cuIture artefacts.
3.4.1.1 TAMs and pMPHs appear as one phenotype, distinct fromMDMs
T@erewas ICttIe dCffereNce CN t@e perceNtage of posCtCve ceIIs for varCousLacrop@age
aNd K2 LarGers betweeN t@e TAK aNd pKP? popuIatCoNs (FCgure 1A, page
123).
ONIy%CD163posCtCve aNd%CD206posCtCve reac@ed basCc statCstCcaI sCgNCficaNce,
but t@e dCstrCbutCoNs were overIappCNg. ON t@e IeveI of LeaN fluoresceNce CNA
teNsCty (KFB), No sCgNCficaNt dCffereNce was observed except for CD206 aNd
?HAADR2 w@Cc@ were CNcreased 2A3 foId oN pKP?s (FCgure 1B, page 123). BN
suLLary t@ere were detectabIe dCffereNces betweeN t@e two ceII types t@at
very weaGIy (aNd uNexpectedIy) suggest a Lore CLLuNoAsuppressCve state CN
pKP?s.
Mext, we coLpared pKP?s wCt@ TAKs aNd wCt@ KDKs (w@Cc@ were in
vitro dCffereNtCated aNd uNactCvated) oN a traNscrCptCoNaI IeveI (4, 17 aNd 3 saLA
pIes, respectCveIy). pKP?s were Luc@ Lore sCLCIar to TAKs t@aN to KDKs
1 PubICs@ed CN F. FCNGerNageI et aI. “T@e traNscrCptCoNaI sCgNature of @uLaN ovarCaN carcCNoLa
Lacrop@ages Cs assocCated wCt@ extraceIIuIar LatrCx reorgaNCzatCoN.” BN: Oncotarget (2016).
doi: 10.18632/oncotarget.12180, see page 121 for fuII text.
2 ?uLaN HeuGocyte ANtCgeN A aNtCgeN D ReIated
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oN bot@ a gIobaI (FCgure 2A, 2B, 2C, page 124) aNd sCNgIe geNe IeveI (FCgure 3A,
page 125) as evCdeNced by RMAseq aNd quaNtCtatCve poIyLerase c@aCN reactCoN
(qPCR) respectCveIy. TAKs aNd pKP?s @ad very sCLCIar Lacrop@age actCvaA
tCoNLarGer expressCoN, t@e patterN ofw@Cc@ dCd Not fit CNto t@e cIassCcaIK1AK2
poIarCzatCoN sc@eLe (or to t@e uNactCvated KDKs, FCgure 3A, page 125).
T@e expressCoN of a set of proAtuLorCgeNCc cytoGCNe aNd sCgNaICNg LoIecuIe
geNes, prevCousIy CdeNtCfied to be prCLarCIy expressed by TAKs (but Not by tuA
Lor ceIIs) CN ascCtes ([81], see page 10) was aNaIyzed by RMAseq. pKP?s (but
NotKDKs) expressed t@ese at TAKAICGe IeveIs (FCgure 3B, page 125). We t@ereA
fore coNcIuded t@at pKP?s aNd TAKs @ave a coLLoN actCvatCoN p@eNotype.
BN LCce, resCdeNtCaI Lacrop@ages caN be dCscrCLCNated froL bIood derCved
Lacrop@ages by t@e expressCoN of resCdeNtCaI LarGer geNes. ADGRE11 [30],
GATA62 [18] aNdTIMD43 [OO] expressCoNLarGs resCdeNtCaILacrop@ages, w@CIe
CD52 Cs a LarGer for LoNocyteAderCved ceIIs [10]. T@e @uLaN @oLoIogues of
t@e resCdeNtCaILarGers (aNd t@eCr proteCNs) are expressed CN TAKs aNdpKP?s,
but Not CNKDKs, aNd t@e CNverse @oIds true forCD52 (FCgure 3A, page 125, FCgA
ure 1D, page 123). T@Cs Cs evCdeNce of a resCdeNtCaI orCgCN of TAKs aNd pKP?s.
3.4.1.2 Activation state of TAMs
T@e sCLCIarCty CN gIobaI expressCoN profiIes betweeN TAKs aNd pKP?s sugA
gested t@at TAKs retaCN soLe Lacrop@ageALedCated CLLuNe fuNctCoNs. BNA
deed, TAKs were capabIe of p@agocytosCs at t@e saLe IeveI as KDKs (as a
posCtCve coNtroI) (FCgure 4A, 4B, page 126). TAKs aIso s@owed No dCffereNce
CN aNtCgeNAspecCfic CD8+TAceII actCvatCoN (FCgure 4C, page 126). BN coNtrast, t@e
traNscrCptCoNaI actCvatCoN of IL12B by HPS Cs abrogated CN TAKs (FCgure 4D,
page 126). T@e saLe Cs true for t@e secretCoN of p404, t@e product of IL12B (FCgA
ure 4E, page 126). p40 Cs a subuNCt of BHA12w@Cc@ eN@aNces t@e cytotoxCc actCvCty
of CD8+TAceIIs [55].
1 EGFAICGe LoduIeAcoNtaCNCNg LucCNAICGe @orLoNe receptorAICGe 1 A aIso GNowN as F4/80
2 GATAAbCNdCNg factor 6
3 TAceII CLLuNogIobuICN aNd LucCN doLaCN coNtaCNCNg 4
4 BNterIeuGCN 12 subuNCt beta proteCN; product of geNe IL12B
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3.4.1.3 Gene expression differences between TAMs and pMPHs reveal an
extracellular matrix related gene cluster
T@oug@ t@e two perCtoNeaI Lacrop@ages groups appeared IargeIy sCLCIar, dCfA
fereNtCaI geNe expressCoN aNaIysCs usCNg edgeR [84] reveaIed 30 geNes t@at @ave
CNcreased expressCoN CN TAKs coLpared to pKP?s (FCgure 5B, page 127). ONIy
five geNes were reguIated CN aN opposCte LaNNer. BN coNtrast, t@e NuLber of
dCffereNtCaIIy CNduced geNes betweeN TAKs aNd KDKs was Luc@ @Cg@er: 4O7
geNes. T@e CNduced geNe sets were overIappCNgwCt@ 20 of t@e geNes fouNd to be
dCffereNtCaIIy reguIated w@eN coLparCNg TAK vs. pKP? aIso s@owCNg sCgNCfA
CcaNt CNductCoNw@eN coLparCNg TAKs aNdKDKs (FCgure 5B, page 127). MoNe
of t@e 5 repressed geNes were seeN CN bot@ coLparCsoNs. We t@erefore focused
oN t@e 20 geNes wCt@ t@e stroNger evCdeNce of TAK specCficCty.
FuNctCoNaI aNNotatCoN CNdCcated t@at t@e set of CNduced geNes was eNrCc@ed
for extraceIIuIar LatrCx (ECK) orgaNCzatCoN (FCgure 5C, page 127). Based oN
PearsoNAcorreIatCoNAbased cIusterCNg across t@e patCeNts, t@e ECKgeNes are Not
oNIy CNduced CN TAKs, but aIso appeared to be coAreguIated (FCgure 5E, page
127, “ECK CIuster”). FCgure 6A, page 127, s@ows t@at aII but t@ree of t@ese
geNeswere CNducedNot oNIyw@eN coLparCNgTAKsvs. pKP?s, but aIsow@eN
coLparCNg TAKs to KDKs.
W@CIe t@ese geNes are TAK specCfic CN t@e seNse t@at t@ey’re CNduced w@eN
coLpared to pKP?s, TAKs are Not t@e oNIy ceIIs expressCNg t@eL CN t@e asA
cCtes eNvCroNLeNt: tuLor ceIIs express t@eLat TAKAICGe IeveIs (FCgure 6B, page
127).
3.4.2 Discussion
3.4.2.1 TAMs are pMPH derived cells
Our data s@owed surprCsCNgIy ICttIe dCffereNce betweeN TAKs aNd tCssue resCA
deNt Lacrop@ages froL patCeNts wCt@ NoNAcaNcerous afflCctCoNs (pKP?s). T@e
actCvatCoN state of TAKs appears CdeNtCcaI to t@at of pKP?s (FCgures 1AAC,
page 123). BN agreeLeNt wCt@ t@eCr expressCoN of t@e K2 LarGers CD163 [51]
aNd CD206 [5], TAKs were capabIe of efficCeNt p@agocytosCs. ANtCgeNAspecCfic
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T ceII respoNse CN TAKs was at IeveIs sCLCIar to pKP?s [10O]. (FCgures 2 AAC,
page 124).
TAKs express proAtuLorCgeNCc proteCNs [81] (see ReCNartz et al. FCgure 4,
page 58), but t@eCr geNe expressCoN dCd Not dCffer betweeN TAKs aNd pKP?s
(FCgure 3B, page 125). BN agreeLeNt wCt@ t@e ICterature [8, 32, 36, 37, 88, O3]),
we fouNd TAKs to be refractory to CNflaLLatory stCLuIC suc@ as HPS (FCgure
2D, page 124), w@Cc@ appears to be ascCtesALedCated1. T@Cs fiNdCNg suggests
t@at t@e tuLor eNvCroNLeNt does Not CNduce aNtCACNflaLLatory poIarCzatCoN CN
Lacrop@ages Nor does Ct CN@CbCt proACNflaLLatory poIarCzatCoN aNy Lore t@aN
t@e beNCgN perCtoNeaI eNvCroNLeNt.
3.4.2.2 Human TAMs resemble residential macrophages
BN LCce, Lacrop@ages derCve froL at Ieast two sources wCt@ dCstCNct fuNctCoNaI
propertCes [30]. ResCdeNtCaI ceIIs, w@Cc@ are of fetaI orCgCN, dCffer froL CNfiItratA
CNgLoNocytes by specCfic expressCoNLarGers, suc@ as TBKD4, GATA6 aNdADA
GRE1. TAKs aNd pKP?s aIso s@ow @Cg@er expressCoN IeveIs for t@ese geNes
t@aN t@e in vitroLoNocyteAderCved Lacrop@ages. T@Cs fiNdCNg suggests t@at, Cf
suc@ a dCc@otoLy Cs aIso preseNt CN Homo sapiens, resCdeNtCaI Lacrop@ages are
a ICGeIy source of TAKs.
3.4.2.3 The extracellular-matrix cluster
Our aNaIysCs of RMAseq data CdeNtCfied a cIuster of 1O cIoseIy coAreguIated
geNes t@at are expressedLore stroNgIy CN TAKs t@aN CN pKP?s orKDKs (FCgA
ure 5E, page 127). AII of t@ese geNes A w@Cc@ we deNote as ECK cIuster A are
CNvoIved CN extraceIIuIarALatrCx reIated processes suc@ as coIIageN deposCtCoN,
fibrCIIogeNesCs aNd ECK reLodeICNg.
Our data Cs coLpatCbIe wCt@ a LodeI CN w@Cc@ Lacrop@ages aCd CN tuLor
progressCoN by secretCNg ECK reLodeICNg factors. Kacrop@ages cIearIy CNA
crease perCtoNeaI coIoNCzatCoN as s@owN CN Lacrop@age depIetCoN experCLeNts
1 Bt wouId @ave beeN of CNterest to perforL t@Cs experCLeNt CN pKP?s, but No approprCate
cuIture LodeI was avaCIabIe
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CN LCce [85]. BN aNot@er study, KKPO1 deIetCoN resuIted CN reduced tuLor CNcCA
deNce, growt@ aNd decreased Lacrop@age CNfiItratCoN w@eN CNEected wCt@ @uA
LaN ovarCaN caNcer ceII [41]. BNEectCNg wCId type spIeeN ceIIs rescued t@e effect.
A ICNG betweeN ECK reLodeICNg geNes aNd a poor cICNCcaI outcoLe CN ovarA
CaN caNcer @as beeN Noted prevCousIy (e.g. [13]). Toget@er wCt@ our data t@Cs
suggests t@at Lacrop@age trCggered ECK reLodeIICNg Cs at Ieast oNe of t@e
Lec@aNCsLs by w@Cc@ TAKs proLote ovarCaN caNcer progressCoN [15].
3.4.3 My contribution
Ky coNtrCbutCoN was t@e exteNsCve aNaIysCs of RMAseq data.
1 LatrCx LetaIIoprotease O
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Abstract
Background: Soluble protein and lipid mediators play essential roles in the tumor environment, but their cellular
origins, targets, and clinical relevance are only partially known. We have addressed this question for the most
abundant cell types in human ovarian carcinoma ascites, namely tumor cells and tumor-associated macrophages.
Results: Transcriptome-derived datasets were adjusted for errors caused by contaminating cell types by an
algorithm using expression data derived from pure cell types as references. These data were utilized to construct a
network of autocrine and paracrine signaling pathways comprising 358 common and 58 patient-specific signaling
mediators and their receptors. RNA sequencing based predictions were confirmed for several proteins and lipid
mediators. Published expression microarray results for 1018 patients were used to establish clinical correlations for a
number of components with distinct cellular origins and target cells. Clear associations with early relapse were
found for STAT3-inducing cytokines, specific components of WNT and fibroblast growth factor signaling, ephrin and
semaphorin axon guidance molecules, and TGFβ/BMP-triggered pathways. An association with early relapse was
also observed for secretory macrophage-derived phospholipase PLA2G7, its product arachidonic acid (AA) and
signaling pathways controlled by the AA metabolites PGE2, PGI2, and LTB4. By contrast, the genes encoding norrin
and its receptor frizzled 4, both selectively expressed by cancer cells and previously not linked to tumor
suppression, show a striking association with a favorable clinical course.
Conclusions: We have established a signaling network operating in the ovarian cancer microenvironment with
previously unidentified pathways and have defined clinically relevant components within this network.
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Background
Ovarian carcinoma ranks fifth as the cause of death from
cancer in women with >40,000 new cases annually in the
European Union [1]. Ovarian cancer has a dire prognosis
with an overall five-year survival rate of <25 %. The
World Health Organization classification distinguishes
six major entities of ovarian tumor [1]. Of these, high
grade serous ovarian carcinoma is not only the most
common ovarian cancer, but also the deadliest of all
gynecological malignancies. Up to 95 % of these patients
with advanced stage disease present with tumor masses
in the abdomen beyond the pelvis and/or lymph node
metastases (FIGO stage III) or organs outside the peri-
toneal cavity (stage IV). These facts clearly attest to the
malicious nature of this disease and identify serous ovar-
ian cancer as a major health issue world-wide.
Several features contribute to the fatal nature of serous
ovarian carcinoma, some of which make this cancer
unique among all human tumors [2]. Tumor cells are
often shed at a very early stage of the disease. Even at a
stage when primary tumors are still confined to one or
both of the ovaries, cancer cells can be detected in peri-
toneal lavage fluid (stage IC). While blood and the
lymphatic system are major routes of dissemenation in
other cancers, the spread of ovarian tumor cells is driven
by the peritoneal fluid. Ovarian cancer cells then adhere
to and superficially invade the omentum and the serous
membranes lining other peritoneal organs, giving rise to
tumor foci growing into the open space of the peritoneal
cavity [2]. The peritoneal microenvironment, which is
formed by the ascites building up in the peritoneal cavity,
is an essential determinant of metastatic disease progres-
sion due to its tumor-promoting soluble factors [3], exo-
somes [4], highly tumorigenic cancer cells [5], and different
types of immune cells, including pro-tumorigenic tumor-
associated macrophages (TAMs) [6, 7].
TAMs are blood monocyte-derived cells polarized by
factors of the tumor microenvironment to adopt pheno-
types that clearly deviate from classically or alterna-
tively activated macrophages [8–10]. This also applies
to TAMs isolated from ovarian cancer ascites [7].
TAMs are pro-tumorigenic and promote all aspects of
cancer growth and progression, including tumor cell
proliferation, invasion, angiogenesis, formation of me-
tastasis, and immune suppression [8, 9, 11, 12]. The
critical role of TAMs has been demonstrated in numer-
ous mouse models and is strongly supported by the
correlation of clinical outcome with intratumoral
macrophage density in different types of cancer [11], in-
cluding ovarian carcinoma [13]. Consistent with these
observations, the presence of CD163high TAMs in the
malignancy-associated ascites showed a strong correl-
ation with early relapse of serous ovarian carcinoma
after first-line therapy [7].
Cytokines and growth factors released into the tumor
microenvironment are pivotal to all aspects of tumor
progression. Tumor growth, cancer dissemination, and
immune escape are promoted by a plethora of growth
factors and cytokines that are also found in ovarian cancer
ascites [7, 14–16]. These factors (1) induce cell prolifera-
tion, such as epidermal growth factor (EGF) family mem-
bers and interleukin (IL)-6, (2) trigger angiogenesis, e.g.
vascular EGF (VEGF), basic FGF, and IL-8, (3) attract im-
mune cells to the tumor, in particular chemokines of the
CCL and CXCL families [17], and (4) polarize these to pro-
tumorigenic and immune suppressive cells, for example
VEGF, IL-6, IL-10, and LIF [18]. One of the central factors
promoting tumor progression is transforming growth fac-
tor (TGF) β [19], which triggers epithelial-mesenchymal
transition (EMT), cancer cell invasion, metastasis, and im-
mune suppression. Soluble factors may also play a role in
promoting stemness properties, for example, KIT ligand
and R-spondins as ligands for CD117 [20] and LGR5 [21,
22], respectively. Several growth factors and cytokines also
inhibit apoptosis and the efficacy of chemotherapeutic
drugs, such as IL-6, IL-10, and TGFβ [23]. Finally, ascites
fluid promotes its own accumulation, mainly though the
action of VEGF as a vascular permeability factor [24].
A recent study evaluating publicly available genomic
data has identified a number of clinical associations of
signaling loops established by polypeptide ligands and
their receptors in advanced ovarian cancer, including
TGFβ, PDGF, VEGF, ephrin, CXCL12, and CCL chemo-
kines [25]. However, since all expression data were derived
from solid tumor tissue, tumor and host cell-specific con-
tributions could not be analyzed, which also suggests that
pathways involving host cells as major constituent were
missed.
Molecules generated by the cleavage of phospholipids
and present in malignant effusions represent another im-
portant class of soluble cancer-promoting mediators, in
particular lysophosphatitic acid (LPA) [26–31] and ara-
chidonic acid (AA)-derived eicosanoids [32–34]. The lat-
ter include prostanoids, hydroxyeicosatetraenoic acids
(HETEs), and leukotrienes that are produced from AA
by enzymatic cascades initiated either by cyclooxy-
genases or lipoxygenases. The importance of lipid medi-
ators for tumorigenesis is exemplified by LPA as a
mediator of cancer cell invasion and chemoresistance
[28, 31, 35] and prostaglandin E2 as an immune suppres-
sor and trigger of angiogenesis [36].
To be able to understand the biological role of the
large number of soluble mediators in the tumor micro-
environment, a global picture of their cellular origins
and targets is indispensible, but currently not available.
One possibility is to address this question by a genomic
approach. However, although transcriptomic data for a
large number of solid tumor samples from ovarian
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cancer patients have been published [37–39], these are
not suitable to determine expression levels in tumor
cells and specific tumor-associated host cells. We have
addressed this issue by determining the transcriptomes
for the major cell types of serous ovarian carcinoma, i.e.
tumor cells and TAMs, purified from the ascites of pa-
tients. Ascites-associated cancer cells occur as single
cells or multicellular spheroids and are likely to be re-
sponsible for peritoneal dissemination and to contribute
to relapse of the disease [2]. In spite of their clinical rele-
vance, genome-wide studies have not been performed
with ascites-associated cells from ovarian cancer.
In the present study, we determined the transcriptome
for tumor cells and TAMs from ovarian cancer ascites and
used these data to construct a network comprising cyto-
kines, growth factors, lipid mediators, and their receptors,
which we confirmed for several components at the level
of the respective proteins or lipids. These data defined a
multitude of specific signaling pathways between tumor
cells and TAMs as well as cell-type restricted, autocrine
mechanisms. Furthermore, by establishing correlations
with disease progression, we provide clear evidence for
the biological relevance of soluble mediators in the ovar-
ian cancer microenvironment. Thus, our data identified a
highly significant link to disease recurrence not only for
several cytokines and AA, but also a striking synergistic
association between these proteins and AA. These find-
ings underscore the biological relevance of functional in-
teractions in the ovarian cancer microenvironment.
Results
Characterization of patient samples
Tumor cells and/or TAMs were isolated from the ascites
of 28 patients with high grade serous ovarian carcinoma
and one patient with serous borderline tumor (low grade
carcinoma) (Additional file 4: Table S1). If feasible,
tumor cell spheroids from the same patients were frac-
tionated according to size (single cells: “sc”; small: <30
μm, “s”; medium: 30–40 μm, “m”; large: >40 μm, “L”).
Surprisingly, small and large spheroids from the same
patients frequently showed clear genetic and biological
differences (Additional file 4: Table S2). For instance,
small spheroids usually comprised pseudo-diploid cells,
rapidly adhered to culture dishes in the presence of au-
tologous ascites and were chemosensitive, whereas large
spheroids were largely aneuploid, persisted as floating
spheres in culture and were completely chemoresistant.
Therefore, both small and large spheroids were included
in all subsequent studies and analyzed separately.
Adjustment of RNA sequencing data for contaminating
cell types
A central goal of the present study was an RNA sequen-
cing (RNA-Seq) based comparison of the expression of
signaling components of tumor cells and TAMs. We fo-
cused our study on primary, non-cultured cells in order
to obtain a faithful picture of the signaling network op-
erating in vivo. However, the presence of variable
amounts (0–50 %) of TAMs in isolated tumor cell frac-
tions and vice versa may lead to incorrect conclusions in
particular for genes that show a differential, cell type-
specific expression. The impact of such “contaminations”
on gene expression profiles is a well-known problem
and has consequently been addressed by numerous pub-
lished algorithms [40–50]. However, none of these fulfills
all the criteria required by our specific conditions, as ex-
plained in detail in Additional file 1.
A particularly relevant aspect in this context is the
mixed-polarization phenotype of ovarian cancer ascites-
associated TAMs, which share only small subsets of
upregulated genes with M1 and M2 macrophages
(Additional file 2: Figure S1). This precludes the use of
literature data obtained with canonically activated
macrophages as, for example, in CIBERSORT [48].
Likewise, the transcriptome of tumor cells from ovarian
cancer ascites has not been determined yet. Therefore, ap-
propriate reference data for ascites-derived tumor cells
and TAMs were not available prior the present study. Fi-
nally, most published algorithms generate estimates of the
fraction of contaminating cell types, but do not adjust the
TPM values in RNA-Seq datasets.
To establish a bioinformatic tool to adjust our data-
sets, we used a simple but highly effective approach.
First, pure reference samples representing the cell type
of interest (“target”) and the contaminating cell type are
selected, the purity of which was confirmed by flow
cytometry or other methods. RNA-Seq data for these
references samples are then used to select a set of con-
tamination marker genes, suitable for estimating the
extent of contamination. Finally, the target dataset is ad-
justed by a linear model. A detailed description of our
algorithms is found in Additional file 1. For testing our
method we simulated mixtures from published RNA-Seq
datasets, which showed a clear improvement, as exem-
plified in Fig. 1a for mixtures of purified immune cells
(RNA-Seq data from GSE60424 [51]) or different tissues
(Additional file 1). Furthermore, none of the previ-
ously described algorithms matched this performance
(Additional file 1).
The algorithm was then applied to our set of RNA-Seq
samples of tumor cells (n = 21), TAMs (n = 18), and
tumor-associated T cells (TATs; n = 5). The detected
contamination of tumor cell or TAM samples ranged
from 0 % to 17 % (Fig. 1b, c) and was in agreement with
prior analyses (as in Additional file 4: Table S2). To test
the power of the algorithm, we also included RNA-Seq
data from a heavily contaminated tumor sample (OC65s:
25.7 % TAMs; striped bars in Fig. 1b) and two heavily
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contaminated TAM samples (TAM66s: 49.4 % tumor cells
and TAM70: 24.9 %; striped bars in Fig. 1c). These three
samples were excluded from all subsequent experiments.
These data were used to adjust the RNA-Seq data for
cross-contaminating tumor cells, TAMs, and TATs. Ad-
justment was successful, as exemplified in Fig. 1d and e
for tumor cells. While the macrophage marker gene
CD163 was reduced, the epithelial cell marker gene
PAX8 was not. The observed increase in PAX8 is due to
the fact that TPM values represent a relative measure,
thus resulting in a redistribution from reduced to non-
reduced genes.
These adjusted RNA-Seq data for 20 tumor cell and
16 TAM samples (Additional file 3: Dataset S1) were an-
alyzed for expression of two classes of mediators and
their receptors: (1) cytokines and polypeptide growth
factors, collectively referred to as protein mediators in
the following; and (2) phospholipid breakdown products
and eicosanoids functioning as lipid mediators, as de-
scribed in detail below.
Common expression of protein mediators and their
receptors by tumor cells and TAMs
We first established datasets of 791 genes encoding pro-
tein mediators and their receptors based on literature
and database-derived data, in total 502 cytokine and
growth factor genes (Additional file 3: Dataset S2) and
289 receptor genes (Additional file 3: Dataset S4). Genes
with TPM values ≥3 in at least 65 % of all tumor cell or
TAM samples were considered expressed and part of a
common signaling network. Using these criteria, we iden-
tified 159 cytokine and 173 receptor genes to be expressed
in tumor cells and/or TAMs (Fig. 2a, b; Additional file 3:
Dataset S4 and S5). Genes were defined as cell type-
selective if expression levels between tumor cells and
TAMs differed at least threefold (thresholds indicated by
the shaded areas in Fig. 2) and the individual TPM values
determined for one cell type were either larger or smaller
than the values for the other cell type, allowing maximum
Fig. 1 Adjustment RNA-Seq data based on RNA-Seq mixture modeling.
a Simulation results from in-silico mixture of different purified immune
cells with purified monocytes from dataset GSE60424 [51]. Deviation of
TPM values from ground truth (unmixed sample) was quantified as the
mean absolute error (MAE). Purple: uncorrected samples; green:
corrected samples. Each dot represents one simulation with a random
mixture percentage between 0 % and 50 %. Violin plots show the
distribution of MAE values. See “Results” for description of dataset used.
The algorithm was applied for estimation of contamination and
data adjustment as described in Additional file 1. b Estimated TAM
contamination of tumor samples used in the present study, based
on RNA-Seq mixture modeling. c Estimated tumor cell contamination
of TAM samples. Striped bars in (b) and (c) denote samples excluded
from further analysis. d, e Effect of adjustment by RNA-Seq mixture
modeling on marker gene expression (PAX8, CD163) in tumor cell
samples. ori, original TPM values; adj, adjusted TPM
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one outlier (Additional file 3: Datasets S4, S5: column “no
overlap”). These datasets were further split into groups
showing low (green bars in Fig. 2a, b), median (blue), or
high (red) expression levels according to the observed
TPM values.
Differences of more than 1000-fold were observed
with respect to the expression levels of different genes as
well as the cell type selectivity of individual genes. These
results were confirmed by RT-qPCR using a larger num-
ber of patient-derived samples for all instances tested,
including a statistically highly significant preferential ex-
pression of IL10, TGFB1, S100A8, S100A9, and IL10RA
by TAMs and LIFR by tumor cells (Fig. 3a). The analysis
of matched tumor cell and TAM samples from the same
patients are in agreement with these conclusions with
the exception of TGFB1 (Fig. 3b).
We next determined the levels of protein expression
for several examples by flow cytometry of non-separated
ascites samples and confirmed the preferential expres-
sion of S100A8/A9 and IL-8 in TAMs, and of LIFR and
TGFBR3 in tumor cells (Fig. 3c and Additional file 2:
Figure S2). Finally, we measured the levels of a number
of protein mediators in the ascites of up to 40 serous
ovarian cancer patients (Additional file 4: Table S3) and
found readily detectable levels for all mediators shown
in Fig. 3d, whereas IL4, IL12, IL13, and GM-CSF were
not detectable, consistent with the RNA-Seq and RT-
qPCR data (Fig. 2a and 3a). However, in a few cases, as-
cites levels were unexpectedly high in view of the low
expression of the corresponding mRNAs in tumor cells
and TAMs, e.g. IL-6 and VEGF-C (Fig. 2; Additional file
3: Datasets S3 and S5). We therefore investigated
Fig. 2 Genes coding for components of cytokine and growth factor signaling expressed in ovarian cancer cells and/or TAMs (RNA-Seq). a Genes
coding for cytokines and growth factors. Values represent the ratio of expression in tumor cells versus TAMs (median and 95 % CI). The color
code indicates the level of expression: green, low expression (TPM 3–20); blue, moderate expression (TPM 20–100); red, high expression
(TPM >100). b Genes coding for cytokine/growth factor receptors. For further details see Additional file 3: Datasets S2–S5
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whether this apparent discrepancy could be due to dif-
ferences in expression levels in unattached tumor cells
in suspension, as in spheroids, and in attached tumor
cells. To address this question, we performed RNA-Seq
analyses for four matched pairs of uncultured and cul-
tured spheroids. The latter were kept in serum-free
medium supplemented with autologous ascites for 6 days,
under which conditions the cells partly adhere to the plas-
tic surface. The results clearly show that a small number
of cytokine genes were indeed induced under these con-
ditions, including IL6 and VEGFC (Fig. 3e), while other
ones, such as IL10 and LIF were not. It is therefore pos-
sible that adherent tumor cells and solid tumor masses
rather than floating cells are the major source of some
of the ascites-associated protein mediators.
Delineation of a common signaling network of protein
mediators established by tumor cells and TAMs
Based on these data, we derived a model of a signaling
network involving ovarian cancer cells and TAMs
(Fig. 4). The predicted cellular origins and targets of
cytokines and growth factors are also summarized in
Additional file 2: Figure S3. In the following sections, we
will describe the most prominent signaling pathways
identified by our analyses.
(i) The STAT3-inducing cytokines IL-10, IL-6, and LIF
were identified as part of the signaling network
established in the present study (Fig. 4a). IL10 and
the gene encoding its receptor IL10R were expressed
mainly by TAMs, LIF and LIFR by tumor cells, IL6
and the genes for IL6 receptor subunits IL6R and
IL6ST by both cell types.
(ii)TGFB1, mainly expressed by TAMs, codes for the
major ligands of the TGFβ network, which also
comprises tumor cell-derived TGFB2 and BMP7
(encoding bone morphogenetic protein 7) as well as
BMP1 expressed by both cell types (Fig. 4b). These
ligands target both cell types, as suggested by the
expression patterns of the TGFBR and BMPR2 genes.
(iii)WNT7A is the most strongly expressed WNT gene
preferentially expressed by tumor cells (Fig. 4c).
A B
C D E
Fig. 3 Expression of cytokines, growth factors, and their receptors in ovarian cancer ascites. a Validation of RNA-Seq data by RT-qPCR of tumor cell
and TAM samples (each dot represents a different sample). b RT-qPCR analysis of matched tumor cell and TAM samples from the same patients
(each dot represents a matched pair). Data are represented as the ratio of expression in tumor cells and TAMs. The dotted line indicates a ratio of
1. c FACS analysis of cytokine (intracellular IL-8, S100A8/A9, and S100A14) and receptor (LIFR and TGFBR3) expression by tumor cells and TAMs.
Data in (a)–(c) were statistically analyzed by Student’s t-test (two-sided, unequal variance). Horizontal bars indicate the median. Gene names are
explained in Additional file 3: Datasets S4 and S5. d Concentrations of cytokines and growth factors in the ascites fluid from ovarian cancer
patients. Each dot represent a different patient, horizontal lines indicate the median. e RNA-Seq analysis of tumor cell spheroids before and after a
6-day culture in serum-free medium supplemented with 10 % autologous ascites (n = 4). The figure shows the ratio of matched pairs for all
protein mediator-encoding genes induced under these conditions at least tenfold (each dot represents a matched pair; median: horizontal bar;
95 % CI: box; min–max: whiskers)
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Other ligands of the network include WNT2B,
WNT5A, and WNT9A, differentially expressed by
tumor cells and TAMs. These ligands include
inducers of both canonical and non-canonical WNT
signaling [52]. The canonical pathway depends on
both frizzled receptors (FZD) and LRP coreceptors,
whereas non-canonical signaling does not require
LRPs. As multiple LRP genes are expressed by tumor
cells and TAMs (Fig. 4c), canonical WNT signaling
would be functional in both cell types.
(iv)Multiple S100 genes are highly expressed in tumor
cells and/or TAMs, including S100A8 and S100A9
(Fig. 4d). S100A8 and S100A9 proteins interact with
surface receptors either as monomers with advanced
glycation end products receptor RAGE (AGER) and
TLR4 or bind as heterodimers to different scavenger
receptors [53], all of which are expressed by TAMs
(MSR1, SCARA/B, CD36). Taken together with the
particular high expression of both genes in TAMs,
these findings point to a pivotal role for TAMs in
generating and processing S100A8/A9-associated
signals, which also applies to S100A12. Tumor cells
express scavenger receptor genes, but not AGER and
TLR4 at significant levels, suggesting that these cells
are primarily targeted by S100A8/A9 heterodimers.
On the other hand, tumor cells but not TAMs
A C
B E
D F
H
G
I
Fig. 4 A common cytokine signaling network of ovarian cancer cells and TAMs. Ligands are represented as “free floating” symbols, receptors as
membrane-associated symbols. Ligands derived from tumor cells are shown in red, ligands originating from TAMs in blue, ligands expressed by
both cell types at similar levels (less than tenfold difference in TPM) in purple. Each ligand or receptor is represented by one or more identical
symbols according to their expression levels (1, 2, and 3 symbols corresponding to green, blue, and red, respectively in Fig. 2). The model is based
on the data in Figs. 2, 9c and Table 1 and assumes that protein levels follow gene expression. Gene names are explained in Additional file 3: Data-
sets S4 and S5. Red asterisks denote components associated with a poor clinical outcome (based on Figs. 7–9). Ligands shown in red letters are
expressed only in a subset of patients (Table 1) and associated with a short relapse-free survival (RFS) (Fig. 9c)
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express ERB2, encoding a receptor for S100A4,
suggesting a tumor-selective effect. In contrast,
multiple S100 members of varying cellular
origins seem to target preferentially TAMs, as
suggested by the lack of RAGE expression by
tumor cells.
(v)Both tumor cells and TAMs express multiple
semaphorins and their receptors (plexins and
neuropilins), thereby establishing autocrine as well
as paracrine signaling mechanisms (Fig. 4e). While
SEMA3F, 5A, 6A, and 6D expression is clearly
higher in tumor cells, the opposite is true for SEMA
4A and 6B. The semaphorin receptor genes
PLXNA1, PLXNA3, NRP1, and NRP2 are expressed
by both cell types, whereas PLXNB1 and PLXND1
expression is selective for tumor cells and TAMs,
respectively.
(vi) Ephrins are also part of the signaling network, with
tumor cells playing a major role (Fig. 4f ). Thus,
tumor cells are the main origin of six different
ephrin family members, compared to one subtype
expressed by TAMs. Likewise, A-type receptor ex-
pression is
restricted to tumor cells and B-type receptor expression
is considerably higher in, or selective for, tumor cells,
the latter exemplified by EPHB3 and EPHB4.
(vii)TAMs play a major role both as producers and
targets of multiple chemokines of the CCL family
(Figs. 2a and 4g). Thus, TAMs preferentially express
multiple CCL genes, with CCL2, CCL3, and CCL4
being the most strongly expressed ones. Moreover,
significant expression of receptor genes for these
cytokines (CCR1, CCR2, CCR5) was detected only in
TAMs. In contrast, several CXCL type chemokine
genes are expressed by both cell types, however,
significant expression of genes coding for their
cognate receptor genes was only detectable for
CXCR4 in both cell types, consistent with its
description as an independent predictor of a poor
clinical outcome of ovarian cancer [54].
(viii)Our study also predict a number of other pathways
known to play important roles in tumor progression
(Figs. 2 and 4h, i). These include: (1) stimulation of
the MET receptor on tumor cells by TAM-produced
HGF; (2) the interaction of amphiregulin (AREG)
produced by both cell types with ERB2, 3, and 4 re-
ceptors on tumor cells; (3) the activation of NOTCH
receptors on both cell types by JAG1/2
ligands, mainly produced by tumor cells; (4) PDGF
signaling by all different family members via
PDGFR-A on both cell types; (5) IGF1/2 signaling
particularly through IGFR2; and (6) the interaction
of angiopoietin-like 4 (ANGPTL4) with integrin β1
(ITGB1).
Expression of signaling components in tumor cells from
subsets of patients
A number of genes encoding protein mediators were
uniformly expressed by tumor cells and/or TAMs (e.g.
IL8, KITLG, LEP), but median expression of the corre-
sponding receptor genes was extremely low in both cell
types (Figs. 2 and 4; Additional file 3: Datasets S2–S5).
Likewise, several receptor genes (e.g. IL4R, INFAR/INFGR,
PTCH/SMO) were consistently expressed by tumor cells
and/or TAMs, but ligand expression was not detectable.
This may be due to the expression of the “missing” ligands
and receptors by other host-derived cells or by tumor cell
subsets not present in ascites. On the other hand, some of
these genes may not be part of the common network due
to a restricted expression in smaller subsets of patients.
Such genes may be of particular interest, since their ex-
pression could be related to the aggressiveness of the dis-
ease and thus to its clinical outcome.
We therefore searched for genes not found in the
common network but potentially complementing this in
a small subfraction of patients. These genes had to fulfill
two conditions: (1) TPM >3 in n ≥2 tumor cell or TAM
samples (but below the 65 % quantile used in Fig. 2);
and (2) coding for proteins representing ligands or re-
ceptors for the pathways constructed in Fig. 4. Genes
identified by this approach in tumor cells (n = 35;
Table 1) and TAMs (n = 14; Additional file 4: Table S4)
may indeed be of high relevance, as they code for com-
ponents of chemokine, TGFβ/BMP, FGF, ephrin, sema-
phoring, and WNT pathways. We also found the gene
coding for norrin (NDP), a frizzled 4 ligand unrelated to
the WNT family [55], to be expressed in tumor cells
from a subset of patients (Table 1).
Identification of a common transcriptome-based signaling
network of lipid mediators between tumor cells and
TAMs
Lipids derived from phospholipids represent another
major group of soluble mediators in ovarian cancer asci-
tes. These comprise mainly breakdown products of
phospholipids and metabolites of polyunsaturated fatty
acids (PUFAs), in particular AA-derived [30] products of
the cyclooxygenase and lipooxygenase pathways [33].
While the first group of mediators, including lysopho-
sphatidic acid (LPA) and PUFAs, is mostly generated by
secreted phospholipases, eicosanoid metabolites of the
second group are produced exclusively intracellularly.
We therefore focused our attention on proteins gener-
ating signaling compounds of either group and their
receptors and performed an analogous study as de-
scribed above using datasets of 93 genes encoding en-
zymes, accessory proteins (Additional file 3: Dataset
S6; n = 69), or lipid receptors (Additional file 3: Dataset
S8; n = 24).
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Table 1 Patient-specific expression of cytokine and receptor genes by tumor cells complementing the signaling networks
constructed in Figs. 4 and 6
Gene Description Min. TPM Max. TPM
Cytokines
BMP8B Bone morphogenetic protein 8b 0.32 32.17
CXCL6 Chemokine (C-X-C motif) ligand 6 0.00 7.74
CXCL14 Chemokine (C-X-C motif) ligand 14 0.00 5.74
DKK1 Dickkopf WNT signaling pathway inhibitor 1 0.00 7.49
EFNA3 Ephrin-A3 0.95 16.74
EGF Epidermal growth factor 0.09 10.16
FGF2 Fibroblast growth factor 2 (basic) 0.02 29.35
FGF9 Fibroblast growth factor 9 0.08 15.31
FGF11 Fibroblast growth factor 11 0.48 6.17
FGF13 Fibroblast growth factor 13 0.08 9.04
FGFBP1 Fibroblast growth factor binding protein 1 0.00 28.97
KITLG KIT ligand 0.04 7.48
NDP Norrin (Norrie disease pseudoglioma) 0.00 5.44
NRG1 Neuregulin 1 0.02 5.23
NRG2 Neuregulin 2 0.04 4.59
NRG3 Neuregulin 3 0.00 13.39
PDGFD Platelet derived growth factor D 0.29 6.58
RSPO3 R-spondin 3 0.02 8.90
S100A7 S100 calcium binding protein A7 0.00 4.03
S100P S100 calcium binding protein P 0.00 12.00
SEMA3D Semaphorin 3D 0.00 6.07
SEMA3E Semaphorin 3E 0.13 93.32
SEMA4G Semaphorin 4G 0.16 6.74
SEMA5B Semaphorin 5B 0.03 19.94
SEMA6C Semaphorin 6C 0.68 4.76
SEMA7A Semaphorin 7A 0.26 9.55
SFRP1 Secreted frizzled-related protein 1 0.00 527.58
TGFB3 Transforming growth factor, beta 3 0.07 4.51
Cytokine receptors
AGER Advanced glycosylation end product receptor 0.30 5.01
EPHA6 EPH receptor A6 0.13 25.52
FGFR4 Fibroblast growth factor receptor 4 0.33 3.76
FZD2 Frizzled family receptor 2 0.22 6.18
FZD10 Frizzled family receptor 10 0.00 7.95
IL10RA Interleukin 10 receptor, alpha 0.00 5.91
Lipid mediators
ALOX15B Arachidonate 15-lipoxygenase, type B 0.06 8.03
Lipid receptors
LTB4R2 Leukotriene B4 receptor 2 1.11 3.78
PTGER3 Prostaglandin E receptor 3 (subtype EP3) 0.10 11.87
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The RNA-Seq data summarized in Fig. 5a and Additional
file 3: Datasets S7 and S9 identified 31 genes involved in
the enzymatic generation of lipid mediators and expressed
in ovarian cancer cells and/or TAMs. Figure 5b shows the
data for expression of the corresponding receptor genes
(n = 17). A number of key observations were confirmed by
RT-qPCR analysis of a larger number of clinical samples
(Fig. 5c, d).
We also investigated whether genes expressed at higher
levels in tumor cells or TAMs only from a small subfrac-
tion (n ≥2) of patients participate might also participate in
lipid-mediated signaling pathways. This analysis identified
three genes expressed in tumor cells, i.e. ALOX15B, the
leukotriene B4 receptor gene LTB4R2 and the PGE2 recep-
tor gene PTGER3 (Table 1).
These findings point to a network of lipid mediators
established by both tumor cells and TAMs, involving
several distinct groups of signaling molecules, as described
below.
(i) The first network is based on products of
phospholipid hydrolysis that are generated by
A
C
D E
B F
Fig. 5 Genes coding for components of lipid signaling expressed in ovarian cancer cells and/or TAMs (RNA-Seq). a, b Genes coding for enzymes
involved in the generation lipid mediators and their receptors. Values represent the ratio of expression in tumor cells versus TAMs (median and
95 % CI). Color code as in Fig. 2. Detailed results are summarized in Additional file 3: Datasets S6-S9. c Validation of RNA-Seq data by RT-qPCR of
tumor cell samples (each dot represents a different sample). d RT-qPCR analysis of matched tumor cell and TAM samples from the same patients
(each dot represents a matched pair). Data are represented as the ratio of expression in tumor cells and TAMs. The dotted line indicates a ratio of
1. Data in (c) and (d) were statistically analyzed by Student’s t-test (two-sided, unequal variance). e Concentrations of lipid mediators in the ascites
fluid from ovarian cancer patients determined by LC-MS/MS. Each dot represents a different patient, horizontal lines indicate the median. f Con-
centrations of autotaxin (ENPP2) and PLA2 isoforms in ascites quantified by ELISA
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specific phospholipases (Figs. 5 and 6a). This
conclusion is consistent with the presence of high
levels of LPA, AA, specific A2-type phospholipases
(in particular PLA2G7), and autotaxin in ascites
(Fig. 5f ). TAMs seem to play an essential role in this
context, since they express PLA2G7 and ENPP2 at
higher levels than tumor cells (Fig. 5a, c). Importantly,
the protein levels of 3 phospolipases (PLA2G2,
PLA2G7, and PLA2G12A) measured in ascites fluid
(Fig. 5f) are consistent with mRNA expression levels
in tumor cells and TAMs (Fig. 5a; Additional file 3:
Dataset S6). LPA in ascites apparently targets tumor
cells and TAMs via specific receptors, since LPAR1
and LPAR2 are expressed at similar levels by both
cell types, LPAR3 is selective for tumor cells, LPAR5
and LPAR6 for TAMs (Fig. 5b–d). AA is taken up
by tumor and host cells [56], where it can regulate
signaling pathways, either directly or after metabolic
conversion.
(ii)The second network is established by prostanoids
(Fig. 6b), in particular prostanglandin E2 (PGE2) and
PGI2 (prostacyclin), both found at substantial levels
in ascites (Fig. 5e; 6k-PGF1a is the stable degradation
product of PGI2), as previously described [56]. Most
genes encoding the enzymes required for their
synthesis (cyclooxygenases and prostaglandin
synthases) are expressed at similar levels by both
cells types (PTGS1, PTGES2/3, PTGIS; Fig. 5a, c, d),
whereas PTGS2 is selective for TAMs. A major
target of their products seem to be TAMs, which
express considerable higher levels of the PGE2 and
PGI2 receptor genes PTGER2, PTGER4, and PTGIR
(Fig. 5b, c) with the exception of PTGER3 expressed
only by a small subset of tumor cells (Table 1). In
A
B
Fig. 6 Common lipid signaling in the ovarian cancer microenvironment. a A transcriptome-derived model depicting the cellular origins and targets
(tumor cells, TAMs) of phospholipid degrading enzymes, AA and LPA. b An analogous model for AA-derived eicosanoid mediators and the sources
of enzymes involved in their synthesis. The models are based on the data in Fig. 5a and b. Genes in square brackets are expressed in tumor cells
in small subset of patients (Table 1). The source of ligands is indicated as follows: red for tumor cells, blue for TAMs, and purple for both. Colored
gene names indicate higher expression tumor cells (red) or TAMs (blue). Each receptor is represented by one or more identical symbols according
to their expression levels (as in Fig. 4). [ ]: expressed in subset of patients. Red asterisks denote components associated with a poor clinical out-
come (based on the data in Figs. 7–9). Gene names are explained in Additional file 3: Datasets S8 and S9
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addition, TAMs also show a higher expression of
PPARD (Fig. 5b–d), encoding the nuclear receptor
PPARβ/δ, a possible target for PGI2 [57]. Figure 6b
shows a schematic representation of these results.
(iii)Products of the lipoxygenase pathway, i.e. 5-HETE,
15-HETE and leukotriene A4 (LTA4) represent the
third network (Fig. 6b). These AA metabolites are
present in ascites at readily detectable concentrations
(Fig. 5e; LTB4 is a stable metabolite of the unstable
LTA4). This is consistent with the expression of the
corresponding lipoxygenase (ALOX5), 5-lipoxygenase
activating protein (ALOX5AP), and leukotriene
synthase (LTA4H) genes (Fig. 5a, c) in TAMs. In
contrast, TAMs also preferentially express the LTB4
surface receptor genes LTB4R, LTB4R2, and
CYSLRT1/2. 15-HETE has been described as a
ligand for the nuclear receptors PPARγ [58] and
PPARβ/δ [59], which are both expressed at higher
levels in TAMs (Fig. 5b–d). The gene coding for the
presumptive 5-HETE receptor OXER1 [60] is
expressed at very low levels in both cell types, if at
all (Additional file 3: Dataset S8), suggesting that
5-HETE is more likely to act as a precursor of LTA4
in these cells.
Association of mediator concentrations with clinical
outcome
We next asked whether mediators in the tumor micro-
environment are associated with the clinical outcome of
high-grade serous ovarian carcinoma. We therefore
assessed potential associations of the ascites levels of cy-
tokines and lipids prior to first-line therapy with RFS by
Kaplan–Meier analysis (see Additional file 4: Table S3
for patient-specific clinical features). The logrank p
values depicted in Fig. 7a demonstrate a clear association
of the STAT3-inducing cytokines IL-10, IL-6, and LIF
with early relapse (Fig. 7a–c), with IL-10 being the strongest
indicator of a poor outcome (p <0.0001; logrank hazard ra-
tio [HR] = 4.54; 95 % confidence interval [CI] = 4.56–40.5;
median survival 12.0 versus 26.0 months), which is in
agreement with a previous study of a smaller cohort of
patients [7]. The present study identified inverse associ-
ations with RFS for four additional mediators, i.e.
TGFβ1, PLA2G7, AA, and its metabolite LTB4 (Fig. 7a,
d–g). In contrast, PLA2G12A, autotaxin, and the PLA2/
autotaxin product LPA did not show any correlation
(Fig. 7a). Likewise, the AA metabolites PGE2, PGI2, 5-
HETE, and 15-HETE, also components of the lipid sig-
naling network identified above, were not linked to RFS.
The relevance of these cytokines and AA as indicators
of an adverse clinical outcome became particularly evi-
dent when we determined the RFS for combinations of
these mediators. Thus, patients with a high level of ei-
ther IL-10 and AA, IL-6 and AA, or TGFβ and AA
showed a clearly worse outcome compared to those with
a high concentration for only one mediator (red versus
gray curves in Fig. 8a–c; p = 0.016 for IL-10; p <0.0001
for IL-6; p = 0.0002 for TGFβ). For IL-10, a similar dif-
ference was observed between patients showing a high
concentration for either IL-10 or AA versus those with
low levels of both mediators (Fig. 8a; p = 0.0045). A simi-
lar analysis for the other two cytokines was not possible
due to an insufficient number of cases in the “both low”
group. A striking association was observed when patients
were compared with high IL-10 and high AA levels to
those with low concentrations of both mediators (Fig. 8a;
p <0.0001; logrank HR = 9.50; 95 % CI = 4.38–47.3; me-
dian survival 12.0 versus >34 months).
Pearson analysis revealed low correlation coefficients
(r) when cytokine levels were compared to lipid concentra-
tions (Fig. 8d), indicating that the observed clinical associa-
tions are not simply a consequence of their co-synthesis.
Likewise, the concentrations of AA did not correlate with
any of the AA metabolites tested. In contrast, IL-6 and LIF
levels were highly correlated (R = 0.87), pointing to com-
mon regulatory pathways.
Association of gene expression levels with clinical
outcome
Finally, we sought to establish clinical correlations with
components of the common signaling network estab-
lished above (Fig. 4). Toward this end, we made use of
published microarray results for 1018 high-grade serous
ovarian cancer patients with documented RFS [38]. The
samples used for these analyses were derived from solid
tumor masses and therefore contained variable amounts
of host-derived cells, including TAMs, as confirmed by
the large range of expression values observed for macro-
phage marker genes across this cohort. Kaplan–Meier
analysis for these genes actually showed a clear association
of RFS with the expression of these genes (Additional
file 2: Figure S4), presumably reflecting the known ad-
verse effect of TAM infiltration on the clinical outcome.
In addition, this scenario means that genes not primarily
expressed in tumor cells cannot be faithfully analyzed,
since it is not possible to separate effects of gene expres-
sion from host cell “contamination” in the sample and
the algorithm developed in the present study for RNA-
Seq cannot be applied to microarrays.
We therefore decided to focus our survival analysis on
genes expressed at a higher level in tumor cells relative
to TAMs (i.e. more than twofold in Fig. 2). We identified
multiple mediator and receptor genes that are clearly
(p <0.01) associated with a shorter RFS (red in Fig. 9a, b),
consistent with their established or suspected functions in
tumor progression. These include the cytokine genes
CCL28, IGF2, SEMA5A, and WNT11, and the receptor
genes EPHB2, ERBB2 and 3, FGFR2, ITGB1, LRP12 as
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well as NPR1 and 3 (Fig. 9a, b). We also found a surpris-
ing association of a favorable clinical outcome with
WNT receptor frizzled 4 (FZD4) gene expression
(Fig. 9a). We performed an analogous survival analysis
for genes associated with lipid signaling and expressed
at higher levels by tumor cells relative to TAMs (right-
most genes in Fig. 9a, b), based on the data in Fig. 5a
and b. A particularly strong association with an adverse
clinical outcome was observed for PTGIS (p = 0.0005),
which codes for prostaglandin I2 (prostacyclin) synthase
(Fig. 6b).
Finally, we performed Kaplan–Meier analyses (Fig. 9d–g)
of genes expressed only in small subgroups of our patients
(Table 1). A very strong adverse effect on RFS (p = 0.0001)
was seen with TGFB3 (Fig. 9c, d), in line with the cen-
tral role of the associated signaling pathways in cancer,
and with PTGER3 (Fig. 9c, e; p <0.0001), encoding a
prostaglandin E2 receptor (Fig. 6b). Strong associations
with poor RFS (p <0.001) were also seen with PDGFD
and SEMA6C. However, the most intriguing finding
was the identification of NDP as a powerful indicator of
a favorable clinical course (p <0.0001; Fig. 9c, f ). NDP
A
B C
E F
D
G
Fig. 7 Association of RFS with the levels of cytokines and lipid mediators in ovarian carcinoma ascites. a Summary of RFS analyses showing the
p values determined by Mantel-Cox log rank test. Patients were dichotomized into high and low expressing groups according to the following
quantiles (best-fit) and number or patients: IL-10, Q = 0.66 (n = 36); IL-6, Q = 0.5 (n = 39); TGFβ1, Q = 0.25 (n = 39); AA, Q = 0.25 (n = 38); LTB4,
Q = 0.25 (n = 38); PLA2G7, Q = 0.33 (n = 33). Significant instances with a HR >1 are shown in red; grey bars indicate lack of significant associations.
Significance was defined as logrank p <0.05 and p < Benjamini-Hochberg critical value for false discovery rate (FDR) = 0.10. b–g Kaplan–Meier plots
showing the RFS of patients with high or low ascites levels (best-fit) of IL-10, IL-6, TGFβ1, PLA2G7, AA, and LTB4 (see “Methods” for details)
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codes for norrin, which interacts with the receptor
frizzled 4 [55, 61] and TSPAN12, a signal-amplifying
component of the norrin–frizzled 4 complex [55]. This
presumably explains the strong association of FZD4
with RFS (p = 0.0004; Fig. 9g) described above. Further-
more, TSPAN12 was also inversely associated with RFS
(p = 0.0343; Fig. 9h). Taken together, these findings provide
strong evidence for novel tumor suppressor function of
norrin–frizzled 4–TSPAN12 signaling in ovarian cancer.
Discussion
We have defined a tumor cell and macrophage-driven
signaling network operating within the environment of
ovarian cancer-associated carcinomatosis involving inter-
leukins, chemokines, members of the TGFβ, WNT,
S100, semaphorin and ephrin families, the phospholipid
breakdown products LPA, and AA as well as AA metab-
olites. This network is composed of mostly common,
but also patient-specific mediators and receptors and in-
cludes pathways previously not identified in the context
of ovarian cancer or intercellular signaling in the tumor
microenvironment (Figs. 4 and 6). We will discuss these
pathways in the following sections, in particular with re-
spect to their association with disease progression after
first-line therapy.
STAT3-inducing cytokines
In agreement with the established function of deregu-
lated STAT3 in ovarian cancer [62], IL-10, IL-6, and LIF
were confirmed as components of the signaling network
established by tumor cells and TAMs (Figs. 3–5). Their
cellular origins and target cells clearly support a pivotal
role for TAMs within this network, since these cells are
the main producers of IL-10, a major source of IL-6 and
the predominant target of IL-10, which presumably plays
an important role in their protumorigenic conversion.
Expression of LIF and its receptor are higher in tumor
cells, pointing to a function for this cytokine beyond
its proposed function in TAM polarization [18]. The
pathways triggered by these cytokines are also directly
relevant to progression of the disease as shown by the in-
verse association of their ascites levels (Fig. 7) with RFS,
consistent with previous studies [7, 63, 64]. Taken to-
gether, these data clearly confirm a critical role for
cytokine-mediated STAT3 deregulation in ovarian cancer
by exerting pro-tumorigenic effects on both tumor cells
and macrophages and its potential as a drug target [65].
TGFβ family
Multiple TGFβ family members have previously been as-
sociated with ovarian cancer [19, 25, 66]. In agreement
A
B
C
D
Fig. 8 Synergistic association of RFS with the levels of AA and cytokines in ovarian carcinoma ascites. a–c Patients were trichotomized for RFS
analysis, using the best fit thresholds determined in Fig. 7: group 1, cytokine and AA high; group 2, one high/one low; group 3, both low. See
“Methods” for details. d Pearson correlation matrix for soluble mediators in ovarian cancer ascites shown to be of particular relevance in the
present study. The heatmap depicts different levels of positive correlation (red: high, yellow: low, corresponding to a range of R = 0.5–1.0)
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with this established knowledge, we identified several
components of this signaling system as important con-
stituents of the ovarian cancer microenvironment, with
both tumor cells and TAMs as essential contributors
(Fig. 4b). This conclusion is strongly supported by the
observed clinical correlations. Thus, the ascites concen-
tration of TGFβ1, mainly produced by TAMs, was asso-
ciated with early relapse (Fig. 7). A similar adverse link
was observed between RFS and the expression of TGFB2
and TGFB3 genes by tumor cells, with the latter repre-
senting one of the strongest indicators of a poor clinical
outcome (Fig. 9c, d). These observations are fully com-
patible with the known functions of TGFβ ligands in
tumor progression [67] and immune suppression [68], as
well as the adverse effect of TGFBR2 and phosphory-
lated SMAD2/3 on survival [66]. Previous studies have
also associated BMP2 and BMP4 with ovarian cancer,
both of which are expressed at extremely low levels in
tumor cells and TAMs (Additional file 3: Dataset S2),
which may be explained by the previous identification of
ovarian cancer-associated mesenchymal stem cells as a
major source of these cytokines [69].
Frizzled-mediated signaling
WNT signaling is another major signaling mechanism
identified in the present study (Fig. 4c). Seven genes en-
coding inducers of canonical and/or non-canonical
WNT signaling [52], most of which were found to be
preferentially expressed by tumor cells. Non-canonical
WNT signaling is induced by WNT interaction with
FZD without involvement of LRP coreceptors and trig-
gers a calcineurin-NFAT pathway. The expression of at
least seven FZD genes strongly suggests that the non-
canonical pathway is operational. The canonical pathway
depends on both FZD and LRP proteins and stimulates
β-catenin signaling. Nine LRP genes are expressed by
tumor cells and/or TAMs (Fig. 4c), suggesting that the
canonical pathway is functional in both cell types and
utilizes cell type-specific receptors. Importantly, we
found a strong inverse association of WNT11 expression
A
D
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Fig. 9 Association of RFS with the expression of genes coding cytokines, growth factors, and lipid mediators or their receptors. Panels (a)–(c)
represent summaries of RFS analyses for 1018 serous ovarian carcinoma patients depicting the results of logrank P tests and the directions of the
respective hazard ratio (HR), using the KM plotter database [38]. a, b Survival analysis for genes in Fig. 2 with an expression ratio (tumor cell/TAM) >0.3.
Genes missing from the microarray datasets used by KM Plotter were not included in panels (a)–(c). Significant instances (for “JetSet best
probe”) are shown in red (HR >1) or green (HR <1); gray bars indicate lack of significant associations (p ≥0.5) or p > Benjamini-Hochberg critical
value for FDR = 0.10. Significance was determines as in Fig. 8. c Survival analysis as before, but for genes expressed only in small subgroups of
patients (see Table 1 and Additional file 3: Dataset S1 ). d–h Kaplan–Meier plots analyzing the RFS of patients with high or low levels of TGFB3,
PTGER3, NDP, or TSPAN12A expression. See “Methods” for details
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with RFS (Fig. 9a), and also confirmed the previously de-
scribed [70] correlation of WNT7A expression with a
poor clinical outcome (Fig. 9a).
R-spondins (RSPO) and their receptor LGR5 are re-
quired for optimal canonical WNT signaling [22], but
expression was insignificant in all samples (LGR5; Add-
itional file 3: Dataset S3) or was found in tumor cells
from a subset of patients only (RSPO genes; Table 1).
Since LGR5 has been identified as a stem-cell specific
gene in ovarian epithelial cells in mice [21], this pathway
may be restricted to tumor cells with stem-like proper-
ties, although the role of LGR5 in human ovarian epithe-
lial cells is unclear.
We also found tumor cell selective expression of the
NDP, FZD4, and TSPAN12 genes (Fig. 4c, f, g), encoding
norrin, its receptor frizzled 4, and a norrin signal-
amplifying component of the receptor complex, respect-
ively [55], which were linked to colon cancer angiogen-
esis in a recent study [61]. Intriguingly, we identified
NDP, FZD4, and TSPAN12 to be associated with a de-
layed tumor progression, thus pointing to a novel tumor
suppressor function of this signaling pathway in ovarian
cancer. This finding is puzzling, since norrin shares with
canonical WNT ligands the ability to induce β-catenin,
generally considered a pro-tumorigenic pathway. In view
of the currently very limited knowledge on norrin-
mediated signaling, the mechanism underlying a putative
function in tumor suppression remains elusive and may
involve hitherto unidentified signal transduction events.
S100 family
S100 proteins play essential roles in tumor growth and
progression, chemoresistance, and immune modulation
[53]. Several S100 members are secreted or otherwise re-
leased in the extracellular space and interact with sur-
face receptors, including the advanced glycation end
products receptor RAGE (AGER), scavenger receptors
(MSR1, SCARA/B gene products, CD36), EGF family re-
ceptors and toll-like receptor 4 (TLR4), and stimulate
multiple signaling transduction pathways, including
NFκB and MAP kinases [53]. Our data show that several
S100 genes, i.e. S100A4, S100A6, S100A10, S100A8, and
S100A9, are expressed at very high levels in both tumor
cells and TAMs (Fig. 4d). Furthermore, multiple recep-
tors interacting with different S100 proteins or S100A8/
A9 heterodimers are expressed by both tumor cells and
TAMs (SCARA/B, CD36), preferentially by TAMs
(AGER, MSR1, TLR4) or by tumor cells (ERBB2), point-
ing to extensive functional interactions between both
cell types. Surprisingly, none of the S100 genes showed
an association with early relapse (Fig. 9b), which is in
line with the lack of literature data supporting a role for
S100 proteins in the clinical progression of ovarian
cancer.
Semaphorins and ephrins
Semaphorins and ephrins, originally identified as axon
guidance molecules, also have essential physiological
functions during organ development, angiogenesis, and
immune regulation [71–73]. More recently, their in-
volvement in cancer cell migration, invasion, and metas-
tasis has been uncovered, but is currently only partially
understood. Activation of plexins by semaphorins results
in the transactivation of oncogenic receptor tyrosine ki-
nases, including MET, ERBB2, and KDR [73, 74]. Indi-
vidual family members can be associated with either
stimulatory or inhibitory effects on tumorigenesis and
angiogenesis. For instance, a potential role in suppres-
sion of malignant melanoma has been described for
PLXNB1 [75], while cooperation with ERBB2 and a pro-
metastatic role was reported for breast cancer cells [76].
We have identified multiple genes encoding components
of both semaphorin and ephrin signaling in both tumor
cells and TAMs, i.e. 13 semaphorins and at least six cog-
nate receptors, as well as six ephrin members and seven
receptors. These findings point to a complex signaling
network established by tumor cells and TAMs (Fig. 4e),
involving both autocrine and paracrine signaling mecha-
nisms, as well as cell type-selective expression of ligands
and receptors. Five of these genes, SEMA3C, 3 F, 5A, 6A
and in particular 6C, are associated with early relapse
(Fig. 9a and c). Likewise, four ephrin receptor genes
(EPHA1, EPHA4, EPHB2, EPHB4) showed an adverse
clinical association (Fig. 9b). Our findings therefore
strongly support a tumor-promoting role for axon guid-
ance ligands and their receptor in ovarian cancer. As
these are expressed by tumor cells as well as TAMs, it is
likely that both cell types play a role in this context.
Chemokines
Chemokines are produced by and target tumor and
tumor-associated host cells through a large number of
ligand-selective surface receptors, thereby establishing a
large intercellular signaling network. These include TAMs
[77], but their precise integration into the microenviron-
ment of a human cancer has not been established. Our
data support an essential role of TAMs within the chemo-
kine network, since they express 11 CCLmembers (Fig. 2a)
and three CCR receptors (Fig. 2b), of which two (CCL2
and CCL5) are also expressed by tumor cells. TAMs also
play an important role as producers of ten different che-
mokines of the CXCL family (Fig. 2a), but express only
two CXCR receptor genes. One of these is CXCR4, thus
confirming the prosed role of the CXCL12–CXCR4 axis
in the progression of many tumor types [78], including
ovarian cancer [54]. Since chemokines mainly address
other cell types, in particular T-cells, the lack of expres-
sion of other CXCR genes in tumor cells and TAMs is
conceivable.
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Phospholipid breakdown products
Tumor cell and TAMs express multiple genes for se-
creted phospholipases, with PLA2G7, preferentially
expressed by TAMs, as the major subtype (Fig. 5a). Intri-
guingly, PLA2G7 ascites levels are associated with a
short RFS (Fig. 7a, e), indicating a clinical relevance for
the phospholipid breakdown products. These include
LPA, generated from lysophospholipids by autotaxin,
and PUFAs. Our survival analyses did not show any sig-
nificant correlation of LPA or autotaxin levels in ascites
with the clinical outcome (Fig. 7a). However, the former
result must be considered with some caution, since LPA
represents a mixture of several compounds with differ-
ent fatty acids in the sn1 position. It has been shown
that different LPA species can exert different biological
effects, which may be obscured when these are collectively
quantified. Furthermore, according to the manufacturer,
the antibody used for this analysis (ELISA) recognizes the
minor forms (e.g. linolenic 18:3 LPA) with a higher affinity
compared to the more common LPA species (e.g. oleic
18:1 LPA). The relevance of LPA as a potential indicator
of early ovarian cancer relapse has therefore to be re-
evaluated in future studies using methods that are able to
discriminate different LPA species.
On the other hand, a clear inverse association with
RFS was observed for AA (Figs. 4, 7a, f ). The clinical
relevance of AA is strongly supported by our finding
that the adverse effect of cytokines, like IL-6, IL-10, and
TGFβ were enhanced by the simultaneous presence of
high AA levels, pointing to a hitherto unknown cooper-
ation in causing therapy failure and disease progression.
Importantly, AA concentrations did not show any sig-
nificant correlation with IL-6, IL-10, or TGFβ (Fig. 8d),
excluding the possibility that the observed clinical corre-
lations are due to a common mechanism regulating the
synthesis of these mediators.
Arachidonic acid metabolites
AA is metabolized to a number of highly bioactive eicos-
anoid derivatives, in particular cyclooxygenase-derived
prostanoids and lipoxygenase-derived HETEs and leuko-
trienes. In ovarian cancer, several components of these
pathways are present in ascites, and the required en-
zymes are expressed by both tumor cells and TAMs
(Fig. 6b). These mediators seem to act primarily on
TAMs, including PGE2, PGI2, and 15-HETE, as judged
by the expression of their cognate receptors. An excep-
tion was LTB4 with receptors on both cell types. A clin-
ical relevance of these mediators is suggested by the
observed inverse associations of RFS with the ascites
levels of LTB4 (Figs. 4, 7a, g) and the expression of the
PTGIS and PTGER3 genes (Figs. 4, 9b, e), encoding PGI2
synthase and a PGE2 receptor, respectively (Fig. 6b).
These findings could, at least in part, explain the adverse
effect of AA on survival, i.e. by serving as a precursor of
pro-tumorigenic metabolites.
It can, however, not be excluded that non-metabolized
AA contributes to this effect. We have recently shown
that PPARβ/δ, which is expressed preferentially in TAMs
(Fig. 2b), is deregulated by PUFA ligands in ovarian can-
cer ascites [56]. It is, however, very unlikely that PPARβ/
δ mediates the adverse effect of AA on RFS, because the
major ascites-associated PUFA with strong agonistic ef-
fect on PPARβ/δ is linoleic acid [56], which, in turn, is
not linked to survival at all (Fig. 7a). Even though other
targets for non-metabolized AA have been identified
[79–82], AA-triggered signaling is poorly understood,
making it difficult to speculate on the molecular mech-
anism underlying the clinical effect discovered in the
present study.
Conclusions
In spite of the clearly documented pivotal role of the
tumor microenvironment in tumor growth, progression,
and immune escape, the reciprocal interactions of tumor
and host cells through soluble mediators are only par-
tially understood. In the present study we have estab-
lished a global RNA-Seq based strategy to address this
problem using tumor cells and TAMs from ovarian car-
cinoma ascites. As a first step, we developed an algo-
rithm to adjust sequencing data for the presence of
contaminating cells in the samples analyzed, i.e. macro-
phages in tumor cell fractions or vice versa. After
optimization on training datasets the algorithm was suc-
cessfully applied to the ovarian cancer samples used in
the present study, indicating that the method should be
generally applicable to tackle the problem of contamin-
ating cells in RNA-Seq samples.
Taken together, our observations suggest that the strat-
egy used in the present work is a generally applicable ap-
proach to address complex interactions in the tumor
microenvironment. These include several important
questions not addressed by the current study. First, it is
possible that we missed clinically relevant genes, because
of the necessity to exclude genes expressed at high levels
in TAMs from our survival analysis. Thus, survival-
associated receptor genes expressed primarily in TAMs
would not have been found. Future sufficiently large
RNA-Seq studies of pure cell types or single cells in con-
junction with survival analyses will have to answer this
question. Second, host cells other than TAMs are clearly
important constituents of the tumor microenvironment,
but their role within a signaling network are even less
understood. In ascites these are primarily other immune
cells and mesothelial cells, while fibroblasts and endo-
thelial cells are rare or absent. Thus, the integration of T
cells into the signaling network operating among the
ascites-associated cells will be an important next step.
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Third, it is unknown how ascites-associated tumor and
host cells differ from their counterparts in solid tumor
masses. Purification of cells from metastases of the same
patients could be used to address this question, and also
to analyze the contribution of host-derived cell types re-
stricted to solid tumor tissue.
Methods
Patient samples
Ascites was collected from patients with high grade ser-
ous ovarian carcinoma undergoing primary surgery at
the University Hospital in Marburg. Written informed
consent for the use of ascites for research purposes and
publication of the results obtained from this research
was obtained from all patients prior to surgery according
to the protocols approved by the ethics committee of
Marburg University (Az 205/10). Patient characteristics
are presented in Additional file 4: Tables S1 and S3.
Clinical courses were evaluated by RECIST criteria [83]
in patients with measurable disease or profiles of serum
CA125 levels [84], according to the recommendations by
the Gynecologic Cancer InterGroup (GCIG). Only patients
with observations periods ≥12 months after first-line sur-
gery were included in the survival analysis. All experimental
methods comply with the Helsinki Declaration.
Isolation of TAMs from ovarian cancer ascites
Mononuclear cells were isolated from ascites by Lympho-
cyte Separation Medium 1077 (PromoCell) density gradi-
ent centrifugation and further purified by magnetic cell
sorting (MACS) using CD14 microbeads (Miltenyi Bio-
tech). TAMs were directly analyzed by FACS as described
below or lysed in PeqGold (Peqlab) for RNA preparation.
Tumor cell/spheroid isolation from ascites
Mononuclear cells were isolated from ascites by Lympho-
cyte Separation Medium 1077 (PromoCell) density gradient
centrifugation. Tumor spheroids were separated by filtra-
tion using 30 μm and 40 μm cell strainer (Miltenyi Bio-
tech) resulting in either spheroids of medium size (30–40
μm= “m”) or large size (>40 μm= “L”). Small tumor
spheroids (<30 μm= “s”) and tumor single cells (sc) were
further purified by depletion of peritoneal leucocytes using
CD45 microbeads and magnetic cell sorting (MACS) (Mil-
tenyi Biotech). Purified tumor cells were lysed in PeqGold
(Peqlab) for RNA preparation, analyzed by flow cytometry,
or cultured for testing of chemoresistance. The purity of
tumor spheroids/cells was >90 % EpCAM+ cells, except
for sample OC84s (>85 %, Additional file 4: Table S2).
Characterization of tumor cells/spheroids by flow
cytometry
Prior to FACS staining, tumor spheroids were dissoci-
ated into single cells by trypsination for 10 min at 37 °C,
followed by vortexing for 10 s. To analyze cell cycle dis-
tribution, tumor single cells were fixed in 70 % ice-cold
ethanol, washed with PBS + 2 % FCS, and treated with
100 μL RNAse (1 mg/mL) at 37 °C for 20 min. Cells
were stained with 10 μL propidium iodide (1 mg/mL)
for 30 min. FACS analysis was performed on a FACS
Canto II instrument using Diva Software (BD Biosci-
ences). Proliferation was analyzed by FACS after staining
tumor single cells with anti-Ki67 PEVio770, anti-CD45
FITC, and anti-EpCAM PE antibodies (all Miltenyi
Biotech).
Flow cytometry analysis of ascites-associated cells
Gene expression profiles generated from RNA-Seq data-
sets were verified in TAMs and tumor cells by FACS
analysis. Mononuclear cells from patients’ ascites were
simultaneously stained with Vioblue-labeled anti-human
EpCAM (Miltenyi Biotech) as tumor marker and FITC-
labeled anti-CD14 (Miltenyi Biotech), PE-labeled anti-
CD163 (eBioscience), or APC-labeled anti-CD206 (Biozol)
as TAM marker. In addition, FITC-labeled anti-TGFbeta
RIII and PE-labeled anti-LIF-R (all R&D Systems) were
used for surface staining. Intracellular staining of perme-
abilized cells was performed with APC-labeled anti-IL-8
(eBioscience), FITC-labeled anti-S100A8/A9 (Life Tech-
nologies) and FITC-labeled anti-S100A14 (antibodies-
online) as described previously [7]. Isotype control
antibodies were purchased from BD Biosciences, Mil-
tenyi Biotech, and eBioscience. Cells were analyzed by
flow cytometry and results were calculated as percent-
age of positive cells and mean fluorescence intensities
(MFI).
In vitro testing of chemoresistance
Tumor spheroids or single cells from patients were
cultured in M199 media (Life Technologies) plus 10 %
autologous, cell-free ascites with or without 10 μM car-
boplatin (Sigma Aldrich) and 10 nM paclitaxel (Adipo-
Gen) at 37 °C, 5 % CO2 (approximately 2.5–5 × 10
5
cells/mL). After 6 days, the 3-[4,5-dimethylthiazol-2-yl]-
2,5-diphenyl tetrazoliumbromid (MTT) assay was per-
formed to assess cell viability as described previously
[85]. The percentage of chemoresistant tumor cells in
the carboplatin/paclitaxel treated culture was calculated
relative to cells treated with solvent control (DMSO).
Analysis of soluble mediators in cell-free ascites
Soluble mediators in ascites of ovarian cancer patients
were quantified using commercial ELISA Kits according
to the instructions of the manufacturers. Human IL-6,
IL-10, LIF, VEGF-A, CCL-2, and TGFβ1 levels in ascites
were analyzed by ELISA kits purchased from
eBioscience. ANGPTL4 levels were determined using
ELISA kit from Aviscera Bioscience, leptin by ELISA Kit
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from RayBiotech and LPA by ELISA kit from Echelon.
The phospholipase A2, Group XIIA (PLA2G12A) ELISA
Kit was from antibodies-online, the PLA2G2A ELISA kit
from Biozol, and the ENPP-2/Autotaxin, CSF-1, S100A8,
and PLA2G7 ELISAs from R&D Systems.
Quantification of lipids by liquid chromatography -
tandem mass spectrometry (LC-MS/MS)
Ascites samples (1 mL) were spiked with 100 μL deuter-
ated internal standard and extracted using solid reverse
phase extraction columns (Strata-X 33, Phenomenex).
Fatty acids derivatives were eluted into 1.0 mL of metha-
nol, lyophilized, and resuspended in 100 mL of water/
acetonitrile/formic acid (70:30:0.02, v/v/v; solvent A) and
analyzed by LC-MS/MS on an Agilent 1290 separation
system. Samples were separated on a Synergi reverse-
phase C18 column (2.1 × 250 mm; Phenomenex) using a
gradient as follows: flow rate = 0.3 μL/min, 1 min (aceto-
nitrile/isopropyl alcohol, 50:50, v/v; solvent B), 3 min (25
% solvent B), 11 min (45 % solvent B), 13 min (60 %
solvent B), 18 min (75 % solvent B), 18.5 min (90 % solv-
ent B), 20 min (90 % solvent B), 21 min (0 % solvent).
The separation system was coupled to an electrospray
interface of a QTrap 5500 mass spectrometer (AB
Sciex). Compounds were detected in scheduled multiple
reaction monitoring mode. For quantification a 12-point
calibration curve for each analyte was used. Data analysis
was performed using Analyst (v1.6.1) and MultiQuant
(v2.1.1) (AB Sciex).
RT-qPCR and RNA-Seq
cDNA isolation and qPCR analyses were performed as
described [86], using L27 for normalization and evalu-
ated by the Cy0 method [87]. Primer sequences are
listed in Additional file 4: Table S5. RNA-Seq was carried
out on an Illumina HiSeq 1500 as described [85]. Sum-
marized read counts are shown in Additional file 3:
Dataset S1. Genome assembly and gene model data were
retrieved from Ensembl revision 74.
Sequencing data availability
Sequencing data were deposited at EBI ArrayExpress
(accession numbers E-MTAB-3167 and E-MTAB-4162).
Bioinformatic analysis of RNA-Seq data
RNA-Seq data were aligned to Ensembl v74 using STAR
(version STAR_2.4.1a) [88]. Gene read counts were
established as read count within merged exons of pro-
tein coding transcripts (for genes with a protein gene
product) or within merged exons of all transcripts (for
non-coding genes). TPM (transcripts per million) were
calculated based on the total gene read counts and
length of merged exons. Genes were considered
expressed if they had a minimum TPM of 3. All genomic
sequence and gene annotation data were retrieved from
Ensembl release 74, genome assembly hg19. Our full
analysis scripts and computational pipeline are available
upon request.
Adjustment of RNA-Seq data for contaminating cells
The development and testing of our algorithm, including
benchmarking against other published algorithms, are
described in detail in Additional files 1 and 5.
Simulations for Fig. 1a were performed 12,000 times
on data retrieved from GSE60424 [51]. The dataset con-
sists of highly purified immune cells from patients with
various autoimmune diseases. Samples annotated “whole
blood” and sample lib264 were excluded, as the latter
showed monocyte contamination. Mixtures were calcu-
lated by resampling the larger sample to the size of the
smaller one and mixing at a chosen percentage. Refer-
ence expressions were calculated from all non-mixed
samples of the respective tissues. Contamination estima-
tion and correction was performed as described in detail
in Additional file 1.
OC66s, TAM72, and TAT31 were used as reference
samples for pure tumor cell, TAM, and TAT popula-
tions, respectively (see Fig. 1b, c). The automated pro-
cedure selected the following marker genes for adjusting
tumor cell datasets:
TAM marker genes: AIF1, C1QB, C1QC, CCR1, CD36,
CMKLR1, CR1, FCGR2A, FCGR3B, FPR3, ITGAM,
MARCO, MPEG1, MRC1L1, STAB1, TLR4, VCAN.
TAT marker genes: ATP2A3, C16orf54, CCR4, CCR7,
CD2, CD247, CD3E, CD96, GZMK, IL2RB, IL2RG,
KCNA3, LEF1, NKG7, PRF1, RHOH, ZNF831.
For adjusting TAM datasets the following marker
genes were selected:
Tumor cell marker genes: ASS1, CDH1, CLDN4,
CT45A1, CT45A3, CT45A4, CT45A5, DSP, EPCAM,
ESRP1, IGFBP3, KRT7, LRP6, MEIS1, PRAME, SLPI,
VTCN1.
TAT marker genes: ATP2A3, CAMK4, CCR4, CD8A,
CD8B, CST7, KCNA3, KLF12, LCK, LIME1, MT1X,
NKG7, PRF1, RHOH, RLTPR, TCF7, TGFBR3.
The source code for implementing our algorithm and
the simulations described in the present study are in-
cluded as Additional file 6 and deposited at GitHib
(https://github.com/IMTMarburg/rnaseqmixture) and
Zonodo (doi:10.5281/zenodo.48872).
Statistical analysis of experimental data
Comparative data were statistically analyzed by Student’s
t-test (two-sided, unequal variance) using GraphPad
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Prism 6.0. Results were expressed as follows: *p <0.05;
**p <0.01; ***p <0.001; ****p <0.0001. CIs were calculated
using the bootstrap method.
Survival-associated gene expression analysis
Associations between gene expression and relapse-free
survival of ovarian cancer patients were analyzed using
the web based tool “KM Plotter” [38] (http://kmplot.com)
with the following settings: “auto select best cutoff,” probe
set option: “JetSet best probe,” histology: serous, datasets:
all; other settings: default). The 2015 version of KM
Plotter used contains the following 13 datasets: GSE14764
(n = 80), GSE15622 (n = 36), GSE18520 (n = 63), GSE19829
(n = 28), GSE23554 (n = 28), GSE26193 (n = 107), GSE26712
(n = 195), GSE27651 (n = 49), GSE30161 (n = 58), GSE3149
(n = 116), GSE51373 (n = 28), GSE9891 (n = 285), TCGA
(n = 565). The GraphPad Prism software was used to
analyze associations of soluble mediator concentrations
in ascites fluid with RFS (Kaplan-Meier plots, logrank p
values, logrank HR, and median survival times). Multiple
hypothesis testing was accounted for out by controlling
the FDR using the Benjamini-Hochberg method.
Additional files
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benchmarking against published methods. (PDF 5117 kb)
Additional file 2: Supplementary Figures S1–S4. (PDF 946 kb)
Additional file 3: Datasets S1–S7. (XLS 26437 kb)
Additional file 4: Supplementary Table S1–S5. (XLS 48 kb)
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Additional file 6: Assembly of gene sets. (PDF 200 kb)
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Algorithms for deconvoluting different cell types from expression data sets: 
applicability to the adjustment of RNA-Seq data of ovarian cancer associated cells 
Background 
Enrichment of specific cell types from ovarian cancer associated ascites is often faced with the 
problem of other “contaminating” cell types. Determining such contaminations from gene 
expression profiles in silico is a well-established problem commonly referred to as 
'”deconvolution” (see a recent review of available algorithms [1]). Once the composition of a 
sample has been established, a correction against the contamination can be implemented. 
We found that none of the available algorithms is suitable for our specific conditions:  
(i) we are dealing with RNA-Seq data, while many older algorithms have been established on 
micro array data,  
(ii) we have a relatively small number of samples to correct and learn from,  
(iii) our datasets reflect two or three cell types involved, which are highly dissimilar,  
(iv) there is no prior knowledge of appropriate marker genes (since TAMs are not canonically 
activated macrophages,  
(v) the profile of tumor cells in ascites was undetermined prior to the present study, and 
(vi) we require both an estimate of the contamination and a correction of expression gene 
profiles. 
Description of algorithm  
Our chosen approach is mathematically straightforward: Starting with two pure reference 
samples representing the cell type of interest ("target") and the contaminating cell type we 
select a set of suitable contamination marker genes, use these to estimate the extent of 
contamination and then adjust the target dataset by a linear model. The purity of reference 
samples must be determined by other methods, e.g. microscopy or flow cytometry. 
Potential marker genes are defined as genes with (i) at least a three fold change between 
target and contaminating cell types and (ii) a maximum expression of 10 TPM in non-target 
cell types. These candidates are ranked by fold change, the top j are skipped (see below) and 
a fixed number is chosen. 
Expression of marker genes is modeled as !!"#$%&$'! ! !!!"#$%&'#%$'"#! ! !!! ! !!!"#$%!! ! !!! ! !! 
 with !!  being gene expression in TPM and !  the contamination percentage of a single 
contamination. We replace !!"#$%! ! ! ! ! !  with the expression in our target cell type 
reference sample (!!"#"!"$%" ), thereby introducing a slight bias to underestimate the 
contamination percentage. Note that for marker genes, !!"#$%! is less than 10 TPM, while !!"#$%&'#%$'"# is typically much larger. An underestimation of the contamination keeps our 
correction conservative, preventing too harsh a correction. 
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Our final estimation (!) is the median of  
!! ! ! !!!"#$%&$' ! !!!"#"!"$%!!!!!!"#$%&'#%$'"#  ! smaller than 0 is replaced by 0, ! >1.0 is rejected. 
To correct, for each gene we replace !!"#$%&!! with  !!!!"##$!%$& ! ! !!!"#$%&$'! ! !!! ! !!!"#$%&'#%$'"#!!!!!! ! !!!  
thereby rescaling to TPM. 
To extend the approach to a three-cell line setting, we estimate contamination percentages for 
each cell type independently using disjunct mark sets and replace !!"#$%&$' with  !!!"##$!%$& ! !!!!"#$%&$'! ! !!!! ! !!!"#$%&'#%$'"#!! ! !!!! ! !!!"#$%&'#%$'"#!!!!! ! !!!! ! !!! !! 
Implausible results (!!! ! !!!! ! !!!!) are rejected. 
Estimation of nuisance parameters 
The algorithm has two nuisance parameters, the number of genes to choose (k), and the 
number of ranks to skip (j). Nuisance parameters were optimized in a simulation setting with 
1,000 repetitions per parameter value. Monocyte samples (contamination) from GSE60424 
(Table 1) were mixed with samples from other blood cells (target) at randomized percentages. 
One monocyte and one target sample (not part of the mixture) were chosen as reference. It 
was found that no straightforward correlation between the nuisance parameters and the 
accuracy of the algorithm exists (Figure 1). 
 
Table 1: Samples in dataset GSE60424 
Tissue Sample count Comment 
B-Cells 20  
CD4 20  
CD8 19 Sample lib264 omitted due to monocyte signal 
NK    14  
Monocytes 20  
Neutrophils  20  
Whole blood 20  
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Figure 1: Parameter sweep. Shown is the change in mean absolute error between (corrected) 
mixture TPM and ground truth. We performed 500 simulations per data point. Blue: values 
chosen for correction in the main paper. 
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Evaluation of algorithms 
We evaluated algorithms in a simulation setting, in which arbitrary percentages of randomly 
chosen samples of different tissues were mixed. Different samples from the same tissue were 
chosen as references. Two RNA-Seq data sets of different tissues were used: the large Gene 
Tissue-Expression (GTEx) dataset [2] (Table 2), and E-MTAB-2836 [3], a smaller dataset that 
includes immune related tissue (Table 3). Simulations were run 10,000 times. 
Table 2: Tissues in GTExdataset  
(retrieved on 2015-06-08, only the samples in the GTEx pilot study were used). 
Tissue Sample count 
Adipose - Subcutaneous 128 
Artery - Tibial 137 
Heart - Left Ventricle 95 
Lung 133 
Muscle - Skeletal 157 
Nerve - Tibial 114 
Skin - Sun Exposed (Lower 
leg) 
126 
Thyroid 120 
Whole Blood  191 
 
Table 3: Tissues in E-MTAB-2836 dataset 
Tissue Sample count 
adipose tissue 7 
bone marrow 8 
colon 8 
endometrium 9 
gall bladder  7 
heart 9 
lung 8 
lymph node  13 
placenta 7 
prostate 7 
small intestine 8 
testis 8 
thyroid 9 
 
The in-silico mixture allowed evaluation of algorithms on the difference between corrected and 
uncorrected Mean-Absolute-Error (MAE)  
deltaMAE = mean(!!!"##$!%$& ! !!!"#$%&'"$'!!! !!!"#$!!!!"#$%&' ! !!!"#$%&'"$'!!!!! 
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Comparison with CIBERSORT and DeconRNASeq   
We next compared our algorithm with two recently published methods, CIBERSORT and 
DeconRNASeq. 
CIBERSORT [4] was established to distinguish 22 closely related immune cell types via 
support vector regression from microarray data, although the authors expect it to work with 
RNA-Seq data. Besides an estimation of the distribution of cell types, it provides a p-value “to 
test the null hypothesis that no cell types in the signature matrix [!] are present in a given 
GEP [gene expression profile] mixture”. The 22 immune cell type signature (LM22) provided 
with CIBERSORT is unable to estimate macrophage contents in our tumor cell samples 
according to its own p-value estimation (our most contaminated sample: p = 0.02; all other 
samples: p > 0.1).  
To generate a custom signature matrix using CIBERSORT's automated procedure three pure 
samples of each cell type are required. In addition, the CIBERSORT FAQ states “Building the 
specific collection of genes in a signature matrix is a nuanced process, and is critical for its 
performance on complex tissues. Construction and validation of LM22 required more than a 
year of investigation”. Consequently, we ran CIBERSORT with ad-hoc signature matrices 
composed of the 500 genes showing the highest extent of differential expression (250 up, 250 
down, min. 10 TPM in the higher tissue).  
DeconRNASeq [5] models RNA-Seq samples as linear mixtures estimated via quadratic 
programing using a signature matrix. The signature matrix captures the expression difference 
of hundreds of genes across pure samples. The implementation does not offer correction, nor 
an automated way to build the signature matrix. We build an ad-hoc signature matrix as above 
for CIBERSORT.  
Our algorithm was run k = 250, j = 0 in order to keep comparable parameters. While our 
algorithm was able to predict the contamination in most cases (r = 0.8), both CIBERSORT and 
DeconRNAseq (r < 0.3) failed using these ad-hoc signature matrices (Figures 2 and 3).  
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Figure 2: Algorithm comparison with CIBERSORT and DeconRNASeq on GTEx samples [2]. 
Conditions: 10,000 simulations per algorithm, random percentage between 0 and 50%, single randomly 
chosen reference per tissue and simulation. (A) Actual versus calculated percentage. Blue: diagonal. 
(B) Resulting deltaMAE between corrected and uncorrected mixtures in comparison to the ground truth.  
A 
B 
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Figure 3: Algorithm comparison on E-MTAB-2836 dataset [3]. Conditions: 10,000 simulations per 
algorithm, random percentage between 0 and 50%, single randomly chosen reference per tissue and 
simulation. (A) Actual vs calculated percentage. Blue: diagonal. (B) Resulting deltaMAE between 
corrected and uncorrected mixtures in comparison to the ground truth.  
A 
B 
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Other algorithms 
A number of other algorithms were considered, but their application was rejected for technical 
reasons. 
ContamDE's [6] focus is on differential expression between tumor (mixture) and normal (pure) 
samples. It requires at least two of each and has a long runtime (on the order of minutes), 
complicating simulations.  
UNDO [7] is a completely unsupervised algorithm that merely uses mixture samples to 
deconvolute tumor and normal tissue. It does not use pure references and determines suitable 
marker genes solely from the mixture data. Although it was established on microarray data, it 
has been used with some success on RNA-Seq data [6]. When adjusting our simulation to 
provide two mixture samples, we found that UNDO only works if both mixtures are mixtures of 
the same (sample, contamination) samples. This makes it unusable in our setting, where there 
is only one mixture per patient available.  
TEMT [8] works on transcription level RNA-Seq alignments. Transcription level analysis is 
inappropriate for the cell-cell network investigated in this study.  
ESTIMATE [9] produces an 'ImmunoScore' that is not usable for correction. 
IsoPure [10] explicitly biases its results to the assumption that the two cell types being 
deconvoluted are closely related (tumor and normal tissue). 
DeMix [11], Dsection [12] and PSEA [13] have only been established on microarrays. 
Limitations of our algorithm 
Finally, two important limitations of our approach need to be briefly addressed, although these 
are not relevant to the present study:  
First, our algorithm is unable to distinguish closely related cell types, such as the CD4 and 
CD8 sample from GSE60424 (Figure 4).  
Second, as shown in Figure 5, small numbers of reference sample combinations caused all 
instances in Figure 3 where the algorithm actually increased MAE. Therefore, the references 
must be well chosen to represent the contaminating cell types. 
Availability 
A python implementation of our algorithm is included as Additional File 6.  
The code is also available, together with our simulation code, from 
https://github.com/IMTMarburg/rnaseqmixture 
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Figure 4: Failure of correction on closely related cell types from GSE604242.  
10,0 simulations. CD4 samples were contaminated with CD8 and vice versa. 
 
Figure 5: Reference sample dependency of the algorithm. Data from Figure 3, ‘median’ subset. 
Red: simulations with worse MAE after correction.  
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ABSTRACT
Peroxisome proliferator-activated receptor /
(PPAR/) is a lipid ligand-inducible transcription
factor with established metabolic functions, whereas
its anti-inflammatory function is poorly understood.
To address this issue, we determined the global
PPAR/-regulated signaling network in human
monocyte-derived macrophages. Besides cell type-
independent, canonical target genes with metabolic
and immune regulatory functions we identified a
large number of inflammation-associated NFB and
STAT1 target genes that are repressed by agonists.
Accordingly, PPAR/ agonists inhibited the ex-
pression of multiple pro-inflammatory mediators
and induced an anti-inflammatory, IL-4-like mor-
phological phenotype. Surprisingly, bioinformatic
analyses also identified immune stimulatory effects.
Consistent with this prediction, PPAR/ agonists
enhanced macrophage survival under hypoxic stress
and stimulated CD8+ T cell activation, concomitantly
with the repression of immune suppressive target
genes and their encoded products CD274 (PD-1
ligand), CD32B (inhibitory Fc receptor IIB) and
indoleamine 2,3-dioxygenase 1 (IDO-1), as well as
a diminished release of the immune suppressive
IDO-1 metabolite kynurenine. Comparison with
published data revealed a significant overlap of the
PPAR/ transcriptome with coexpression modules
characteristic of both anti-inflammatory and pro-
inflammatory cytokines. Our findings indicate that
PPAR/ agonists induce a unique macrophage ac-
tivation state with strong anti-inflammatory but also
specific immune stimulatory components, pointing
to a context-dependent function of PPAR/ in
immune regulation.
INTRODUCTION
Macrophages display an enormous degree of plastic-
ity and react to their microenvironment by profoundly
different phenotypes, with classically activated, pro-
inflammatory macrophages [e.g. by tumor necrosis factor-
(TNF) or interleukin-1 (IL-1)] and anti-inflammatory
macrophages [e.g. by interleukin 4 or 10 (IL-4 or IL-10)]
as the extremes, originally designated as M1 and M2
macrophages (1). However, the macrophage phenotype
is highly dynamic, depending on the precise environ-
mental cues (2). Consequently, a spectrum of defined
activation/polarization states has recently been proposed
(3). A protein involved in the regulation of macrophage
activation and polarization is the nuclear receptor per-
oxisome proliferator-activated receptor / (PPAR/).
PPAR/ is a ligand-inducible transcription factor with
established functions in intermediary metabolism and a
less well-defined anti-inflammatory role in immune regu-
*To whom correspondence should be addressed. Tel: +49 6421 2866236; Fax: +49 6421 2868923; Email: rmueller@imt.uni-marburg.de
†These authors contributed equally to the paper as first authors.
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lation (4–7). Thus, PPAR/ deficiency exacerbated the
inflammatory response to topical O-tetradecanoylphorbol-
13-acetate in mice (8). Furthermore, PPAR/ dampened
the inflammatory response in a human model of dermal
wound healing by stimulating the secretion of IL-1 receptor
antagonist in dermal fibroblasts (9). Anti-inflammatory
effects of PPAR/ agonists have also been observed in
mouse models of intestinal inflammation (10) and exper-
imental allergic encephalomyelitis, the latter involving an
inhibition of interferon  (IFN ) and IL-17 production by
Th1 and Th17 cells (11). An anti-inflammatory function
of PPAR/ in macrophages has been demonstrated
in two studies reporting that M2 polarization of murine
macrophages in adipose tissue and liver is dependent on the
induction of PPAR/ expression by IL-4 or IL-13 (12,13).
The precise mechanism of anti-inflammatory macrophage
polarization by PPAR/ remains, however, unclear.
Moreover, inconsistent with a purely anti-inflammatory
function, PPAR/ is overexpressed in human psoriasis
(14) and ligand activation induces a proinflammatory
psoriasis-like response in a mouse model (15,16), even
though the molecular mechanisms underlying the latter
observation and its relevance for the human system remain
unclear.
PPAR/ regulates its direct target genes through bind-
ing to PPAR response elements (PPREs) as a heterodimer
with a retinoid X receptor (RXR) (17). Genome-wide anal-
yses have identified PPRE-mediated repression as a major
mechanism of transcriptional regulation in the absence of
a PPAR/ agonist and showed that an agonist-mediated
switch induces a subset of these genes (18). PPRE-mediated
repression is enhanced by inverse agonists, which establish a
repressor complex that apparently is different from the unli-
ganded receptor complex (19). Besides this canonical mech-
anism, agonist-bound PPAR/ can also repress genes by
interacting with specific transcription factors without es-
tablishing direct DNA contact. For example, PPAR/ in-
teracts with the p65 subunit of the nuclear factor kappa B
(NFB) dimer in different cell types (14,20,21), PPAR/
ligands decrease NFB activity via crosstalk with other sig-
naling pathways, including ERK in adipocytes (22) and
BCL-6 in macrophages (23). BCL-6 is a transcriptional re-
pressor of inflammatory genes, many of which are targets of
NFB (24). Deletion ofPpard or application of a PPAR/
ligand abolishes the sequestration of BCL-6 by PPAR/,
resulting in the repression of BCL-6 target genes (23).
PPAR/ serves as a receptor for a broad range
of natural agonists with function in inflammatory pro-
cesses, including unsaturated fatty acids (25) and 15-
hydroxyeicosatetraenoic acid (15-HETE) (26). The func-
tion of prostaglandin I2 (prostacyclin) as a PPAR/ ag-
onist is controversial (27,28), which might be due to its
extreme instability at pH values below 7.8 (29), making
the microenvironment an essential determinant in this con-
text. Owing to the association of PPAR/ with major hu-
man diseases a number of PPAR/-specific agonists have
been developed, several of which are well characterized and
have been used in numerous preclinical studies (30,31). Fur-
thermore, several synthetic inhibitory ligands for PPAR/
have been described over the past years. These include the
PPAR/-specific GSK0660 (32) and its improved deriva-
tive ST247 (33,34). These ligands inhibit the basal expres-
sion of PPAR/ target genes by enhancing the recruitment
of transcriptional corepressors, classifying them as inverse
agonists (33).
To date, genome-wide studies addressing the tran-
scriptional PPAR/ signaling network in primary
macrophages have not been performed. Recently published
transcriptome data for myeloid leukemia THP-1 cells,
induced to differentiation toward macrophage-like cells
by phorbol ester exposure, do not reflect the situation in
normal primary macrophages (35). However, such studies
are urgently required to understand the multi-faceted role
of PPAR/ in immune regulation. In the present study,
we applied next-generation sequencing technologies to
determine the PPAR/-regulated transcriptome and the
PPAR/-RXR cistrome in human monocyte-derived
macrophages (MDMs) with the goal to establish the
PPAR/-controlled regulatory network in these cells.
MATERIALS AND METHODS
Ligands
L165,041 was purchased from Biozol (Eching, Germany)
and GW501516 from Axxora (Lo¨rrach, Germany). ST247
was synthesized as described (33,34). The inverse PPAR/
agonist PT-S264 is a novel derivative of ST247 with im-
proved plasma stability (Toth, P.M. et al., submitted for
publication). Ligands were used at a concentration of 1 M
in all experiments.
Cell culture
MDA-MB-231 cells were purchased from Caliper Life Sci-
ence (MDA-MB-231-luc2). WPMY-1 cells were obtained
from the ATCC. Cells were maintained in Dulbecco’s mod-
ified Eagle’s medium supplemented with 10% fetal bovine
serum, 100 U/ml penicillin and 100 g/ml streptomycin in
a humidified incubator at 37◦C and 5% CO2.
Isolation of CD14+ cells
Peripheral blood mononuclear cells were obtained from
healthy adult volunteers for MDM stimulation. Mononu-
clear cells were isolated by Lymphocyte Separation
Medium 1077 density gradient centrifugation (PromoCell
GmbH, D-69126 Heidelberg, Germany) and further
purified by adherent cell positive selection.
Cell culture and cytokine treatment of MDMs
CD14+ monocytes were cultured either in RPMI1640 with
10% fetal calf serum (FCS) (R10 medium) or in serum-
free macrophage X-VIVO 10 medium (Biozym Scientific
GmbH, Hessisch Oldendorf, Germany; subsequently re-
ferred to as XV0medium).MDMswere differentiated from
CD14+ monocytes of healthy volunteers for 5–7 days at 1
× 106 cells/ml. In some experiments MDMs were treated
with 20 ng/ml IL-4 (Biozol, Eching, Germany), 100 ng/ml
(lipopolysaccharide (LPS); Escherichia coli 0111:b4 L4391;
Sigma Aldrich, Steinheim, Germany) or 10 ng/ml IFN
(Biomol, Hamburg, Germany) during differentiation for
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5–7 days. Isolation of murine bone marrow cells (BMCs),
differentiation to macrophages (BMDMs) by granulocyte-
macrophage colony stimulating factor (GM-CSF) and lig-
and treatment were carried out as described (36).
Propidium iodide uptake under hypoxia
MDMs were treated with ligands as indicated and kept un-
der 1% oxygen starting directly after isolation of mono-
cytes. Propidium iodide (Sigma Aldrich, Steinheim, Ger-
many) was added to a 1 ml cell suspension containing 1–
2 × 106 MDMs to yield a final concentration of 1 g/ml.
Cells were kept at ambient temperature in the dark for 1 h
followed by fluorescence-activated cell sorting (FACS) anal-
ysis using an FACS Canto cytometer and BD FACSDiva
software (BD Biosciences, Heidelberg, Germany).
Phagocytosis assay
Phagocytosis assaywas performedwith d6MDMsusing 0.5
mg/ml fluorescein isothiocyanate (FITC) dextran (Sigma
Aldrich, Steinheim, Germany). Cells were kept under stan-
dard culture conditions for 1 h. Negative control cells were
incubated for 1 h at 4◦C. Following the incubation, cells
were washed three times and analyzed by FACS.
FACS phenotyping
Cells were pretreated and stained for macrophage mark-
ers as previously described (37). In addition, FITC-labeled
anti-human CD86 (Miltenyi Biotech, Bergisch Gladbach,
Germany), FITC-labeled anti-CD32A (Clone IV.3, Stem-
cell Technologies, Cologne, Germany) and allophycocyanin
(APC)-labeled anti-CD274 (BD Biosciences) were used. In-
tracellular staining of permeabilized cells with anti-CD32B
(Clone C2C3, Genetex, Irvine, CA, USA) and FITC-
labeled secondary antibody (eBioscience, Frankfurt a.M.,
Germany) was performed as published (37). Isotype con-
trol antibodies were purchased from BD Biosciences, Mil-
tenyi Biotech and eBioscience. Cells were analyzed using an
FACS Canto cytometer and BD FACSDiva software (BD
Biosciences). Results were calculated as mean fluorescence
intensities.
T cell activation
For antigen-specific T cell activation, autologous CD14+
monocytes from buffy coats of healthy donors were dif-
ferentiated to MDMs in the presence of different stim-
uli for 5–7 days and used as antigen-presenting cells for
antigen-specific T cell activation. Eighty thousand MDMs
per 96 well culture plate were loaded with 1 g/ml
cytomegalovirus, Epstein-Barr virus, influenza virus and
tetanus toxoid (CEFT) peptide pool of 27 peptides (jpt
Peptide Technologies, Berlin, Germany) for 24 h (37◦C,
5% CO2). After washing with phosphate buffered saline,
peptide-pulsed MDMs were cocultured with 4 × 105 au-
tologous lymphocytes (CD14− fraction after MACS se-
lection of buffy coats) at a 5:1 ratio of lymphocytes to
MDMs in XV0 medium. MDMs pulsed with dimethylsul-
foxide (DMSO; 0.2% final concentration) were used as un-
stimulated controls for antigen-specific T cell activation.
For polyclonal T cell stimulation, 4 × 105 lymphocytes
were incubated in 96 well culture plates coated with mouse
anti-human CD3 mAb (500 ng/well; clone OKT3, Biole-
gend, San Diego, CA, USA) in the absence of autologous
MDMs. Experimental controls included non-stimulated
lymphocytes cultured without anti-CD3 mAb. Polyclonal
and peptide-specific T cell stimulation were performed at
37◦C and 5%CO2 for a total of 18 h with 5 g/ml Brefeldin
A (Sigma Aldrich, Steinheim, Germany) for the last 16
h. Activated lymphocytes were harvested and stained with
surface markers anti-human CD8 APC (Miltenyi Biotec,
BergischGladbach, Germany). After permeabilization (BD
Cytofix/Cytoperm Kit, BD Bioscience, Heidelberg, Ger-
many) anti-human IFN FITC (eBioscience, Frankfurt
a.M., Germany) was added according to themanufacturer’s
instructions. Frequencies of activated T cells were measured
by flow cytometry (FACS Canto, BD Bioscience, Heidel-
berg, Germany) and expressed as IFN+/CD8+ cells af-
ter subtracting background staining of corresponding non-
stimulated controls.
Immunoblotting
Immunoblots were performed according to standard proto-
cols using the following antibodies: -PPAR/ (sc-74517;
Santa Cruz, Heidelberg, Germany); -IDO-1 (MAB10009;
Millipore, Darmstadt, Germany), -LDH (sc-33781; Santa
Cruz, Heidelberg, Germany), -rabbit IgGHRP-linked AB
and-mouse IgGHRP-linkedAB (cs7074, cs7076; Cell Sig-
naling, NEB, Frankfurt, Germany). Imaging and quantifi-
cationwas done using the ChemiDocMP system and Image
Lab software version 5 (Bio-Rad, Mu¨nchen, Germany).
Kynurenine assay
Kynurenine was measured according to a published pro-
cedure (38). Supernatant of MDM cultures (360 l) was
incubated with 180 l of 30% trichloroacetic acid (TCA)
for 30 min at 50◦C. After centrifugation at 3000 × g
for 10 min, the supernatant was collected, mixed with an
equal volume of freshly prepared Ehrlich Reagent (2% p-
dimethylaminobenzaldehyde in glacial acetic acid) and in-
cubated for 12–30 min at ambient temperature. The ab-
sorbance was measured at 492 nm and compared to a cal-
ibration curve obtained with L-kynurenine (Santa Cruz,
Heidelberg, Germany).
Reverse transcription quantitative polymerase chain reaction
(RT-qPCR)
cDNA isolation and qPCR analyses were performed as de-
scribed (33). L27 was used for normalization. Primer se-
quences are listed in Supplementary Table S1.
RNA sequencing
RNA was extracted with TRIfast (Peqlab, Erlangen, Ger-
many) according to the manufacturer’s instructions. Ge-
nomic DNA was removed by incubation with RNase-free
DNase (Macherey-Nagel, Du¨ren, Germany) for 15 min at
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room temperature. After column-based purification (Qi-
agen Minelute, Hilden Germany), 0.1–0.5 g of DNA-
depleted RNA was used for library preparation accord-
ing to the manufacturer’s instructions (ScriptSeq Com-
plete Gold Kit, Human/Mouse/Rat-Low Input, Epicen-
tre,Madison,WI, USA) utilizing QiagenMinelute columns
and Beckman Coulter Agencourt AMpure XP beads. Sam-
ples were sequenced on an Illumina HiSeq 1500.
Chromatin immunoprecipitation (ChIP) sequencing
ChIP was performed and evaluated as described (18,19)
using the following antibodies: IgG pool, I5006 (Sigma-
Aldrich, Steinheim, Germany); -PPAR/, sc-7197; -
RXR, sc-774 (Santa Cruz, Heidelberg, Germany). For pre-
cipitation, a mixture of Dynabeads Protein A (10002D) and
Dynabeads Protein G (10004D; both from Life Technolo-
gies, Carlsbad, CA, USA) was blocked with 1 g/l bovine
serum albumin overnight, and 50 l was used per immuno-
precipitation (IP). DNA was purified using Qiagen Mine-
lute columns. Preceding the PE washing step, the mem-
branes were washed twice with pure methanol in order
to remove contaminating DNA-binding lipids that inhibit
subsequent low-temperature enzymatic modification steps,
which we found to be present in samples from primary
macrophages. Libraries were synthesized from 1–2 ng of ge-
nomic DNA using the MicroPlex kit (Diagenode, Seraing,
Belgium). Samples were sequenced on an Illumina Hi-Seq
1500 (Illumina, San Diego, CA, USA).
Mapping of ChIP sequencing reads and peak calling
ChIP sequencing (ChIP-Seq)mapping and peak calling was
performed as described (18,19) except that (i) Subread (ver-
sion 1.4.3-p1) (39) was used for alignment, (ii) reads were
filtered to a maximum of five mismatches and five repeti-
tions of each read start site (deduplication) and (iii) updated
versions of Ensembl (v74) and MACS (1.4.0rc2 20110214)
were employed. The number of usable reads was 46 299 322
(PPAR/), 39 483 674 (RXR) and 42 750 342 (IgG con-
trol). Peaks were filtered for at least 15 deduplicated tags,
a fold change (FC) over IgG of ≥2 (normalized total read
counts) and at most 60 deduplicated IgG tags. Venn dia-
grams for peak overlaps were calculated by building the in-
terval union and testing each resulting interval for overlaps
with the initial peak sets. Genes were associated with peaks
based on the closest transcription start site (TSS) from the
peak summit and all TSSswithin 50 kb of the summit (inter-
nal TSSs were considered). A peak could thus be assigned
to multiple genes.
RNA sequencing analysis
RNA sequencing (RNA-Seq) data were aligned to Ensembl
v74 using STAR (version STAR 2.3.1z13 r470) (40). Gene
read counts were established as read count within merged
exons of protein coding transcripts (for genes with a pro-
tein gene product) or within merged exons of all transcripts
(for non-coding genes). FPKM (fragments per kb per mil-
lion) were calculated based on the total gene read counts
and length of merged exons. Raw read counts were quantile
normalized within each comparison and logFC values were
calculated (after adding 1/60 to the normalized FPKM val-
ues to avoid undefined values). Genes were considered regu-
lated if they had a logFC of at least 0.7 (∼1.62-fold), a min-
imum FPKM of 0.3 in any condition and at least 50 raw
reads.
Comparisons with published ChIP-Seq data
For comparison of the PPAR bound gene sets, signal trans-
ducer and activator of transcription 1 (STAT1) data were
retrieved from (41) and gene IDs updated to Ensembl
v74. STAT3 data were retrieved from Supplementary Ta-
ble S1 in (42), updated to Ensembl v74 and translated from
mouse to human via Ensembl Compara. NFB bound re-
gions (24) were retrieved from Gene Expression Omnibus
(GSM61116,GSM61117, union), lifted frommm9 tomm10
using UCSCs liftOver utility and associated with the mouse
gene with the closest transcription start site (internal TSSs
were considered). Translation to human genes was again by
Ensembl Compara. BCL6 bound sites from the same publi-
cation (24) (GSE16723, top level data file) were treated iden-
tically. P300 associated genes were extracted from (43) (Sup-
plementary Table S1), assigned to mouse stable IDs using
the ‘Official Gene Symbol’ column and Ensembl v64, up-
dated to Ensembl v74 and translated to human genes via
Ensembl Compara.
Comparisons with published stimulus-specific MDM tran-
scriptomes
Raw microarray data (3) (GSE46903, ‘GSE46903 non-
normalized.txt.gz’) quantile normalized using the lumi Bio-
conductor package annotated using Supplementary Ta-
ble S1B in (3) were used to calculate logFC values ver-
sus basal (M0) condition based on expression values av-
erages within each condition. Only GM-CSF stimulated
macrophage samples were analyzed. WGCNA output (49
modules; Supplementary Table S2B in (3)) was translated
to Ensembl stable gene IDs using Illumina Human-HT-
12 v3 annotation (‘HumanHT-12 V3 0 R3 11283641 A’).
Translation was preferentially based on Entrez IDs with
gene symbols as a fall back. Overlaps between modules and
L165,041 regulated genes were assessed by Fisher’s exact
test. For Figure 8, a directional score for overlapping genes
was calculated as follows: the number of genes regulated in
the same direction by L165,041 and a given stimulus mi-
nus the number of genes regulated in the opposite direc-
tion. Only genes showing an at least 1.5-fold induction by
the respective stimulus [3] and 1.62-fold by L165,041 (Sup-
plementary Table S2) were included.
Comparison with published genomic PPAR/ data for
other cell types
For comparisons based on peaks, original sequencing data
(18,19) were reanalyzed as described in section ‘Mapping of
ChIP-Seq reads and peak calling’. Microarray based tran-
scription assay results were retrieved from supplementary
tables of the aforementioned publications and their gene
stable IDs updated to the Ensembl revision used. In com-
parisons depicting both RNA-Seq and microarray data,
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genes were filtered to those occurring on both microarray
chip types used (Agilent-028004 and Agilent-014850).
Databases
All genomic sequence and gene annotation data were re-
trieved from Ensembl release 74, genome assembly hg19.
Our full analysis scripts and computational pipeline are
available upon request.
Statistical analysis of experimental data
Data are presented as the average of biological replicates
(n ≥ 3; precise numbers for each experiment indicated in
the figure legends)± standard deviations (error bars). Com-
parative data were statistically analyzed by Student’s t-test
(two-sided, equal variance) using GraphPad Prism 6.0. Re-
sults were expressed as follows: *P < 0.05, **P < 0.01 and
***P < 0.001. When appropriate, correction for multiple
hypothesis testing was done by Benjamini–Hochberg ad-
justment, as indicated.
Functional annotations, networks and pathway analyses
RNA-Seq data were analyzed using the Ingenuity Pathway
Analysis (IPA) application and knowledge database (Qia-
gen Redwood City, CA, USA). The functions ‘Upstream
Regulators, Diseases and Bio Functions and Networks’
were applied using the default settings. Results were sorted
according to P-value of overlap (minimum 10−5) and acti-
vation z-scores (≤−2.0 or ≥+2.0 required).
RESULTS
Induction of PPAR/ during differentiation of human
monocytes to MDMs
First, we sought to identify an experimental system suitable
for studying the PPAR/ cistrome and ligand-regulated
transcriptome. Human monocytes were differentiated to
MDMs in RPMI1640 with 10% FCS medium (R10) and
characterized with respect to PPAR/ expression and
activity. RT-qPCR analysis showed increasing PPARD
mRNA levels after initiation of cultures reaching a maxi-
mum around day 5 (Figure 1A), which was paralleled by
a strong increase in PPAR/ protein expression (Figure
1B and Supplementary Figure S1) and ligand inducibility
of the well-established target gene PDK4 (Figure 1C), both
reaching maximum levels around day 6. Chromatin-bound
PPAR/ and RXR were detected by ChIP at the PPAR-
responsive PDK4 enhancer already on day 0 (monocytes;
Figure 1D), which explains the ligand responsiveness of the
PDK4 gene at early time points (Figure 1C). Re-ChIP anal-
yses showed that PPAR/ and RXR formed complexes
on the PDK4 enhancer, as expected (Supplementary Fig-
ure S2). The induction of PPAR/ expression and activity
during differentiation was paralleled by an increased sur-
face expression of the macrophage markers CD32, CD63,
CD86, CD206 and HLA-DR and an induction of intracel-
lular CD68 (Supplementary Figure S3). MDMs thus ap-
pear to be suitable for investigating effects of PPAR/ lig-
ands onmacrophage activation and/or polarization, in par-
ticular since plastic adherence partially activates monocytes
and macrophages (44–48), including increased STAT1 and
NFB signaling (49,50), thus allowing for a potential mod-
ulation by agonists or inverse agonists in either direction.
We therefore chose day-6 MDMs for the subsequent stud-
ies.
The transcriptome of PPAR/ ligand-regulated genes in
human MDMs
We used this experimental system to identify ligand-
responsive genes as well as PPAR/ and RXR bind-
ing sites in macrophages by deep sequencing technologies.
RNA-Seq data obtained with MDMs cultured either in
R10 or serum-free synthetic X-VIVO 10 medium (XV0)
revealed a total of 285 protein-coding genes upregulated
by PPAR/ agonist L165,041 and 246 genes downregu-
lated by the inverse agonists ST247 or PT-S264; logFC ≥
0.7; FPKM ≥ 0.3), 29.6% of the latter (n = 73) overlap-
ping with the agonist-induced gene set (Figure 2A; Supple-
mentary Table S2). Our RNA-Seq also identified a large
fraction of genes repressed by the agonist L165,041 (n =
388) and upregulated by the inverse agonist ST247 (n =
174), with 40 genes (10.3%) overlapping (Figure 2B; Sup-
plementary Table S2). Diseases and functions annotation
of the L165,041-induced gene set showed a strong asso-
ciation with the inhibition of cell death of immune cells
and suppression of immune cell functions, including mi-
gration, inflammatory response, activation, homing, ad-
hesion, chemotaxis and phagocytosis (Figure 2C; Supple-
mentary Table S3). The gene set representing inflammation
clearly overlapped with cell survival, migration/movement,
adhesion and recruitment/infiltration/ chemotaxis (Fig-
ure 2D), suggesting that these to a large extent repre-
sent genes with functions in immune regulation. Interest-
ingly, ‘Inflammation of intestine’ and ‘Colitis’ showed a
positive activation z-score (Figure 2C), providing a first
hint that the response to L165,041 may not be strictly
anti-inflammatory. Likewise, lipidmetabolism (‘Concentra-
tion of acylglycerol’) was upregulated, consistent with the
known metabolic role of PPAR/. Finally, analysis of
the known upstream regulators of these genes (signaling
molecules and transcription factors) identified two groups:
canonically regulated (L165,041-induced) genes known to
be activated by PPARagonists (pirixinic acid, fibrates, glita-
zones) were upregulated by L165,041, while genes induced
by pro-inflammatory signaling via LPS, TNF, IFN , IL-
1, STAT3 or TLR4 were downregulated (inverse target
genes).
To rule out the possibility that inverse regulation may
be due to PPAR/-independent off-target mechanisms we
analyzed the regulation of target genes in bone marrow-
derived macrophages (BMDMs) from wild-type and Ppard
null mice. As shown in Figure 2F, Ccl24, Tnfsf15 and Ser-
pinb2 were repressed upon agonist treatment specifically in
wild-type cells. Two other genes found to be repressed by ag-
onists in human MDMs were not regulated (Ccl8) or not
expressed (Enpp2) in murine BMDMs, while the canon-
ical target genes Pdk4 and Angptl4 showed the expected
PPAR/-dependent induction. These observations con-
firm the PPAR/ dependence of agonist-mediated regu-
lation, but also point to cell type (BMDM versus MDM)
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Figure 1. PPAR/ expression and activity in differentiating human MDMs. Human monocytes were differentiated in R10 medium for 11 days and
analyzed at the indicated times after initiation of differentiation. (A) Expression of PPARD mRNA measured by RT-qPCR relative d1 (sample size = 3).
(B) Quantitation of immunoblot analyses of PPAR/ protein expression in differentiating MDMs from four different donors relative to LDH (loading
control). The individual blots are shown in Supplementary Figure S1. Values were normalized to 1.0 on d6 (maximum expression). (C) Ligand-mediated
induction relative to DMSO of PDK4 determined by RT-qPCR. Cells (sample size= 3) were exposed to L165,041 for 1 or 3 days (+1 or +3) at the indicated
d (d0, d5, d8, d11). (D) PPAR/ and RXR enrichment at the PDK4 enhancer at −12 kb from the transcription start site and an irrelevant control region
(Con) in human monocytes (ChIP analysis; sample size = 6). Statistical significance was tested relative to d0 (panel (A)) or DMSO (panel (C)).
and/or species-specific differences in the regulation of in-
verse PPAR/ target genes.
To gain further insight into the diverse functions and reg-
ulatory mechanisms suggested by the data in Figure 1 we
separately analyzed canonically regulated and inverse tar-
get genes as described in the following.
Canonical PPAR/ target genes in MDMs
ChIP-Seq analyses identified 1175 enrichment sites for
PPAR/ associated with 3798 genes located within a dis-
tance of 50 kb, and 27 255 RXR enrichment sites associ-
ated with 32 720 genes (Figure 3A and B; Supplementary
Tables S4 and S5). The majority of overlapping binding
sites occurred at transcription start sites (within 1250 bp,
29.1%), within introns (31.6%) or upstream locations (5000
bp, 5.7%) (Figure 3C). A large fraction of the L165,041-
induced genes (n= 132; 46.3%) showed clear enrichment of
PPAR/ in vivo, and most of these sites (n = 130; 98.5%)
were co-occupied byRXR (Figure 3A andB). Another frac-
tion of L165,041-induced genes were occupied by RXR,
but enrichment for PPAR/ at the same genomic region
was less clear or not visible (n = 139; 48.8%; Figure 3A).
These include the strongly regulated (Supplementary Fig-
ure S4) and established (51) canonical PPAR/ target gene
ANGPTL4, which shows readily detectable ChIP-Seq peaks
in other cell types under identical assay conditions (18,19).
This may be due to cell type-specific PPAR/ transcrip-
tion complexes inmacrophages that limit accessibility to the
antibody. We therefore assume that the presence of RXR
on PPREs of L165,041-induced genes indicates canonical
PPAR/ regulation. This is supported by the results of
the upstream regulator analysis of L165,041-induced genes,
which identified PPAR ligands and the PPAR coactivator
PPARGC1A as the top regulators (nine out of 10; Figure
3D).
Diseases and functions annotation of the canonical target
genes showed the strongest positive correlation (byP-value)
with lipid metabolism (Figure 3E). The identified genes in-
clude established PPAR target genes with functions in lipid
metabolism, such as ACADVL, ACAA2, ANGPTL4, CAT,
CPT1A, FABP4, ECH1, PDK4, SLC25A20 and PLIN2,
but also novel target genes, such as ETFB, ETFDH and
ISCA1, the products of which play important roles in elec-
tron transfer and iron-sulfur cluster assembly, respectively.
Other sets of canonical target genes were either positively
associated with cell movement or negatively correlated with
systemic autoimmune syndrome (Figure 3E). Consistent
with this finding, the canonical target gene set encompasses
a number of genes with functions in immune regulation,
e.g. CD1D, CD36, CD52, CD300A, LRP5, NLRC4 and
PHACTR1 (Table 1 and Figure 3B). Several of these exam-
ples were validated by RT-qPCRwithMDMs from three to
seven independent donors (Supplementary Figure S4).
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Figure 2. Genome-wide identification of PPAR/ target genes in macrophages. (A) Overlap of genes induced by L165,041 and repressed by ST247 or
PT-S264 in MDMs cultured for 6 days followed by treatment with DMSO or ligands for 24 h. Data are derived from two independent experiments using
either R10 (L165,041, ST247) or XV0 (L165,041, PT-S264) medium. Genes with a logFC > 0.7 in one culture condition, a logFC > 0 in both media, an
FPKM ≥ 0.3 and a raw tag count of at least 50 were scored as positive. (B) Overlap of genes repressed by L165,041 and activated by ST247 in MDMs
(conditions as in (A)). (C) IPA ‘Diseases and Functions Annotation’ of L165,041-regulated genes (examples of functionally different clusters with low P-
values and high z-scores). (D) Overlap of L165,041-regulated genes linked to different functions (according to IPA ‘Diseases and Functions Annotation’;
all clusters with n > 30 genes). (E) IPA ‘Upstream Regulator Analysis’ of L165,041-regulated genes (top regulators by P-value). (F) RT-qPCR analysis
of target gene regulation by the PPAR/ agonist GW501516 in BMDMs from wild-type and Ppard null mice differentiated for 6 days in the presence
of GM-CSF (sample size: 3 each). The data show the fold change (mean of triplicates) in response to the ligand relative to solvent treated wild-type and
Ppard null control cells.
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Figure 3. Genome-wide identification of agonist-induced direct PPAR/ target genes in MDMs. (A) Overlap of genes associated with PPAR/ and
RXRbinding sites inMDMs (ChIP-Seq; peaks filtered and associated with genes as described in theMaterials andMethods section) and L165,041-induced
genes (RNA-Seq). (B) Examples of RXR (green) and PPAR/ (red) enrichment peaks at novel canonical target genes (ChIP-Seq data). Blue: control IgG.
(C) Locations of PPAR/ sites identified by ChIP-Seq. tss: within 1250 bp of a transcription start site; upstream: within 5 kb upstream of a transcription
start site. (D) IPA ‘Upstream Regulator Analysis’ of L165,041-induced genes (top regulators by P-value). (E) IPA ‘Diseases and Functions Annotation’ of
L165,041-induced genes in MDMs.
Inverse PPAR/ target genes in MDMs
As described above, our RNA-Seq also identified a large
fraction of genes repressed by the agonist L165,041, which
we subsequently refer to as ‘inverse target genes’. As shown
in Figure 4A, less than 9% of these genes (34 out of 385)
harbored a PPAR/-RXR binding site, which almost uni-
formly showed low enrichment compared to canonical,
agonist-induced PPAR/ genes (Figure 4B). This could be
due to their regulation by a non-canonical mechanism in-
volving indirect chromatin recruitment, but these genomic
regions could also be fortuitous non-functional enrichment
sites.
Upstream regulator analysis of the inverse target gene set
identified exclusively cytokine signaling pathways (12 out
of 12) as top regulators (Figure 4C). In agreement with this
finding, published binding sites detected by ChIP-Seq for
IFN -induced STAT1 (41), LPS-induced NFB-p65 (24),
BCL-6 (24) or LPS-induced P300 (43) were found in a sub-
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Table 1. Canonical and inverse PPAR/ target genes with immune regulatory functions in MDMs (examples)
Canonical target genes
CD1D CD1D molecule
CD36 CD36 molecule (thrombospondin receptor)
CD52 CD52 molecule
CD300A CD300a molecule
CD300LB CD300 molecule-like family member b
DIXDC1 DIX domain containing 1
LRP5 Low density lipoprotein receptor-related protein 5
MME Membrane metallo-endopeptidase
NLRC4 NLR family, CARD domain containing 4
PHACTR1 Phosphatase and actin regulator 1
S100Z S100 calcium binding protein Z
SCARB2 Scavenger receptor class B, member 2
SLAMF9 SLAM family member 9
ST14 Suppression of tumorigenicity 14
Inverse target genes
ARG2 Arginase 2
BCL3 B-Cell CLL/Lymphoma 3
CASP5 Caspase 5, apoptosis-related cysteine peptidase
CCL13 Chemokine (C-C motif) ligand 13
CCL24 Chemokine (C-C motif) ligand 24
CCL8 Chemokine (C-C motif) ligand 8
CD1A CD1a molecule
CD1B CD1b molecule
CD1E CD1e molecule
CD300E CD300e molecule
CXCL1 Chemokine (C-X-C motif) ligand 1
CXCL10 Chemokine (C-X-C motif) ligand 10
CXCL11 Chemokine (C-X-C motif) ligand 11
CXCL6 Chemokine (C-X-C motif) ligand 6
CXCL9 Chemokine (C-X-C motif) ligand 9
FCGR2B Fc fragment of IgG, low affinity IIb, receptor (CD32B)
IDO1 Indoleamine 2,3-dioxygenase 1
IDO2 Indoleamine 2,3-dioxygenase 2
IL10 Interleukin 10
IL8 Interleukin 8
NLRP12 NLR family, pyrin domain containing 12
TLR3 Toll-like receptor
TNF Tumor necrosis factor 
stantial fraction of the inverse PPAR/ target genes (Fig-
ure 4D), with BCL-6 and LPS-induced P300 presumably
indicative of NFB recruitment. These associations suggest
thatNFBplays an essential role in the regulation of inverse
target genes by PPAR/ agonists. RNA-Seq analyses also
identified BCL3 as an inverse target gene (Supplementary
Table S2). Since BCL-3 can activate transcription via nu-
clear NFB complexes (52), its repression by L165,041 po-
tentially contributes to the inhibition of NFB target genes.
Proteasome inhibitors block the function of NFB by
different mechanisms, including a blockade of IB degra-
dation or an inhibition of NFB precursor processing (53).
Consistent with the predicted role of NFB in the regula-
tion of inverse PPAR/ target genes, we found that the
‘bona fide’ (24) NFB target genes APOBEC3A, BCL3,
CCL24, FCGR2B, IL10, S100A8 and S100A9were strongly
downregulated by the proteasome inhibitor MG132. The
only exception was IL8, which was strongly induced by
MG132, indicating a different mechanism of regulation,
consistent with published observations (54). A role of
NFB in the agonist-mediated regulation of inverse tar-
get genes is supported by our observation that MG132 di-
minished the magnitude of repression of several of these
genes to a statistically not significant level in all cases but
APOBEC3A and BCL3. However, repression by L165,041
was not completely abrogated, pointing to the involvement
of other signaling pathways.
In contrast to the canonically regulated genes, the inverse
target genes aremostly associated with functions in immune
regulation as indicated by the diseases and functions an-
notation in Figure 4F. Strong negative correlations were
found for leukocyte migration/movement/homing, prolif-
eration and cell death, indicating an anti-inflammatory and
pro-survival agonist effect via inverse target genes.However,
positive associations with pro-inflammatory functions were
also observed (‘Inflammation of organ’ and ‘Colitis’).
The inverse target genes include cytokines, chemokines
and enzymes involved in immune regulation (Table 1).Most
of these genes are pro-inflammatory (e.g. IL8), but a small
number of immunosuppressive genes are also found among
the inverse target genes (e.g. IDO1), consistent with the
results of the diseases and functions annotation analysis
above.
Functional networks derived from genomic data
In view of the above findings, several functional networks
centered on NFB (or its upstream regulator TNF) or
biological functions relevant to immune regulation were
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Figure 4. Genome-wide identification of agonist-repressed (inverse) PPAR/ target genes. (A) Overlap of genes associated with PPAR/ and RXR
binding sites in MDMs with L165,041-regulated genes. Number in parentheses indicates low enrichment sites. (B) Cumulative read distribution for all
PPAR/ binding sites separated into agonist induced and agonist repressed genes. Plotted is the percentage of reads with n or fewer reads in PPAR/
ChIP-Seq analyses. (C) IPA ‘Upstream Regulator Analysis’ of L165,041-repressed genes (top regulators by P-value). (D) Percentage of inverse PPAR/
target genes in MDMs (this study) with published binding sites (ChIP-Seq) for STAT1 (INF induced) (41), STAT3 (IL-10 induced) (42), NFB-p65 (24),
BCL-6 (24) (43) or P300 (LPS-induced). (E) Effect (fold change) of MG132 (10 M), L165,041 or a combination of both compounds on inverse target
genes with ‘bona fide’ NFB binding sites (24-h treatment) in MDMs from five donors. T-tests of the corresponding groups in the two L165,041 panels
against each other showed a statistical significance for CCL24 (P < 0.05). (F) IPA ‘Diseases and Functions Annotation’ of L165,041-repressed genes in
MDMs.
studied in further detail. It is obvious from the pathways
depicted in Figure 5 that numerous L165,041-regulated
genes impact on various aspects of inflammation and/or
immune modulation. Anti-inflammatory, agonist-mediated
mechanisms include inhibition of the NALP1 inflamma-
some through modulation of caspase 5 and multiple mem-
bers of the NOD-like receptor (NLR) family (Figure 5A),
reduced TLR signaling (Figure 5B) and diminished NFB
activation (Figure 5A).
In contrast, repression of indoleamine 2,3-dioxygenase
1 (encoded by IDO1; Figure 5B), which catabolizes tryp-
tophan to kynurenine, would be predicted to be immune
stimulatory, since both tryptophan depletion and kynure-
nine production have been linked to T cell suppression (55).
Moreover, CD274, which codes for the transmembrane gly-
coprotein PD-L1 (PD-1 ligand; B7-H1) and suppresses T
cell proliferation (56), is repressed by PPAR/ agonists
(Figure 5B). L165,041 also impinges on the regulation of
macrophage activity by immunoglobulin binding to Fc re-
ceptors (Figure 5C). In this context, repression of the in-
hibitory FCGR2B gene encoding CD32B is of particular in-
terest and points to another immune stimulatory action of
PPAR/ agonists.
In addition, different pathways of antigen presentation
are modulated by PPAR/ agonists. These include both
MHCI and MHCII (HLA-DR, HLA-B27) complexes and
MHC-like CD1 proteins involved in the presentation of dif-
ferent lipid antigens (57). These are modulated either di-
rectly by PPAR/ ligands, by ligand-regulated members
of the leukocyte immunoglobulin-like receptor (LIR) family
and/or by NFB (Figure 5A and D). As the genes involved
are either canonically or inversely regulated by ligands, and
their encoded proteins include both inhibitory and stimula-
tory molecules, the immune modulatory effect of L165,041
on antigen presentation is likely to be context-dependent.
These predictions clearly point to a specific phenotype
triggered by PPAR/ agonists that includes both positive
and negative effects on immune regulation, consistent with
the conclusions drawn from the functional annotation anal-
yses above (Figures 2–4).
Ligand-induced anti-inflammatory alterations in human
MDMs
To elucidate the phenotypic alterations induced by
PPAR/ agonists in MDMs we first analyzed potential
morphological alterations triggered by the PPAR/
agonists during the 6-day differentiation period of MDMs.
For comparison, LPS with or without IFN (inducing M1
polarization) or IL-4 (triggering M2 polarization) were
added to separate cultures. Figure 6A–E shows a clear
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Figure 5. Effects of L165,041 on immune regulatorymodules. The scheme displays functionalmodules derived from the IPA ‘FunctionalNetworkAnalysis’
(Supplementary Table S6; modules 2, 3, 4 and 10). Pink symbols: genes upregulated by L165,041; green symbols: genes downregulated by L165,041. Dashed
lines: indirect effects or interactions. Encircled areas indicate functional units with pro-inflammatory (red), anti-inflammatory (blue) or context-dependent
(black) functions.
morphological resemblance between L165,041 (agonist)
and IL-4 treated cultures, while PT-S264 (inverse agonist)
induced a morphology reminiscent ofM1 cells. Very similar
results were obtained irrespective of the culture medium
(R10 in Figure 6; XV0 medium in Supplementary Figure
S5).
These morphological alterations are in agreement with
the observed downregulation of pro-inflammatory genes
by L165,041, exemplified by IL8 and CCL24 (Figure
4E), which was confirmed for GW501516 (Supplemen-
tary Figure S6). Consistent with this conclusion we
also found that L165,041 inhibited phagocytosis. As
shown in Figure 6F, L165,041 significantly decreased the
macropinocytotic/phagocytotic activity for FITC-dextran
upon PPAR/ activation in six independent experiments,
as determined by the diminished uptake of fluorescent
FITC-dextran by MDMs.
Ligand-induced immune stimulatory alterations in human
MDMs
The functional networks in Figure 5 also predicted an
increased T cell activation by agonist-treated MDMs as
antigen-presenting cells. We tested this hypothesis by mea-
suring intracellular IFN in CD8+ T cells after coculture
with MDMs exposed to an antigen peptide mix (CEFT).
Figure 7A shows that L165,041 pretreatment of MDMs
(during the 6-day differentiation period) led to a clear in-
crease in the fraction of IFN+CD8+ cells with samples
from five out of six donors.
The product of the inverse PPAR/ target gene IDO1,
which suppresses T cell activation via the production of
kynurenine (55), may be involved in this effect. As shown
in Figure 7, the agonist-mediated transcriptional repres-
sion of IDO1 (Figure 7B) was paralleled by a decreased
protein level (Figure 7C; Supplementary Figure S7) and
a clearly diminished release of kynurenine into the super-
natant ofMDMcultures (Figure 7D). Importantly, the level
of kynurenine produced under these conditions was suf-
ficient to significantly inhibit polyclonal (CD3 antibody-
mediated) T cell activation (Figure 7E).
Another potentially important player in this scenario is
the CD274 gene. Figure 7F shows that the inverse regula-
tion of CD274 resulted in a reduced surface expression of
its encoded product, the PD-1 ligand, a key regulator of an
inhibitory T cell checkpoint (56). The agonist-mediated in-
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Figure 6. Inhibitory effects of PPAR/ ligands on human MDMs. Human monocytes were differentiated in XV0 medium for 6 days in the presence
of the indicated additives. Cells were stained with Giemsa dye after treatment with (A) DMSO (solvent control), (B) L165,041 (agonist), (C) IL-4 (‘M2’
macrophages), (D) PT-S264 (inverse agonist) and (E) LPS (‘M1’macrophages). (F) Effect of L165,041 on FITC-dextran uptake (FACS analysis) byMDMs.
Data of six biological replicates with cells from four different donors are shown.
hibition of kynurenine production may thus cooperate with
downregulation of PD-1 ligand expression to stimulate T
cell activation.
Our bioinformatic analyses also pointed to immune stim-
ulatory effects via the agonist-mediated repression of the
FCGR2B gene. FCGR2B codes for CD32B, a low affinity
Fc receptor that inhibits the phagocytosis of opsonized
antigens (58). In contrast to FCGR2B, FCGR2A was only
weakly repressed by L165,041 and not significantly affected
by the inverse agonists ST247 (Figure 7G). FCGR2B repres-
sion led to downregulation of CD32B protein as determined
by flow cytometry (Figure 7H). FCGR2B thus represents
a PPAR/ target gene potentially mediating an agonist-
triggered immune stimulatory event.
The functional annotation and networks analysis (Figure
2C; Supplementary Table S3) also predicted an inhibition of
cell death of immune cells by L165,041 (Figure 2C), which
could be relevant under the stressful conditions of inflam-
mation. We therefore tested this prediction in the context of
hypoxia and found a clear pro-survival effect of L165,041,
while PT-S264 exacerbated hypoxia-induced cell death, as
indicated by the fraction of healthy cells and cell debris in
Supplementary Figure S8A. A similar effect was seen in
MMT-based viability assays of the adherent cell fraction
(Supplementary Figure S8B). Propidium iodide uptake as-
says showed a time-dependent pro-survival effect of both
PPAR/ agonists tested (L165,041, GW501516) peaking
on day 4 (Figure 7I). As MDMs do not proliferate under
the culture conditions used here, a ligand effect on prolifer-
ation could not contribute to these observations.
Finally, time-lapse video microscopy revealed a slight,
but statistically significant inhibitory effect of L165,041 on
the motility of MDMs (Supplementary Figure S9), as pre-
dicted by the functional annotation analysis in Figure 2C.
Comparison of the PPAR/ agonist-induced transcriptome
with defined MDM activation states
A recent study (3) defined a spectrum of macrophage
activation/polarization states extending theM1/M2-model
based on microarray data derived from MDMs exposed to
an array of different stimuli (28 plus baseline). In an at-
tempt to define the PPAR/ agonist-induced MDM phe-
notype more precisely we compared the L165,041-induced
transcriptome to the 143 comparable microarray data sets
provided by the quoted study (3), as outlined in Figure 8A.
Toward this end, we first identified overlaps between the
PPAR/ target gene set and the 49 modules representing
coregulated gene sets as defined by Xue et al. (3). Five mod-
ules yielding P-value <0.001 by hypergeometric test were
identified and further analyzed (modules 8, 15, 16, 21 and
43; Figure 8B). For each gene in the overlap between amod-
ule and the L165,041 regulated set, we determined the di-
rection of regulation by L165,041 (as in Supplementary Ta-
ble S2) and the 28 non-baseline stimuli. The heatmap in
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Figure 7. PPAR/ ligand-induced immune stimulatory alterations in human MDMs. (A) Effects of L165,041 on T cell activation by the recall antigen
peptide mix CEFT. MDMs from six different donors differentiated in the presence of agonist or DMSO (solvent control) were analyzed for their ability to
stimulate CEFT-peptide induced INF production by co-cultured autologous T cells. The fraction of CD8+IFN+ cells was determined by FACS. The
experiment was performed with six independent donors (Do1–Do6) showing a CEFT-directed response. (B) RT-qPCR analysis of IDO1 by L165,041 (24 h)
in MDMs from three donors relative to DMSO control. Each dot represents the average of technical triplicates. (C) Quantitation of immunoblot analyses
of IDO-1 protein expression in L165,041-treated (24 h) MDMs from five different donors relative to DMSO control. Blots are shown in Supplementary
Figure S7. (D) Kynurenine production by MDMs from three different donors treated with L165,041 for 24 h relative to DMSO control. (E) Effect of
L165,041 on polyclonal T cell activation relative to DMSO control (four different donors). (F) FACS analysis of CD274 expression onMDMs treated with
L165,041 or solvent (DMSO) during differentiation (four different donors). (G) RT-qPCR analysis of FCGR2A and FCGR2B expression onMDMs treated
with L165,041 or ST247 during differentiation relative to DMSO control (four donors as in (F)). (H) FACS analysis of CD32A and CD32B, conditions as
in (F). (I) Effect of PPAR/ ligands on the time course of hypoxia-induced cell death. MDMs were cultured in XV0 medium at <1% oxygen for up to 5
days in the presence or absence of L165,041 or GW501516 and analyzed for propidium (PI) uptake by flow cytometry. Data represent the mean of three
biological replicates with cells from different donors. Horizontal lines in panels (B–H) and error bars in panel (I) indicate the average.
Figure 8B represents gene subsets regulated in the same or
opposite direction in red and blue, respectively. It is evi-
dent that for most stimulation conditions the five module-
specific subsets show divergent directions of regulation. For
instance, the classical inducers of alternative macrophage
polarization (M2), IL-4 and IL-13, regulate genes in mod-
ules 15 and 43 in the same direction as L165,041, but in the
opposite direction in module 16. Pro-inflammatory stim-
uli, like TNF, IFN and LPS (stimulation conditions 10,
19–29), predominantly yield opposite patterns (modules 8
and 16), but also show a weak coordinate regulation within
modules 15 and 43, consistent with a predominantly, but
not exclusive anti-inflammatory effect exerted by L165,041.
On the other hand, lipid-triggered (conditions 14–18) and
agonist-induced patterns are similar in modules 15, 21 and
43. These data are in good agreement with our conclusion
that PPAR/ induces a unique activation phenotype with
components of anti-inflammatory, pro-inflammatory and
fatty acid-mediated activation states.
Common and cell type-specific PPAR/ target genes
Finally, we compared the PPAR/ cistrome and the
ligand-responsive transcriptome with those obtained with
the human myofibroblastic cell line WPMY-1 (18) and the
human breast cancer cell lineMDA-MB-231 (19). TheVenn
diagrams in Figure 9A indicate a clear overlap of genes with
PPAR/ binding sites in all three cell types (n= 129; Sup-
plementary Table S7). Diseases and functions annotation
revealed a statistically highly significant overlap with energy
production and lipid metabolism (P = 4.3 × 10−9). In con-
trast, there was no inverse target gene common to all three
cell types (Figure 9B). Our genomic studies in conjunction
with the RT-qPCR analyses thus led to three conclusions:
(i) a subgroup of canonical target genes are common tar-
get genes, including those with functions in intermediary
metabolism (Figure 9A); (ii) another subgroup of canon-
ical target genes are cell type-specific, such as CD52 and
LRP5, which are ligand-responsive only inMDMs (Supple-
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mentary Figure S4 and Supplementary Table S2) compared
to WPMY-1 and MDA-MB-231 cells (Figure 9C); and (iii)
inverse target genes, such as IDO1 and IL8, are not regu-
lated in WPMY1 and MDA-MB-231 cells (Figure 9C) as
opposed to the clear ligand regulation in MDMs (Figures
4E and 7B; Supplementary Table S2).
DISCUSSION
Our data show that PPAR/ target genes in normal
macrophages (MDMs) fall into two major classes. The
first class represents canonical genes with PPAR/–RXR
binding sites (PPREs), induced by agonists and repressed
by inverse agonists. The second class is composed of genes
lacking direct PPAR/ contact sites that are repressed by
agonists, which we have termed inverse regulation. Impor-
tantly, inverse regulation was also seen in murine BMDMs
for several target genes, and was impaired in cells with dis-
rupted Ppard alleles, unequivocally demonstrating the de-
pendence of non-canonical, ligand-mediated repression on
functional PPAR/. Clear evidence for the high selectivity
of one of the ligands (GW501516) used in our study is also
provided by published microarray data (36) obtained with
differentiating murine BMCs, as depicted in the evaluation
in Supplementary Figure S10.
Canonical and inverse target genes
A considerable fraction of canonical PPAR/ target
genes have roles in lipid metabolism shared with other
cell types. These include the known PPAR target genes
with functions in fatty acid oxidation (ACADVL, ACAA2,
CAT, CPT1A, ECH1, PDK4, SLC25A20) or other as-
pects of lipid metabolism (ANGPTL4, FABP4, PLIN2),
but also genes not previously described as PPAR/ tar-
gets, such as ETFDH and ISCA1. Another large fraction
of direct PPAR/ target genes are associated with non-
metabolic functions, in particular immune regulation, such
as CD300A, CD52, LRP5, NLRC4 and PHACTR1, and
most of these genes are cell type-selective with respect to
agonist-mediated regulation.
In contrast, inverse target genes are almost exclusively
regulated by PPAR/ ligands in a cell type-specific
fashion, at least for the three cell types analyzed, i.e.
macrophages, myofibroblastic cells and breast cancer cells.
Consistent with this finding, a large fraction of these genes
are associated with pro-inflammatory functions exerted by
macrophages, including immune cell activation, migration,
chemotaxis and cellular survival, exemplified by a number
of cytokine and chemokine genes (e.g. IL8, CCL24). How-
ever, several inverse target genes have immune suppressive
rather than pro-inflammatory functions, for example IDO1,
CD274 (PD-1L) and CD32B, which play essential roles in
the inhibition of T cell activation. This data strongly sug-
gested that the response to PPAR/ agonists is mainly
anti-inflammatory, but also has immune stimulatory com-
ponents.
Bioinformatic analyses showed that many of the inverse
target genes are controlled by NFB and STAT1 signaling
pathways. This finding is consistent with the reported up-
regulation of inflammatory signaling through these path-
ways in adherent monocytic cells (49,50), which appar-
ently is attenuated by PPAR/ agonists. PPAR/ has
been reported to impinge on NFB signaling by physi-
cally and/or functionally interacting with p65 in endothe-
lial cells, cardiomyocytes, smooth muscle cells and ker-
atinocytes (14,20,59,60) or though ERK1/2 signaling in
adipocytes (22). However, in most cases the precise un-
derlying mechanisms are not entirely clear. In mouse
macrophages, a cell type selective mechanism involving the
transcriptional repressor BCL-6 has been identified (23).
BCL-6 is a repressor of NFB target genes, which is se-
questered by PPAR/ in the absence of PPAR/ ago-
nists.
Our own data are consistent with the conclusion that
PPAR/ agonists repress a subset of NFB-regulated
genes in macrophages, based on the observation that
MG132 diminished the L165,041 effect on several NFB
target genes previously identified by ChIP-Seq in mouse
macrophages (24). This effect of MG132 is presumably
due to the inhibition of IB degradation or a block-
ade of proteasome-dependent processing of p105 to p50
(53). Both effects would lead to the loss of regulation by
NFB and agonist-mediated regulation, as observed in
our experiments, independent of a potential role of BCL-6
and/or other signaling pathways impinging on NFB regu-
lation. Obviously, proteasome inhibitors also target numer-
ous other signaling pathways and transcription factors that
might contribute to the observed effect, as exemplified by
IL8, which has been suggested to be induced by protea-
some inhibitors via reactive oxygen-mediated AP-1 activa-
tion (54).
The involvement of PPAR/ in modulating STAT ac-
tivity is even less understood with all published evidence
restricted to STAT3 (61–64). The identification of strongly
regulated inverse target genes in the present study paves the
way for addressing these open questions using individual
genes as experimental models and for elucidating the mech-
anisms underlying the crosstalk betweenPPAR/and pro-
inflammatory signaling cascades.
Effects of PPAR/ agonists on inflammatory pathways
‘Functional Annotation and Networks Analysis’ indicated
that inflammatory signaling is targeted by PPAR/
agonists at two different levels. First, several genes en-
coding pro-inflammatory cytokines (e.g. IL8, IFNG)
and chemokines (e.g. CCL3/MIP1A, CCL8/MCP2,
CCL11/eotaxin, CCL13/MCP4) are downregulated as in-
verse target genes with predicted anti-inflammatory effects.
In addition, a few anti-inflammatory cytokine genes (e.g.
IL10, IL13) are similarly affected, suggesting that agonist
effects on immune cells are not exclusively inhibitory.
Second, our RNA-Seq analyses identified several key
components of NALP inflammasomes as novel PPAR/
targets (Figure 5C). These include the canonical target
gene NLR4C and the inverse target genes NLRP1, NLRP3
and CASP5. NLR family proteins act as a sensor of
pathogenic signals and promotes inflammasome assembly,
leading to caspase-1 activation and inflammatory cytokine
(IL-1, IL-18) production (65).NLR4C encoded CARD12
is activated by microbial proteinaceous ligands, while
 by guest on June 2, 2016
http://nar.oxfordjournals.org/
D
ow
nloaded from
 
O7
Nucleic Acids Research, 2015, Vol. 43, No. 10 5047
Figure 8. Comparison of the PPAR/ transcriptome with a spectrum of defined MDM activation states. (A) Scheme outlining the basis for the com-
parative analyses. (B) Relationship of PPAR/ target genes to expression data obtained with 29 different stimuli grouped into 49 coexpression modules
(3). Overlaps between PPAR/ target genes and each module were determined by hypergeometric test. Modules yielding P-values <0.001 (modules 8,
15, 16, 21 and 43) were further analyzed by determining for each gene the direction of regulation by L165,041 (Supplementary Table S2) compared to
all 29 stimuli (3). Results are displayed for each subset of genes (defined by specific stimulation conditions within individual modules) as a heatmap. The
color code is based on a directional score reflecting the number of genes regulated in the same direction (red) or in opposite directions (blue; for details see
the Materials and Methods section). GC, glucocorticoid; HDL, high density lipoprotein; IC, immune complexes; LA, lauric acid; LiA, linoleic acid; OA,
oleic acid; P3C, Pam3CysSerLys4; PA, palmitic acid; SA, stearic acid; sLPS, standard lipopolysaccharide; TPP, TNF+PGE2+P3C; upLPS, ultrapure
lipopolysaccharide.
NLRP1 recognizes muramyl dipeptide and diverse stimuli
(e.g. crystalline material, peptide aggregates, bacterial
toxins) can trigger NLRP3 activation (65). Non-canonical
inflammasome activation by Gram-negative bacteria can
involve the additional recruitment of caspase 5, encoded
by another inverse PPAR/ target gene. Taken together,
these findings indicate that PPAR/ agonists can have
pro- and anti-inflammatory effects on specific inflamma-
some functions and suggest that the precise outcome is
stimulus-dependent.
Our data confirm and extend a previous study identi-
fying CD300A as a PPAR/ target gene in macrophage-
like cells derived from the human leukemia cell line
THP-1 (35). In mice, disruption of the Cd300a gene
resulted in pro-inflammatory activation of peritoneal
macrophages, identifying CD300a-mediated inhibitory sig-
naling in macrophages as a critical regulator of intestinal
immune homeostasis (35). CD300E, coding for an activat-
ingCD300 subtype, is repressed byL165,041 (Figure 5D) si-
multaneously with the induction of the inhibitory CD300A
gene, consistent with an immunosuppressive agonist func-
tion via regulation of CD300 family members.
We also identified PHACTR1 as a novel canonical
PPAR/ target gene. This gene encodes phosphatase and
actin regulator 1, which is involved in the G-actin mediated
control of actomyosin assembly (66) and may thus play a
role in modulating macrophage migration and phagocyto-
sis. However, the agonist-mediated induction of PHACTR1
appears to be inconsistent with the observed inhibition of
phagocytosis/macropinocytosis of FITC-dextran, suggest-
ing that other genes contribute to this effect. An example
isDIXDC1, another canonical PPAR/ target gene impli-
cated in cell migration by modulating the WNT and PI3K
signaling pathways (67,68).
Immune stimulatory effects of PPAR/ agonists
As shown by our functional studies, PPAR/ agonists
stimulate CD8+ T cell activation. Based on our bioinfor-
matic analyses at least two mechanisms may be involved
in this effect, i.e. the IDO-1 mediated catabolism of tryp-
tophan and synthesis of PD-1 ligand (CD274). The in-
hibitory effect of agonists on CD274 and IDO1 transcrip-
tion resulted in a decreased expression of both proteins and
synthesis of the IDO-1 product kynurenine. The latter is a
known suppressor of T cell activation (55), which we con-
firmed for the concentrations achieved in our experimental
system. Repression ofCD274 by PPAR/ agonist has pre-
viously also been described for human myofibroblastic cells
(69), emphasizing the potential relevance of this regulatory
effect of PPAR/. CD274/PD-L1 engagement of the PD-
1 receptor on T cells activates a key checkpoint restraining
T cell activation (56), which constitutes a key component of
immune suppression in the tumor microenvironment. We
also found several genes with functions in antigen presenta-
tion to be modulated by PPAR/ agonists. Whether these
changes play a role in the observed stimulation of T cell ac-
tivation remains to be investigated.
Pro-survival effects of PPAR/ agonists
Another clear biological effect of PPAR/ agonists is the
suppression of macrophage cell death under hypoxia, which
is frequently associated with inflammation (70) and im-
poses environmental stress on the resident inflammatory
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Figure 9. Identification of common and cell type-specific PPAR/ target genes. (A) Overlap of PPAR/ binding sites in WPMY-1 myofibroblast-like
cells, MDA-MB-231 breast cancer cells and MDMs. Common target genes (n = 129) were analyzed by IPA Diseases and Functions Annotation. The box
shows the top term by p-value of overlap. (B)Overlap of agonist-repressed genes. (C)RT-qPCR validation of common and macrophage-specific PPAR/
target genes in WPMY-1 and MDA-MB-231 cells. Values were normalized to 1 for untreated cells (solvent only) individually for each gene and cell line.
Statistical significance was tested relative to DMSO-treated cells.
cells. This biological effect of PPAR/ agonists is mirrored
by the observed changes in gene expression. Thus, several
transcription factor genes with death promoting functions
(e.g. ID3 and MYC) are downregulated by agonists, while
genes with pro-survival effects are upregulated (e.g. EGR3
andVDR). Our functional annotation analyses also showed
a strong overlap of PPAR/ target genes associated with
the inhibition of inflammation and cell survival, suggesting
a functional link. This group indeed harbors a number of
inverse target genes with both pro-inflammatory and death-
promoting functions, for example the cytokines TNF and
IL-1. In these cases, the downregulation of the same genes
by PPAR/ agonist may thus contribute to both an atten-
uation of the inflammatory response and a promotion of
cell survival.
A specific macrophage activation state induced by PPAR/
agonists
The bioinformatic analyses and biological data described
above clearly indicate that PPAR/ agonists have a pre-
dominantly, but not exclusively, anti-inflammatory effect on
MDMs. A recent study (3) reporting the transcriptomes for
MDMs exposed to 28 different stimuli provided a resource
to characterize the phenotype of agonist-stimulatedMDMs
in further detail. The authors used these data to define 49
modules of coregulated genes and determined the extent to
which each of these modules was associated with the dif-
ferent stimulation conditions, resulting in the development
of a spectrum model of macrophage activation. Compari-
son of these modules with the transcriptomes of L165,041-
stimulated cells unraveled highly significant overlaps with
activation states triggered by IL-4/IL13, TNF/INF and
fatty acids. These observations clearly confirm the hypothe-
sis that PPAR/ induces a unique activation phenotype
with components of anti-inflammatory, immune stimula-
tory and lipid-triggered activation states.
CONCLUSIONS
Numerous literature reports have documented an anti-
inflammatory effect of PPAR/ agonists with few dis-
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crepant findings. However, the molecular mechanisms un-
derlying the regulation of immune cells by PPAR/
are only partially understood. In the present study,
we have determined the PPAR/ transcriptome and
PPAR/-RXR cistrome in human MDMs to establish
the global PPAR/-regulated signaling network in hu-
man macrophages. This study showed that genes with im-
mune regulatory functions are regulated by PPAR/ ag-
onists in a macrophage-selective fashion by at least two
mechanisms: (i) canonical regulation, analogous to ubiqui-
tous PPAR/ target genes withmetabolic functions, which
involves transcriptional induction by agonists and direct
DNA contacts of PPAR/-RXR heterodimers, and (ii) re-
pression by agonists (inverse regulation) in the absence of
PPAR/ DNA binding. The latter mechanism affects to
a large extent NFB and STAT1 target genes, resulting in
the inhibition of multiple pro-inflammatory mediators in
line with the known anti-inflammatory effect of PPAR/
activation. However, consistent with the results of differ-
ent bioinformatic approaches, we also identified specific im-
mune stimulatory effects exerted by PPAR/ agonists. Be-
sides a pro-survival effect onmacrophages and inhibition of
CD32B surface expression, the most prominent example in
this context is the stimulation of T cell activation. The lat-
ter is presumably linked to the repression of the CD274 and
IDO1 genes, resulting in a diminished surface expression
of PD-1 ligand and a decreased production of the immune
suppressive kynurenine. Consistent with these observations,
the PPAR/ agonist-regulated transcriptome shows a sig-
nificant overlap with coexpression modules triggered by ei-
ther the anti-inflammatory IL-4 and IL-13 cytokines or the
pro-inflammatory mediators TNF and IFN . These find-
ings clearly indicate that PPAR/ agonists induce a novel
and unique macrophage activation state with strong anti-
inflammatory but also specific immune stimulatory compo-
nents. Collectively, these findings suggest that contrary to
the prevailing opinion PPAR/ exerts context-dependent
rather than merely inhibitory functions in immune regula-
tion.
It is obviously of great interest to analyze the effects of
PPAR/ ligands on macrophages in the context of other
immune cells in vivo. However, the identification of a mouse
model suitable to recapitulate the global role of PPAR/ in
the human immune system is associated with problems that
cannot easily be solved, if at all. Thus, as suggested by our
own data obtained with murine BMCs, murine BMDMs
and human MDMs, the effect of PPAR/ ligands on the
transcriptome of myeloid cells appears to be influenced by
their differentiation and/or activation state, and perhaps
also by species-specific effects. This suggests that data ob-
tained with human MDMs may not be easily transferable
to a mouse model. Testing the relevance of our findings in
a physiological setting therefore remains a major challenge
of future studies.
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AbstrAct
The nuclear receptor peroxisome proliferator-activated receptor β/δ (PPARβ/δ) 
is a lipid ligand-inducible transcription factor associated with macrophage 
polarization. However, its function in tumor-associated macrophages (TAMs) has 
not been investigated to date. Here, we report the PPARβ/δ-regulated transcriptome 
and cistrome for TAMs from ovarian carcinoma patients. Comparison with monocyte-
derived macrophages shows that the vast majority of direct PPARβ/δ target genes 
are upregulated in TAMs and largely refractory to synthetic agonists, but repressible 
by inverse agonists. Besides genes with metabolic functions, these include cell type-
selective genes associated with immune regulation and tumor progression, e.g., LRP5, 
CD300A, MAP3K8 and ANGPTL4. This deregulation is not due to increased expression 
of PPARβ/δ or its enhanced recruitment to target genes. Instead, lipidomic analysis of 
malignancy-associated ascites revealed high concentrations of polyunsaturated fatty 
acids, in particular linoleic acid, acting as potent PPARβ/δ agonists in macrophages. 
These fatty acid ligands accumulate in lipid droplets in TAMs, thereby providing a 
reservoir of PPARβ/δ ligands. These observations suggest that the deregulation of 
PPARβ/δ target genes by ligands of the tumor microenvironment contributes to the 
pro-tumorigenic polarization of ovarian carcinoma TAMs. This conclusion is supported 
by the association of high ANGPTL4 expression with a shorter relapse-free survival 
in serous ovarian carcinoma.
INtrODUctION
Macrophages of the tumor microenvironment 
play a pivotal role in promoting the growth, invasion, 
metastazation and therapy resistance of malignant tumors, 
as suggested by the correlation of disease progression with 
macrophage density in different types of human cancer and 
shown in mouse tumor models [1, 2]. Under the influence 
of chemokines, cytokines and growth factors secreted by 
tumor cells and other host-derived cells, monocytes are 
recruited from the circulation and differentiate into tumor-
associated macrophages (TAMs) that are programmed 
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to promote tumor progression [3-5]. Macrophages react 
to their microenvironment with an extreme plasticity 
[6], resulting in highly diverse phenotypes, with pro-
inflammatory “M1” and anti-inflammatory “M2” 
macrophages [4] as the extremes. Macrophages can also 
adopt mixed-polarization phenotypes with properties 
of both M1 and M2 cells [6], TAMs being a prominent 
example [4, 5, 7, 8]. 
Macrophage polarization is regulated by a plethora 
of signaling molecules and transcriptional regulators. 
These include the nuclear receptor proliferator-activated 
receptor β/δ (PPARβ/δ), a ligand-inducible transcription 
factor with established functions in intermediary 
metabolism and immune regulation [9, 10]. The latter has 
been documented in several reports addressing the role of 
PPARβ/δ in inflammatory responses of the skin [11, 12] 
and the M2-like polarization of macrophages in adipose 
tissue and liver [13, 14]. PPARβ/δ has also been implicated 
in tumorigenesis in a number of studies with conflicting 
results [15], which may be due to divergent functions of 
the receptor in tumor cells and tumor-associated host cells 
as well as differences in the experimental models used 
(mouse strains, synthetic ligands). 
PPARβ/δ binds to PPAR response elements (PPREs) 
at its target genes as a heterodimer with a retinoid X 
receptor (RXR), which is activated only upon interaction 
with an agonistic ligand (canonical regulation) [15]. 
These include unsaturated fatty acids [16], prostaglandin 
I2 (prostacyclin) [17], 15-hydroxyeicosatetraenoic 
acid (15-HETE) [18] and a range of synthetic ligands, 
originally developed in light of the association of PPARβ/δ 
with metabolic diseases [15]. Genome-wide analyses 
have identified PPRE-mediated repression as a major 
mechanism of transcriptional regulation by unliganded 
PPARβ/δ, and showed that an agonist-mediated switch 
induces a subset of these genes [19]. PPRE-mediated 
repression is enhanced by inverse agonists, such as ST247 
[20], which establish a repressor complex that apparently 
is different from the unliganded receptor complex [21]. 
PPARβ/δ can also regulate genes by interacting with 
specific transcription factors both in a PPRE-dependent 
[22] and independent fashion [23]. For example, 
unliganded PPARβ/δ in murine macrophages sequesters 
BCL6, a transcriptional repressor of inflammatory NFκB-
regulated genes [23]. PPARβ/δ also modulates NFκB 
signaling by other mechanisms, including its interaction 
with the p65 subunit of NFκB [24-27]. 
We have recently addressed the function of 
PPARβ/δ in normal human macrophages by determining 
the global PPARβ/δ-regulated signaling network in 
primary monocyte-derived macrophages [28]. Besides 
canonically regulated genes with metabolic functions, 
we also identified a number of target genes with immune 
regulatory functions. These are type-selective and 
subject to either canonical regulation, such as CD1D, 
CD52, CD300A, LRP5, NLRC, or indirect repression by 
agonists, mainly affecting NFκB and STAT target genes. 
Consistent with these findings, PPARβ/δ agonists triggered 
hallmarks of an anti-inflammatory phenotype. However, 
we also identified positive regulatory effects on specific 
immune modulatory modules, in particular a stimulation 
of T-cell activation. PPARβ/δ agonists thus induce a 
unique macrophage activation state with strong anti-
inflammatory but also specific stimulatory components, 
suggesting a context-dependent function of PPARβ/δ in 
immune regulation.
To date, transcriptome data for human TAMs has 
not been reported. Furthermore, the gene regulatory 
function of PPARβ/δ in TAMs has not been analyzed. 
Ovarian cancer is an excellent model to study TAMs, 
since these cells can be isolated in large quantities from 
the malignancy-associated peritoneal ascites. These 
ascites-derived macrophages display a mixed-polarization 
phenotype expressing both M1 and M2 markers [8]. 
Consistent with this finding, interpatient polarization 
differences unrelated to the M1/M2 classification scheme 
showed a clear association with the clinical outcome 
[8]. To elucidate the mechanisms underlying the pro-
tumorigenic polarization of TAMs in ovarian cancer and 
the role of PPARβ/δ in this context we determined the 
PPARβ/δ-regulated transcriptome and PPARβ/δ cistrome 
in ovarian carcinoma TAMs in comparison to normal 
human monocyte-derived macrophages (MDMs). 
rEsULts
Ligand-induced cellular alterations in human 
MDMs
CD14+ cells from human serous ovarian carcinoma 
ascites (TAMs) rapidly adhere to cell culture dishes 
and assume a macrophage-like morphology. We used 
this experimental system to investigate the affects of 
the synthetic PPARβ/δ agonist L165,041 on freshly 
isolated TAMs in short-term culture in comparison 
to normal monocyte-derived macrophages (MDMs). 
This comparison is conceptually relevant, since TAMs, 
including ascites-associated macrophages, are derived 
from blood monocytes [29-32]. Under the experimental 
conditions used TAMs showed a clearly enhanced 
expression of CD163 and a very low level of MMP9 
mRNA relative to MDMs (Figure 1A), which is consistent 
with the polarization phenotype of TAMs in vivo [8]. We 
therefore conclude that our experimental system is suitable 
to investigate ligand-induced changes in TAMs compared 
to MDMs. 
 We have previously described that the synthetic 
PPARβ/δ agonist L165,041 induces a morphology in 
MDMs that resembles that of IL-4 treated macrophages 
[28] (Figure 1B and 1C). TAMs, on the other hand, 
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displayed an unchanged morphology upon L165,041 
treatment (Figure 1D and 1E). This observation suggests 
that TAMs are largely unresponsive to exogenous 
PPARβ/δ ligands. In order to address the mechanistic basis 
of this observation we performed comprehensive genome-
wide studies as described below. 
Impaired ligand response and upregulation 
of PPARβ/δ target genes in cultured ovarian 
carcinoma tAMs
Ascites-derived adherent macrophages showed a 
clear accumulation of PPARβ/δ and RXR at the upstream 
enhancer of the established PPARβ/δ target gene PDK4 
[19, 33] in vivo (Figure 2A) with a strong enrichment of 
both factors (30-fold relative to IgG control for PPARβ/δ; 
40-fold for RXR). This is similar to the enrichment in 
MDMs (30- and 43-fold, respectively), but much higher 
compared to monocytes (4- to 5-fold, respectively). 
These data are therefore consistent with the definition of 
ascites-derived CD14+ cells as TAMs rather than ascites-
associated monocytes and confirm their suitability for 
PPARβ/δ centered genome-wide studies.
Toward this end, MDMs in normal growth medium 
and freshly isolated TAMs in ascites were exposed to a 
synthetic PPARβ/δ agonist, inverse PPARβ agonists or 
solvent (DMSO) for 1 day and analyzed by RNA-Seq 
(Table S2). The specificity of these ligands for PPARβ/δ is 
illustrated in Figure S1. Only a small number of genes (n 
= 30) were found to be induced by the agonist L165,041 
in TAMs (logFC≥1; FPKM≥0.3) compared to MDMs (n 
= 102) with a small intersection (n = 7; Figure 2B, top; 
Figure 2C; Table S3). On the other hand, the number of 
genes downregulated by the inverse agonists ST247 or PT-
S264 was considerably greater in TAMs (n = 50) relative 
to MDMs (n = 18) with a minor overlap (n = 8; Figure 
2B, bottom; Table S3). These findings would be consistent 
with the presence of high concentrations of PPARβ/δ 
agonists in TAMs relative to MDMs.
The observation that the majority of PPARβ/δ target 
genes were refractory to synthetic agonists was confirmed 
by RT-qPCR for PDK4 and ANGPTL4 (Figure 2D). Both 
genes were induced by L165,041 in MDMs >50-fold 
(average; blue symbols), whereas induction in TAMs 
cultured in ascites (orange symbols) was <10-fold (PDK4) 
or undetectable (ANGPTL4). When TAMs were cultured 
in R10 for 24 h instead of ascites, PDK4 induction was 
only slightly higher (grey symbols). These findings 
indicate that the loss of ligand regulation in TAMs is not 
dependent on the continuous presence of ascites, pointing 
to a relatively stable alteration affecting the regulation of 
PPARβ/δ target genes.
We have previously identified canonical PPARβ/δ 
Figure 1: Effects of PPARβ/δ ligands on the morphology of human MDMs and ovarian carcinoma TAMs. A. Expression 
of the macrophage polarization marker genes CD163 and MMP9 in cultured TAMs and MDMs. The data were obtained by RT-qPCR 
analysis of TAMs (red data points; n = 4) and MDMs (blue: n = 11) from different donors. Horizontal lines show the medians; asterisks 
indicate statistical significance. B, C. Giemsa staining of human MDMs differentiated in XV0 medium for 8 days in the presence of the 
PPARβ/δ agonist L165,041 or solvent (DMSO). D, E. TAMs treated with agonist or DMSO as in panel B and C.
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target genes in human MDMs that are agonist-induced 
and occupied by PPARβ/δ-RXR complexes [28]. In 
combination with the additional RNA-Seq data of the 
present study, a total of 195 ligand-regulated target 
genes were identified, defined as “upregulated by agonist 
versus inverse agonist”, 95 of which were associated with 
PPARβ/δ enrichment sites (Figure 2E; Table S3, columns 
“L” and “K”). Delineation of the PPARβ/δ cistrome for 3 
different patient samples in the present study (Suppl. Table 
S4) showed that at least 45 of these genomic loci were 
also occupied by PPARβ/δ in TAMs (Figure 2E; Table S3, 
column “J”), including those genes showing an altered 
ligand regulation in TAMs, exemplified by PDK4, CPT1A, 
SLC25A20, CD52 and PHACTR1 (Figure 2F). 
Deregulation of PPARβ/δ target genes in ovarian 
carcinoma tAMs in vivo
We next compared the expression and ligand 
regulation of PPARβ/δ target genes in ascites-associated 
macrophages from ten different patients (Table S5) with 
the set of 195 ligand-regulated target genes in MDMs 
identified by RNA-Seq analysis of cells from 5 healthy 
donors (see above; Table S3). Intriguingly, a large fraction 
of these PPARβ/δ target genes (dark blue dots; n = 54) 
Figure 2: Deregulation of PPARβ/δ target genes in cultured ovarian carcinoma TAMs. A. PPARβ/δ and RXR enrichment 
at the PDK4 enhancer and an irrelevant control region in human monocytes, MDMs and TAMs (ChIP-qPCR; sample size: 4). B. Venn 
diagrams of RNA-Seq data showing overlaps of ligand-regulated high-confidence direct target genes in MDMs grown in R10 medium or 
purified TAMs cultured in ascites for 1 day in the presence of agonist (L165,041), inverse agonist (ST247or PT-S264) or solvent (DMSO). 
C. Ligand response of PPARβ/δ target genes in TAMs versus MDMs. Data represents the log2 fold change (L165,041 relative to DMS0) 
calculated from RNA-Seq data. The diagonal line indicates equal regulation in both cell types. D. Expression and ligand response of PDK4 
and ANGPTL4 by L165,041 in MDMs in R10 (n = 7) and TAMs (n = 3) cultured in either ascites or R10 medium. Cells were cultured in 
the presence of ligand or DMSO for 24 h and analyzed by RT-qPCR. Data are expressed as fold regulation (FC) relative to DMSO-treated 
cells. E. Overlap of genes regulated in MDMs (agonist versus inverse agonist), genomic regions with PPARβ/δ binding sites in MDMs 
and PPARβ/δ enrichment sites in TAMs (ChIP-Seq). F. PPARβ/δ enrichment (ChIP-Seq) at the PDK4, CPT1A, SLC25A20, CD52 and 
PHACTR1 loci for 3 different TAM samples (bottom 3 lines: dark blue, green, red). The top 3 lanes (magenta, yellow, light blue) represent 
the corresponding control IgG runs. 
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Gene Description agonist MDM (FC)2
PPARβ/δ 
peak3
refractory in 
TAM4
ACADVL acyl-CoA dehydrogenase, very long chain 3.3 + +
ACSS3 acyl-CoA synthetase short-chain family member 3 2.3 - +
AMOTL1 angiomotin like 1 1.9 - +
ANGPTL4 angiopoietin-like 4 37.8 + +
ANKRD1 ankyrin repeat domain 1 (cardiac muscle) 1.8 - -
C19orf59 chromosome 19 open reading frame 59 6.7 + +
C1orf162 chromosome 1 open reading frame 162 2.2 + +
C1QC complement component 1, q subcomponent, C chain 1.5 - -
CABLES1 Cdk5 and Abl enzyme substrate 1 3.2 - +
CACNB1 calcium channel, voltage-dependent, beta 1 subunit 2.4 + +
CD300A CD300a molecule 1.5 + -
CLDND2 claudin domain containing 2 2.2 + +
CPT1A carnitine palmitoyltransferase 1A (liver) 3.4 + +
CXorf21 chromosome X open reading frame 21 1.8 + +
DLG4 discs, large homolog 4 (Drosophila) 1.6 + +
FAM3B family with sequence similarity 3, member B 2.7 - +
FCGR3A Fc fragment of IgG, low affinity IIIa, receptor (CD16a) 1.5 + -
FCGRT Fc fragment of IgG, receptor, transporter, alpha 1.5 + -
FOS FBJ murine osteosarcoma viral oncogene homolog 1.1 + -
GPA33 glycoprotein A33 (transmembrane) 1.8 - +
HMOX1 heme oxygenase (decycling) 1 1.3 + -
HP haptoglobin 2.2 - -
HPR haptoglobin-related protein 2.6 - -
HS3ST1 heparan sulfate (glucosamine) 3-O-sulfotransferase 1 4.4 - +
IL27 interleukin 27 1.2 - -
IMPA2 inositol(myo)-1(or 4)-monophosphatase 2 2.6 + +
INF2 inverted formin, FH2 and WH2 domain containing 1.5 - +
KBTBD11 kelch repeat and BTB (POZ) domain containing 11 1.3 - -
KLF11 Kruppel-like factor 11 1.4 - -
KRT4 keratin 4 1.9 - +
LRP5 low density lipoprotein receptor-related protein 5 6.6 + +
MACC1 metastasis associated in colon cancer 1 1.8 + -
MAP3K8 mitogen-activated protein kinase kinase kinase 8 1.5 - +
MEGF9 multiple EGF-like-domains 9 1.5 + -
MS4A14 membrane-spanning 4-domains, subfam. A, member 14 1.6 - +
MS4A7 membrane-spanning 4-domains, subfamily A, member 7 1.6 - -
Table 1: PPARβ/δ target genes upregulated1 in ovarian cancer TAMs.
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were upregulated (log2FC ≥0.7) in freshly isolated TAMs 
relative to MDMs (Figure 3A). Approximately half of the 
genes upregulated in cultured TAMs (21/40) overlapped 
with the genes upregulated in vivo (Figure 3B; Table 
S3), thus validating the results obtained in vitro. Most of 
the genes upregulated in TAMs were also refractory to 
regulation by a synthetic agonist (n = 32; Figure 3C; Table 
S3), suggesting a link between upregulation and loss of 
ligand regulation. A summary of these data is shown in 
Table 1.
Comparison of the expression levels of three 
PPARβ/δ target genes, PDK4, ANGPTL4 and CPT1A 
in TAMs from 12 patients and MDMs from 12 healthy 
donors confirmed this result (Figure 3D). As shown 
for PDK4, deregulation of gene expression in TAMs 
correlated with increased protein levels, which, in contrast 
to MDMs, were largely insensitive to ligand stimulation 
(Figure 3E).
Interestingly, we also found a number of PPARβ/δ 
target genes downregulated in TAMs relative to MDMs, 
for example FABP4 and ABCG2 (Figure 3A; cyan data 
points). Ovarian cancer is known to consist of a plethora 
of signaling mediators, including cytokines [8] and lipids 
(see data below). It is therefore likely that a subset of 
target genes is downregulated by repressive signaling 
pathways triggered by specific components of the ovarian 
cancer microenvironment, thereby preventing their 
potential stimulation analogous to the PPARβ/δ target 
genes discussed in the preceding paragraph.
The deregulation of ANGPTL4 is of particular 
interest, since its secreted product has been associated 
with cancer cell invasion and metastasis and is present in 
substantial amounts in the malignancy-associated ascites 
of most serous ovarian carcinoma patients (Figure 3F). We 
therefore tested the Cancer Genome Atlas (TCGA) cohort 
of 506 high grade serous ovarian cancer patients [34] for 
a potential link of ANGPTL4 expression to the clinical 
outcome of the disease. As depicted by the Kaplan-Meier 
plot in Figure 3G, ANGPTL4 levels showed a significant 
inverse association with relapse-free survival (RFS) [p 
= 0.0154; hazard ratio = 1.38 (1.06-1.79); median RFS: 
15.63 versus 19.8 months].
Annotation of all PPARβ/δ target genes 
constitutively upregulated in TAMs by Ingenuity Pathway 
Analysis (IPA) identified metabolism (glucose, lipid), 
inflammation, cell migration and survival as top functions 
(Figure 4A). As expected, the PPAR ligands (benzafibrate, 
EPA, rosiglitazone, pirinixic acid) were found among the 
top upstream regulators (Figure 4B). The presence of the 
pro-inflammatory mediator LPS in this list is consistent 
with the results obtained by the functional annotation 
analysis (inflammation).
PCOLCE2 procollagen C-endopeptidase enhancer 2 1.9 - -
PDE1B phosphodiesterase 1B, calmodulin-dependent 2.2 - -
PDK4 pyruvate dehydrogenase kinase 4 99.0 + +
PHACTR1 phosphatase and actin regulator 1 3.1 + +
PLIN2 perilipin 2 5.5 + +
PPP1R15B protein phosphatase 1, regulatory subunit 15B 1.6 + -
RBP7 retinol binding protein 7, cellular 1.8 - +
RCN3 reticulocalbin 3, EF-hand calcium binding domain 2.6 + +
RETN resistin 1.3 + +
S100Z S100 calcium binding protein Z 3.1 + -
SIPA1L2 signal-induced proliferation-associated 1 like 2 2.1 + +
ST14 suppression of tumorigenicity 14 (colon carcinoma) 2.4 + +
TCF7 transcription factor 7 (T-cell specific, HMG-box) 6.3 + +
TMEM150B transmembrane protein 150B 1.2 + -
TMEM37 transmembrane protein 37 1.7 + +
TRIM14 tripartite motif containing 14 1.6 - +
TSKS testis-specific serine kinase substrate 0.8 + -
VSIG10L V-set and immunoglobulin domain containing 10 like 1.4 + -
1 LogFC TAMs in vivo vs MDMs > 0.7 (Figures 4A and 4B; Tables S3, S5)
2 Ratio FPKM L165,041 / FPKM DMSO in MDMs (Figure 2B; Table S2)
3 Peak in MDMs or TAMs: ChIP-Seq data (Figures 2E ad 2F; Table S4; Adhikary et al., 2015)
4 Refractory to synthetic agonist in TAMs (Figure 3C; Table S3); <2.0-fold (Fig. 2D, 4A, 4C; Table S2)
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Deregulation of PPARβ/δ target genes by soluble 
mediators in malignancy-associated ascites
The data in Figure 2 suggests that the unaltered 
occupancy of direct target genes by PPARβ/δ-RXR in 
conjunction with a TAM-specific mechanism activating 
these chromatin-bound complexes is responsible for 
their deregulation in TAMs. One explanation for this 
deregulation could be the presence of ascites-associated 
activators of PPARβ/δ. We addressed this question by 
testing the effect of cell-free ascites samples on the 
regulation of PPARβ/δ target genes in MDMs. Figure 
5A shows a clear upregulation of the target genes 
PDK4, CPT1A, ANGPTL4, LRP5 and CD300A by two 
different ascites samples, which in several cases reached 
the level of L165,041 induction (Figure 5B; blue dots). 
Furthermore, induction of all 5 genes by L165,041 was 
severely diminished in the presence of ascites (Figure 5B; 
orange dots).
Therefore, we sought to investigate whether 
deregulation of target genes by ascites might be 
attributable to the activation of PPARβ/δ, and thus 
dependent on PPARβ/δ binding sites (PPREs) in these 
genes. It has previously been shown that an upstream 
enhancer with three contiguous PPREs mediates 
induction of PDK4 by PPARβ/δ ligands [19]. A luciferase 
construct with a genomic 1.5 kb fragment encompassing 
this enhancer showed a dramatic upregulation by three 
Figure 3: Deregulation of PPARβ/δ target genes in ovarian carcinoma TAMs in vivo. A. Expression of PPARβ/δ target genes 
(median FPKM values) in freshly isolated TAMs (median of 10 samples) versus MDMs (5 samples). The diagonal line indicates equal 
levels in both cell types. Blue dots: upregulation in TAMs ≥2-fold; cyan dots: downregulation ≥2-fold in TAMs; grey dots: no change. B. 
Overlap of PPARβ/δ target genes upregulated in freshly isolated TAMs versus MDMs (blue dots in A) and in cultured TAMs (experimental 
setup as in Figure 2). C. Overlap of PPARβ/δ target genes upregulated in TAMs versus MDMs (blue dots in A) and target genes refractory 
to synthetic agonists in TAMs (data from Figure 2B). D. RT-qPCR analysis of PDK4, ANGPTL4 and CPT1A mRNA expression levels in 
freshly isolated TAMs and MDMs from ovarian cancer patients (n = 12) and healthy donors (n = 12), respectively. Horizontal bars indicate 
the median. Statistical significance was tested between the respective TAM and MDM groups. E. Immunoblot analysis of PDK4 protein 
induction by PPARβ/δ agonist in MDMs and TAMs. The figure shows representative immunoblots (including PPARβ/δ and LDH as the 
loading control) for both cell types and a quantitative evaluation of biological replicates with TAMs from 3 different patients and MDMs 
from 3 donors. Cells were exposed to ligands for 1 d in R10 medium; TAMs were also analyzed directly after isolation (“ex vivo”). Signal 
intensities were quantified and standardized to LDH. The diagram on the right depicts the induction by L165,041 (fold change) in TAMs 
and MDMs in vitro; boxes show the ranges of inducibility and the median for each group of samples. Induction values for MDMs represent 
estimations due to the extremely low basal level of PDK4 in MDMs. The α-PDK4 antibody was validated as shown in Figure S2. n.s., non-
specific band. F. Concentrations of ANGPTL4 protein in the ascites of serous ovarian carcinoma patients (n = 32) determined by ELISA. 
The horizontal line indicated the median. G. Meier-Kaplan plot showing a correlation of high ANGPTL4 expression with the relapse-free 
survival of high grade serous ovarian carcinoma patients of the TCGA cohort (n = 377 in ANGPTL4 high group; n = 129 ANGPTL4 low) 
[62].
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different ascites samples (Figure 5C). These effects were 
clearly PPRE-dependent, since the mutation of 1, 2 or 
3 sites gradually abrogated the induction of luciferase 
activity by ascites (Figure 5C).
We found that PPARβ/δ target genes are inducible 
by ascites in murine bone marrow-derived macrophages 
(BMDMs), similar to human MDMs. We were therefore 
able to show that the observed target gene deregulation 
was dependent on functional PPARβ/δ. Ascites 
upregulated the Pdk4 and Angptl4 genes and abrogated 
their induction by L165,041 in wild-type BMDMs, 
whereas no significant ascites effect was detected on 
PDK4 in cells with disrupted Ppard alleles (Figure 5D). 
Likewise, the ascites-mediated induction of ANGPTL4 
was either absent (Asc69) or strongly reduced (Asc78) in 
Ppard null cells. These observations indicate that PPARβ/δ 
is responsible for the deregulation of PPARβ/δ target 
genes by ascites, even though a minor contribution by 
other PPAR subtypes cannot be unequivocally ruled out. 
ANGPTL4 is induced by a plethora of signaling pathways 
[35], which presumably explains the residual induction by 
Asc78 in Ppard null cells.
Endogenous agonists present in ovarian 
carcinoma ascites deregulate PPARβ/δ target 
genes in MDMs
The results described above suggest that ovarian 
cancer associated ascites might contain high levels of 
endogenous PPARβ/δ agonists. Since all known PPARβ/δ 
agonists are fatty acids or fatty acid derivatives, we 
performed a systematic lipidomic analysis of 97 molecules 
in 38 different ascites samples by LC-MS/MS (Suppl. 
Table S6). This analysis revealed consistently very high 
concentrations of several polyunsaturated fatty acids 
(PUFAs) known as PPARβ/δ agonists [16], with the 
highest levels observed with linoleic acid (LA) (Figure 
6A). The median concentration for LA was ~50 µg/
ml (~180 µM), which is far above the described IC50 of 
0.75 µM for PPARβ/δ binding [16]. This also applies to 
arachidonic acid (AA) and docosahexaenoic acid (DHA) 
with median ascites concentrations around 10 µg/ml 
(Figure 6A).
Addition of AA, LA or DHA to MDM cultures at 
a concentration of 20 µM for 24 h resulted in a strong 
induction of the PDK4 gene, while eicosapentaenoic 
acid (EPA) and α-linolenic acid (ALA) had only very 
modest effects (Figure 6B). PDK4 induction by LA was 
dose-dependent and rapid with a nearly 10-fold induction 
Figure 4: Pathway analyses of PPARβ/δ target genes constitutively upregulated in TAMs. A. IPA Diseases and Functions 
Annotation (functionally different clusters with lowest p-values and highest z-scores). Gene names are shown for the clusters with the 
largest number of genes. B. IPA Upstream Regulator Analysis (5 top regulators by p-value; z-score >2). 
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already after 3 h (Figure 6C). Similar results were obtained 
with the conjugated LAs 9(Z),11(E)LA and 10(Z),12(E)
LA (Figure 6C). LA also potently induced other direct 
PPARβ/δ target genes, and this induction was close, 
or even equal, to activation by L165,041, as shown for 
PDK4, CPT1A, PLIN2, SLC25A20, ANGPTL4, LRP5 and 
CD300A in Figure 6D. 
A number of PPARβ/δ target genes deregulated 
by ovarian cancer ascites have functions in oncogenesis 
and immune regulation. It was therefore of great interest 
to investigate whether their overexpression could be 
reverted by inverse PPARβ/δ agonists in spite of the high 
concentrations of agonists in ascites. As shown in Figure 
6E, treatment of MDMs cultured in ascites with increasing 
concentrations of PT-S264 for 24 h led to progressively 
lower levels of PDK4 mRNA expression. At the highest 
tested concentration (20 µM), expression was reduced to 
less than 5%. Likewise, CPT1A, SLC25A20, LRP5 and 
ANGPTL4 mRNA expression was reduced to basal levels 
by PT-S264, with LRP5 and ANGPTL4 being strongly 
repressed already at concentrations of 1 µM. These 
results clearly indicate that inverse agonists are suitable 
to counteract the deregulation of PPARβ/δ target genes in 
ovarian carcinoma TAMs. 
We also found two other endogenous PPARβ/δ 
agonists, 15-HETE [18] and 6-keto-prostglandin F
1α
 
(6-kPGF
1α
), the stable degradation product of prostacyclin 
[17, 36] in all ascites samples (Figure 6F). Both, 6-kPGF
1α
 
and 15-HETE were found at median levels of ~10 ng/ml 
(~30 nM), which corresponds to approximately 3% of the 
IC50 concentrations required for PPARβ/δ activation [18, 
36]. Both metabolites are therefore unlikely to play a role 
in the deregulation of PPARβ/δ target genes in TAMs.
Figure 5: Ascites deregulates PPARβ/δ target genes in normal macrophages and in a PPARβ/δ-dependent fashion. 
A. Upregulation of PPARβ/δ target genes by ascites in MDMs (n = 8; 4 different MDM samples; 2 different ascites samples). RT-qPCR 
data are expressed as fold change (FC) relative to MDMs R10 medium. B. Regulation of target genes by L165,041 in MDMs (n = 4) in 
R10 or ascites (2 different samples). Data indicate FC relative to DMSO-treated cells. C. PPRE-dependent induction of a PDK4 enhancer-
luciferase construct in transiently transfected HEY cells (n = 3). Constructs were mutated in either 1, 2 or all 3 PPREs, as indicated. Data 
were normalized to β-galactosidase activity from a co-transfected CMV-β-gal expression vector. D. Response of the direct PPARβ/δ target 
genes Pdk4 and Angptl4 to two different ascites samples and L165,041 in bone marrow-derived macrophages from wild-type and Ppard 
null mice (sample size: 3 each). Statistical significance was tested for induction by ascites relative to DMSO-treated cells in C and D 
(asterisks/ns above square brackets) and for induction by L165,041 or in D (asterisks/ns above blue bars).
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Fatty acid accumulation in lipid droplets 
correlates with transcriptional deregulation
The data in Figure 2D showed that ligand regulation 
in TAMs can only be partially restored by culturing the 
cells in normal cell culture medium. Since macrophages 
have a propensity to accumulate intracellular lipids, 
which is enhanced by PPARβ/δ [37], we tested this for 
ovarian carcinoma TAMs. As shown by staining with the 
fluorescent dye Nile Red, ascites-derived TAMs harbor a 
huge amount of lipid droplets, which remains basically 
unchanged upon culturing these cells in normal growth 
medium for 4 days (Figure 7A, 7B). The stability of 
lipid droplets correlated with a compromised ligand 
regulation of the PPARβ/δ target gene PDK4 (Figure 7C). 
Consistent with this finding, MDMs rapidly accumulate 
lipid droplets when exposed to LA at a high level found 
in ascites, which persisted upon withdrawal of the fatty 
acids (Figure 7D, 7E), concomitantly with an impaired 
inducibility by synthetic ligands (Figure 7F). It is 
therefore likely that internalization of PUFAs from the 
tumor microenvironment generates a reservoir of agonists 
contributing to a stable upregulation of PPARβ/δ target 
genes.
DIscUssION
PPARβ/δ regulates a large group of genes with 
functions in intermediary metabolism, inflammation and 
tumor progression, which are coordinately upregulated in 
TAMs by PUFA ligands present at high concentrations in 
the ascites of ovarian cancer patients (Table 1). Functional 
annotation analyses showed that these genes are not only 
associated with cell type-independent roles in energy 
production, fatty acid oxidation and lipid storage, but also 
figure in inflammation, cell migration and cell survival. 
Upregulation of several of these genes in TAMs is 
compatible with the pro-tumorigenic role of TAMs and 
may serve not only to skew TAM polarization but may 
Figure 6: PPARβ/δ ligands are present in ascites at high concentrations and induce PPARβ/δ target genes. A. LC-MS/
MS analysis of polyunsaturated fatty acids (PUFAs) in ascites from ovarian carcinoma patients (n = 38). B. Induction of PDK4 in MDMs 
after 24 h exposure to different PUFAs in different donors (n = 4-8). Each data point represents a biological replicate. C. Rapid induction 
(3 h stimulus) of PDK4 by LA and conjugated 9(Z),11(E)-LA and 10(Z),12(E)-LA in MDMs (triplicates). D. Induction of PPARβ/δ target 
genes in MDMs after 24 h exposure to linoleic acid (LA) in comparison to L165,041 (triplicates). E. Repression of PPARβ/δ target genes in 
MDMs (n = 3) cultured in ascites for 48 h by different concentrations of PT-S264 added during for the last 24 h of the experiment. Values 
were normalized to 1 for cells in ascites. F. LC-MS analysis of 15-HETE and the stable prostacyclin derivative 6k-PGF1α in the same 
samples as in A. Horizontal bars show the medians in panels A and B. Values represent averages of triplicate measurements ± standard 
deviation in all panels. Significance was tested relative to control cells.
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also directly promote tumor progression, for instance via 
the secretion of soluble mediators, such as ANGPTL4. 
We therefore propose that the deregulation of PPARβ/δ 
target genes by mediators of the tumor environment acts 
in conjunction with other signaling mechanisms to effect 
the pro-tumorigenic conversion of host-derived monocytic 
cells. 
Fatty acid PPARβ/δ ligands in ascites
Several PUFAs known to act as PPARβ/δ agonists 
were found in all ascites samples tested at levels exceeding 
the concentrations required for maximal PPARβ/δ 
activation, in particular LA, but also arachidonic acid and 
docosahexaenoic acid [16]. High levels of lipoprotein 
complexes in ovarian cancer ascites have been described 
in a previous study, but their fatty acid composition 
was not determined [38]. Another report suggests the 
mobilization of LA from omentum in ovarian cancer 
patients [39], consistent with the very high levels of this 
fatty acid in the malignancy-associated ascites found in 
the present study. Several studies also indicate that fatty 
acids are relevant to the biology and clinical outcome of 
ovarian cancer. Thus, the increased expression of the fatty 
acid synthase gene (FAS) predicts shorter survival [40], 
dietary fat intake and altered lipid metabolism are linked 
to ovarian cancer risk [41] and in a mouse model tumor 
growth and invasion are fueled by direct transfer of lipids 
from omental adipocytes to ovarian cancer with a key role 
for fatty acid-binding protein 4 [42].
Blood plasma also contains high concentrations 
of PUFAs [43], yet PPARβ/δ target genes are expressed 
at low levels in blood monocytes, which is presumably 
Figure 7: Association of the stable accumulation of lipid droplets in TAMs with the deregulation of the PPARβ/δ target gene PDK4. 
A. Staining of primary TAMs with Nile Red 0 h (ex vivo) and 4 d after plating in serum-free XV0 or R0 medium. B. Quantification of 
Nile Red stained TAMs (n = 3) treated as in A. C. L165,041 induction of PDK4 in MDMs (n = 3) and in TAMs (n = 3) cultured for 4d in 
ascites or R10 medium. D. Staining of MDMs with Nile Red before (d0) and after a 24-hour exposure to LA (d1), followed by a 4d fatty 
acid withdrawal in serum-free R0 medium (d1+4). E. Quantification of Nile Red stained MDMs (n = 2) before and after LA exposure as in 
D. F. L165,041 induction of PPARβ/δ target genes in MDMs (n = 4) pretreated with LA for 1 d, followed by a 4d serum-free R0 medium 
lacking fatty acids.
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due to the low level of PPARβ/δ expression in monocytes 
(Figure 2A and [28]), at least in part. TAMs represent a 
special situation in that these cells express PPARβ/δ at 
readily detectable levels and at the same time are exposed 
to high levels of ligands in the tumor microenvironment. 
Our findings also suggest that PPARβ/δ may serve as a 
marker to distinguish monocytes from macrophages, and 
also support the conclusion that ascites-associated CD14+ 
cells are macrophages rather than monocytes. 
Deregulated PPARβ/δ target genes in TAMs
The target gene ANGPTL4 [44, 45] is of particular 
interest in the context of the present study, since it not only 
figures in lipid metabolism as a regulator of lipoprotein 
lipase, but also plays an apparently essential role in tumor 
progression [46]. Thus, ANGPTL4 secreted by tumor cells 
in response to TGF-β and released into the circulation 
increases the permeability of lung capillaries and 
facilitates the extravasation of disseminated breast cancer 
cells in a mouse model [35]. Furthermore, ANGPTL4 
increases cancer cell invasion [21] and is part of gene 
expression signatures associated with distant metastasis in 
human cancer patients [35, 47]. ANGPTL4 also inhibits 
anoikis, which is essential for the survival of circulating 
tumor cells [48]. Consistent with these observations, 
several oncogenic signaling pathways converge on the 
ANGPTL4 gene, including TGFβ [21, 35, 45] and AP1 
[45].
Deregulated PPARβ/δ target genes with potential 
roles in macrophage regulation are CD300A and 
FOS. CD300A is a membrane glycoprotein with anti-
inflammatory functions. For example, deletion of the 
Cd300a gene in mice has been shown to result in pro-
inflammatory activation of peritoneal macrophages [49], 
suggesting that its upregulation in TAMs has an immune 
suppressive effect. On the other hand, FOS has been 
strongly associated with the pro-inflammatory activation 
of macrophages [50]. These observations are compatible 
with a role of deregulated PPARβ/δ target genes in 
mediating the mixed-polarization phenotype of TAMs [4, 
5, 7, 8].
Several other novel PPARβ/δ target genes 
upregulated in TAMs potentially play a role in promoting 
macrophage migration. i.e., PHACTR1 (phosphatase and 
actin regulator 1), MACC1 and ST14. PHACTR1 plays 
a role in the G-actin mediated control of actomyosin 
assembly [51], MACC1 is a transcriptional activator 
of MET (HGF receptor) and acts as a key regulator 
of cell motility [52], and ST14/epithin is a protease 
transcriptionally induced in macrophages by pro-
inflammatory pathways to mediate transendothelial 
migration [53].
Another PPARβ/δ target gene upregulated in TAMs 
is LRP5. Its product LRP5 acts as a Frizzled co-receptor 
and activator of Wnt signaling [54]. In macrophages, 
LRP5 is involved in the innate inflammatory reaction 
to lipid infiltration by activating the Wnt pathway and 
promoting lipid uptake, leading to the formation of foam 
cells [55]. It is possible that the deregulation of LRP5 in 
TAMs contributes to the intracellular accumulation of fatty 
acids in lipid droplets observed in the present study.
Finally, the dramatic upregulation of PDK4 
probably affect energy metabolism in TAMs such that 
glucose catabolism is shifted towards glycolysis and 
lactate production (Warburg effect) [56]. This would 
render TAMs largely independent from the availability of 
oxygen, thus endowing the cells with the ability to cope 
with the hypoxic conditions frequently encountered in the 
tumor microenvironment.
Our data also show that a large number of target 
genes that are deregulated by ovarian cancer ascites are 
repressed by inverse PPARβ/δ agonists, with PT-S264 
being able to suppress these genes below the basal level 
observed in the absence of ascites. Since several of these 
genes have functions in disease-associated processes as 
discussed above, inverse PPARβ/δ agonists may represent 
invaluable experimental tools to interfere with the tumor-
promoting effects of the ovarian cancer microenvironment. 
Expression of indirect PPARβ/δ target genes in 
tAMs
A large group of PPARβ/δ target genes in 
macrophages is repressed by PPARβ/δ agonists 
independent of direct DNA contacts (see Introduction). 
These genes are mostly associated with pro-inflammatory 
functions exerted by macrophages. In TAMs these inverse 
target genes are also frequently deregulated and refractory 
to synthetic ligands. However, the underlying mechanisms 
are complex, as indicated by the extreme variability of 
expression levels, ligand inducibility and ascites effects 
observed for different genes as well as individual patients 
(see Suppl. Figures S3 and S4 for examples). It is likely 
that the inverse target genes are highly prone to such 
variations, since they are regulated by multiple signaling 
pathways that are triggered by numerous cytokines whose 
concentrations are highly divergent among patients. It is 
obvious that these variabilities contribute to the observed 
heterogeneity, in many cases presumably without a 
significant contribution of PPARβ/δ itself. To understand 
the mechanistic basis of the altered transcriptome of 
inverse PPARβ/δ target genes in TAMs it will be necessary 
to perform in-depth analyses of transcription factor 
occupancy and epigenetic modifications at individual 
genes and relate this data to specific pathways and 
mediators.
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MAtErIALs AND MEtHODs
Ligands
L165,041 was purchased from Biozol. ST247 was 
synthesized as described [20, 57]. The inverse PPARβ/δ 
agonist PT-S264 is an optimized derivative of ST247 
with improved plasma stability (Toth et al., manuscript 
submitted). Synthetic ligands were used at a concentration 
of 1 µM in all experiments unless indicated otherwise. 
Cells were treated for 24 h unless indicated otherwise. 
PUFAs were obtained from Biomol. 
Mice
Ppard null and wt mice were generated by crossing 
floxed Ppard mice [58] and Sox2-Cre mice [59] as 
described [60]. Sox2-Cre mice were obtained from 
Jackson Laboratory (Bar Harbor, Maine), the floxed Ppard 
mouse strain was kindly provided by Dr. R. Evans (Salk 
Institute, La Jolla, CA). For genotyping the following 
primers were used: Ppard intron 3 (forward: GGC TGG 
GTC ACA AGA GCT ATT GTC TC), Ppard exon 4 
(forward: GGC GTG GGG ATT TGC CTG CTT CA); 
Ppard intron 4 (reverse: GAG CCG CCT CTC GCC ATC 
CTT TCA G; fragment sizes: Ppard wt: 360 bp; Ppard 
floxed: 400 bp; Ppard ko: 240 bp; Cre (forward: CCT 
GGA AAA TGC TTC TGT CCG; reverse: CAG GGT 
GTT ATA AGC AAT CCC); fragment size: 390 bp. 
Patient samples
Peripheral blood mononuclear cells (PBMCs) 
were obtained from healthy adult volunteers. Ascites 
was collected from untreated high-grade serous ovarian 
carcinoma patients undergoing surgery at the University 
Hospital Marburg. Informed consent was obtained from 
all patients according to the protocols approved by the 
institutional ethics committee. 
Isolation of cD14+ cells
Mononuclear cells were isolated from ascites and 
peripheral blood by Lymphocyte Separation Medium 1077 
(PromoCell) density gradient centrifugation and purified 
by magnetic cell sorting (MACS) using CD14 microbeads 
(Miltenyi Biotech) or adherence selection on cell culture 
dishes for 30 min. For ChIP experiments, TAMs were 
purified by adherence selection. The purity of CD14+ cells 
was > 90%. Purified TAMs and MDMs were analyzed by 
FACS, lysed in PeqGold (Peqlab) for RNA preparation or 
cultured as described below.
Cell culture and cytokine treatment of TAMs and 
MDMs
CD14+ monocytes and TAMs were cultured either 
in RPMI1640 with 10% fetal bovine serum (FCS; R10 
medium), serum-free RPMI1640 (R0 medium) or in 
serum-free macrophage X-VIVO 10 medium (XV0 
medium) (Biozym Scientific). Monocyte-derived 
macrophages (MDMs) were differentiated from CD14+ 
monocytes of healthy volunteers for 5-7 d at 1x106 cells/
ml. HEY ovarian cancer cells (ATCC) were maintained in 
DMEM plus 10% FCS.
Lipidomic analysis
Ascites samples (1 ml) were spiked with 100 
µl deuterated internal standard and extracted using 
solid reverse phase extraction columns (Strata-X 33, 
Phenomenex). Fatty acids derivatives were eluted into 1.0 
ml of methanol, lyophilized and resuspended in 100 ml of 
water/acetonitrile/formic acid (70:30:0.02, v/v/v; solvent 
A) and analyzed by LC-MS/MS on an Agilent 1290 
separation system. Samples were separated on a Synergi 
reverse-phase C18 column (2.1×250 mm; Phenomenex) 
using a gradient as follows: flow rate =0.3 µl/min, 1 min 
(acetonitrile/isopropyl alcohol, 50:50, v/v; solvent B), 3 
min (25% solvent B), 11 min (45% solvent B), 13 min 
(60% solvent B), 18 min (75% solvent B), 18.5 min (90% 
solvent B), 20 min (90% solvent B), 21 min (0% solvent). 
The separation system was coupled to an electrospray 
interface of a QTrap 5500 mass spectrometer (AB Sciex). 
Compounds were detected in scheduled multiple reaction 
monitoring mode. For quantification a 12-point calibration 
curve for each analyte was used. Data analysis was 
performed using Analyst (v1.6.1) and MultiQuant (v2.1.1) 
(AB Sciex).
Immunoblotting
Immunoblots were performed following standard 
protocols using the following antibodies: α-PPARβ/δ 
(sc-74517; Santa Cruz, Heidelberg, Germany), α-PDK4 
(ab110336; Abcam, Cambridge, United Kingdom), α-LDH 
(sc-33781; Santa Cruz, Heidelberg, Germany), α-rabbit 
IgG HRP-linked AB and α-mouse IgG HRP-linked 
AB (cs7074, cs7076; Cell Signaling, NEB, Frankfurt, 
Germany). ChemiDoc MP system and Image Lab software 
version 5 (Bio-Rad, München, Germany) were used for 
detection and quantification.
Quantification of secreted ANGPTL4 protein
ANGPTL4 levels in ascites from ovarian cancer 
patients were determined by ELISA (Aviscera Bioscience, 
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Santa Clara, CA), according to the instructions of the 
manufacturer. The antibody used in this kit recognizes the 
bioactive C-terminal processing product (cANGPTL4). 
Nile red staining
Cells were stained for 10 minutes at 37 °C with 500 
nM Nile Red (Biomol, Hamburg, Germany) in PBS and 
visualized using a Leica DM5000 B microscope. Nuclei 
were stained using Vecta Shield with DAPI (Biozol, 
Eching, Germany). For quantification the percentage of 
Nile Red positive cells was determined by counting 20 
faces per donor or patient per treatment.
Luciferase reporter assay
The PDK4 upstream enhancer region was cloned 
into pGL3-TATAi [61] via KpnI sites using the following 
primers:
5’-AAAGGTACCAAATGCTGAGTTTGGGCAAC 
and 5’-AAAGGTACCAGCCTTGTGAGCAACCAAAG. 
PPREs were mutated with the following primers 5’ 
-CAGGCTAAGTTGGTGTATGGTCAGTCCCACACC, 
5’-GAAGTTTAGTAGGTGTACGGTCACTGCTGCCGA 
and5’-AGAGCTCACTAGGGGTATGGTCGGGGAGAC
CAAG,  and their respective reverse complement primers. 
HEY1 cells were transfected with the indicated reporter 
vector and pEF6/V5-His-TOPO/lacZ (Life Technologies) 
as described [18] and incubated overnight in DMEM with 
2% FCS. On the next day, cells were washed with PBS 
and received either fresh medium with or without 1 µM 
L165,041 or ascites for 24 h. Lysates were prepared and 
measured according to the manufacturer’s instructions 
(Beetle Juice Big and β-Gal Juice PLUS Kit for 
normalization; pjk GmbH) with an Orion L luminometer 
(Berthold).
rt-qPcr and rNA-seq
cDNA isolation and qPCR analyses were performed 
as described [20]. L27 was used for normalization. Primer 
sequences are listed in Suppl. Table S1. RNA-Seq was 
carried out as described elsewhere [28]. Sequencing data 
were deposited at EBI ArrayExpress (accession number 
TAM data: E-MTAB-3167; MDM data: E-MTAB-3114 
and E-MTAB-3398). Data were quantile normalized using 
all RNA-Seq datasets. Gene model data were retrieved 
from Ensembl revision 74.
Bioinformatic analysis of RNA-Seq data
We sequenced 10 TAMs samples from 10 patients 
directly after harvesting (“in vivo”), one additional 
TAM sample was used for ligand response experiments 
in autologous ascites (“in vitro”; L165,041, ST247 and 
DMSO). In addition to previously described MDM ligand 
response experiments from two donors [28] in R10 and 
X0 medium (L165,041, ST247, PT-S264, DMSO), we 
performed three additional sets from three donors in R10 
(L165,041, PT-S264 and DMSO control). ST247 was used 
at a concentrations of 300 nM, all others at 1 µM. 
Genes were considered for differential expression 
analyses only if they had an FPKM of at least 0.3 and 
a minimum of 50 tags in at least one sample. LogFC 
values for ligand experiments were calculated pairwise 
for individual donors. For ligand regulation in MDMs 
(Figure 2B) a logFC of at least 0.7 in 4 out of 5 replicates 
was required. Figure 2C shows median pairwise logFC 
data. Regulated target genes in MDMs (n = 195; Figures 
2E and 3A) were defined as genes showing regulation 
in at least one of the following comparisons: agonist vs 
DMSO control (up regulated), inverse agonist vs DMSO 
control (down regulated) or agonist vs inverse agonist (up 
regulated). Figure 3A shows median FPKM values of 10 
TAM samples and 5 MDM DMSO control samples. In 
Figure 3B and 3C, “up in TAM in vivo” is a subset of 
the canonical target genes that showed a 2-fold (1 logFC 
unit) difference between TAMs and MDMs. Table S5 was 
filtered based on t-tests between 10 TAM in vitro samples 
and 5 MDM DMSO samples (FDR/Benjamini-Hochberg 
≤0.05). The set “up in TAM in vitro” is similarly defined 
as canonical target genes that (i) were upregulated (0.7 
logFC) in TAM/DMSO compared to the two previously 
reported MDM/DMSO samples, and (ii) showed an at 
least 0.5 units higher FPKM value in the TAM sample 
compared to both MDM samples. Agonist refractory genes 
(Figure 3C) are agonist inducible genes in MDMs that 
showed no such regulation (same logFC threshold) or less 
than 50% induction (fold change) by L165,041 in TAMs 
relative to MDMs. 
chIP-Pcr and chIP-seq
ChIP was performed and evaluated as described 
using the following antibodies: IgG pool, I5006 (Sigma 
Aldrich); α-PPARβ/δ, sc-7197; α-RXR, sc-774 (Santa 
Cruz, Heidelberg, Germany). ChIP-Seq, mapping of ChIP-
Seq reads and peak calling were carried out as described 
[28].
Bioinformatic analysis of ChIP-Seq data
ChIP-Seq peaks were filtered for at least 30 
deduplicated tags and a fold change (FC) over IgG of ≥2 
(normalized total read counts). Regions were considered 
bound by PPARβ/δ in TAMs if they enrichment sites 
were observed in at least two out of three TAM samples 
sequenced. PPARβ/δ binding in MDMs has been described 
elsewhere [28]. For Figure 2E, PPARβ/δ-occupied genes 
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were identified as genes with a transcription start site close 
to, or within 50 kb of, an enrichment site. All genomic 
sequence and gene annotation data was retrieved from 
Ensembl revision 74. 
Functional annotations and pathway analyses
Functional annotations and pathway analyses were 
performed using the Ingenuity Pathway Analysis (IPA) 
application and knowledge database (Qiagen Redwood 
City, CA, USA). Results were sorted according to p-value 
of overlap (minimum 0.001) and activation z-scores (≤-
2.0 or ≥+2.0) Sequencing data were deposited at EBI 
ArrayExpress (accession number E-MTAB-3166). 
Statistical analysis of experimental data
Data are presented as the average of replicates (n = 
3 unless indicated otherwise) with error bars indicating 
standard deviations and horizontal lines in dot plots 
representing averages. Comparative data were statistically 
analyzed by Student’s t-test (two-sided, equal variance) 
and results expressed as follows: ns, not significant (p ≥ 
0.05); *p < 0.05, **p < 0.01 or ***p < 0.001.
Survival-associated gene expression analysis
Associations between gene expression and relapse-
free survival of ovarian cancer patients were analyzed 
using the web based tool “KM Plotter” (http://kmplot.com/
analysis/index.php?p=service&cancer=ovar) [62] with the 
following settings: ‘auto select best cutoff’, stage: 2+3+4, 
histology: serous, dataset: TCGA; other settings: default). 
Logrank Mantel-Cox test (p-values), logrank Hazard Ratio 
(HR) and median survival times were calculated using the 
GraphPad Prism software.
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ABSTRACT
Macrophages occur as resident cells of fetal origin or as infiltrating blood 
monocyte-derived cells. Despite the critical role of tumor-associated macrophages 
(TAMs) in tumor progression, the contribution of these developmentally and 
functionally distinct macrophage subsets and their alteration by the tumor 
microenvironment are poorly understood. We have addressed this question by 
comparing TAMs from human ovarian carcinoma ascites, resident peritoneal 
macrophages (pMPHs) and monocyte-derived macrophages (MDMs). Our study 
revealed striking a similarity between TAMs and pMPHs, which was considerably 
greater that the resemblance of TAMs and MDMs, including their transcriptomes, 
their inflammation-related activation state, the presence of receptors mediating 
immune functions and the expression of tumor-promoting mediators. Consistent with 
these results, TAMs phagocytized bacteria, presented peptide antigens and activated 
cytotoxic T cells within their pathophysiological environment. These observations 
support the notion that tumor-promoting properties of TAMs may reflect, at least to 
some extent, normal features of resident macrophages rather than functions induced 
by the tumor microenvironment. In spite of these surprising similarities between 
TAMs and pMPHs, bioinformatic analyses identified a TAM-selective signature of 30 
genes that are upregulated relative to both pMPHs and MDMs. The majority of these 
genes is linked to extracellular matrix (ECM) remodeling, supporting a role for TAMs 
in cancer cell invasion and ovarian cancer progression.
INTRODUCTION
High-grade serous ovarian carcinoma (HGSC) is the 
most common ovarian malignancy with a dire prognosis 
with an overall 5-year survival rate of <40% [1]. The 
features that contribute to the fatal nature of ovarian 
HGSC and distinguish this cancer from other human 
malignancies include the peritoneal environment, which 
is frequently formed by the effusion building up in the 
peritoneal cavity. This malignancy associated ascites is 
rich in tumor-promoting soluble factors [2] and immune 
cells, in particular tumor-associated T cells (TATs) [3] and 
tumor-associated macrophages [4, 5] (TAMs).
TAMs play a crucial role in promoting tumor cell 
proliferation, dissemination, chemoresistance and immune 
evasion, as suggested by the correlation of disease 
progression with macrophage density in different types 
of human cancer and mouse models, including ovarian 
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HGSC [6–8]. Although TAMs can be derived from 
recruited blood monocytes [9–11], more recent evidence 
clearly points to a substantial contribution by tissue-
resident macrophages [12–18].
A hallmark of macrophages is their plasticity in 
response to their microenvironment [19], with “M1” and 
“M2” macrophages as operationally defined extremes 
[20]. Classical M1 activation confers immune stimulatory, 
pro-inflammatory properties, while alternatively activated 
M2 macrophages comprise a wide spectrum of subtypes 
with functions in tissue repair, angiogenesis and immune 
regulation. TAMs have been proposed to resemble “M2” 
macrophages, in agreement with their role in tumor 
promotion and immune suppression. Consistent with this 
conclusion, expression of the classical M2 marker CD163 
on TAMs showed a strong correlation with early relapse 
of serous ovarian carcinoma after first-line therapy [4]. 
Furthermore, data derived from mouse models showed 
that pro-inflammatory signaling pathways are defective in 
TAMs [7, 20–23]. However, macrophages can also adopt 
properties of both M1 and M2 cells [19], and several 
studies suggest that TAMs represent such a mixed-
polarization phenotype [4, 11, 20, 24].
Macrophages in the adult mouse can have two 
developmentally different origins. While infiltrating 
macrophages are derived from blood monocytes produced 
by the bone marrow, tissue macrophages, including 
alveolar, peritoneal, splenic, hepatic (Kupfer cells) and 
dermal (Langerhans cells) macrophages, are of fetal (yolk 
sac) origin [17, 25–30]. The transcription factor MYB 
is essential for the development of murine bone-marrow 
macrophages [25], whereas GATA6 is indispensable for 
the fetal lineage and distinguishes resident from infiltrating 
macrophage [26, 31]. Whether ovarian cancer ascites-
associated macrophages are derived from infiltrating 
monocytes, resident peritoneal macrophages or both is 
unclear.
Our current view of the tumor-mediated activation 
state of macrophages is largely based on studies comparing 
TAMs to monocyte-derived macrophages (MDMs) [9, 
32]. Systematic analyses comparing TAMs to normal, 
uncultured macrophages are currently not available. 
The present study reveals for the first time a surprising 
similarity between TAMs and resident peritoneal 
macrophages (pMPHs) with respect to both their 
differentiation and polarization state, but also delineates a 
TAM-selective signature associated that is associated with 
extracellular matrix remodeling.
RESULTS
Similar expression of differentiation and 
activation markers by TAMs and pMPHs
We first compared pMPHs from patients undergoing 
hysterectomy for non-malignant diseases and TAMs from 
ovarian cancer ascites (Supplementary Table S1) for 
expression of inflammation and activation markers by 
flow cytometry. The data in Figure 1A and 1B show that 
surface expression of the Fcγ receptors CD16 (FCGR3), 
CD32 (FCGR2) and CD64 (FCGR1) was similar for both 
cell types, with respect to both the fraction of positive 
cells (Figure 1A) and the mean fluorescence intensity 
(MFI; Figure 1B). HLA-DR was expressed on >95% 
of all cells analyzed, but the measured MFI was clearly 
higher on MPHs (Figure 1B). The “M2” markers CD163, 
CD206 and intracellular IL-10 were similarly expressed 
by both TAMs and pMPHs, except for a tendency towards 
a higher fraction of CD163+ and CD206+ in MPH samples 
(Figure 1B). Our data also indicate that neither CD163 
nor CD206 distinguishes TAMs from pMPHs, regardless 
of the underlying non-malignant condition of the patients 
(Figure 1C). Consistent with our observation, human 
pMPHs have previously been shown to express high levels 
of CD163 and display characteristics of anti-inflammatory 
macrophages [33]. Thus, while there are detectable 
differences between TAMs and pMPHs, both cell types 
do not differ in terms of a directional inflammation-related 
polarization switch.
To identify differences between TAMs and pMPHs 
by a systematic approach we compared the transcriptome 
of 17 TAM, 4 pMPH and 3 of non-polarized (M0) 
MDM samples by RNA sequencing (all RNA-Seq data 
in Supplementary Dataset S1; TAM and pMPH samples 
were uncultured primary cells). Pearson correlation of 
median gene expression values showed a high similarity 
of all TAM and pMPH transcriptomes (r = 0.93), while 
MDM were considerably more divergent (r = 0.79; 
Supplementary Figure S1). Pearson correlation analysis 
for individual samples yielded a similar result (median r = 
0.84 for TAMs versus pMPHs; r = 0.74 for TAMs versus 
MDMs; Figure 2A, 2B). These results were confirmed 
by PCA which split our samples in two groups: TAM/
pMPH and MDM (Figure 2C). As expected the correlation 
between TAMs and TATs or tumor cells was very low (r = 
0.34; Figure 2B).
Consistent with the global resemblance of TAMs 
and pMPHs, at least 3 markers selectively expressed 
in resident macrophages in the mouse [26–29, 31, 34–
36], i.e., ADGRE1 (F4/80), GATA6 and TIMD4, were 
expressed at similar levels in both TAMs and pMPHs, 
but much lower, if at all, in MDMs (Figure 3A). The 
opposite scenario was observed for CD52, reported to be 
preferentially expressed in monocyte-derived cells [37]. 
In agreement with these data, TIMD4 surface expression 
was stronger on TAMs compared to MDMs (Figure 1D), 
whereas CD52 was higher on MDMs (Figure 1E).
The RNA-Seq data also revealed similar expression 
levels in TAMs and MPHs for all markers of macrophage 
functions tested, including phagocytosis-associated 
receptor genes (CD36, MSR1, SCAR family genes, TIMD4, 
CD163), FCGR genes, complement receptor genes (CD93/
C1Q-R1, C3AR, CR1, C5AR1) and all polarization marker 
genes tested, including CD163 and IL10 (Figure 3A). 
122
Oncotarget3www.impactjournals.com/oncotarget
These observations are in perfect agreement with the flow 
cytometry analysis described above (Figure 1A–1C). 
Similar observations were made for genes encoding 
pro-tumorigenic cytokines or growth factor (Figure 3B), 
previously found to be mainly expressed by TAMs within 
the ovarian cancer microenvironment [38]. These results 
indicate that ovarian carcinoma ascites-associated TAMs 
closely resemble pMPHs not only with respect to their 
activation state but also with regard to some of their pro-
tumorigenic functions.
Immune functions of TAMs
The similarity with pMPHs described above 
suggested that macrophage-mediated immune functions 
might be preserved in ovarian carcinoma TAMs, at least 
to some extent. While TAMs can be maintained ex vivo 
for functional assays under conditions resembling their 
pathophysiological microenvironment (ascites), it is not 
possible to culture pMPHs under physiological conditions 
(e.g, peritoneal fluid). We therefore focused our analyses 
on short-term cultures of TAMs in ascites, and used 
MDMs as positive controls.
An essential function of tissue resident macrophages 
is the phagocytosis of pathogens and apoptotic cells 
[27, 33, 39–41]. Consistent with the expression pattern 
of phagocytosis-associated receptors (Figure 3A) the 
TAMs were able to efficiently phagocytize labelled E. coli 
particles (Figure 4A, 4B).
Figure 1: Similarities of TAMs and pMPHs. A, B. Flow cytometry analysis of freshly isolated TAMs and MPHs for cell surface 
receptor and intracellular IL-10 expression. The data show the fraction of CD14+ cells (A) or the median fluorescence intensity (MFI) 
of positive cells (B). Sample sizes were n=71 (TAM) and n=10 (pMPH), respectively. C. Quantification of CD163+ and CD206+ cells in 
TAM (n=71) and pMPH (n=10) samples isolated from patients undergoing surgery for myomatosis (squares), ovarian cysts (triangles) or 
endometriosis (circle). D, E. Flow cytometry analysis of TIMD4 (% positive) and CD52 (MFI) on TAMs (n=3) and MDMs (n=3). *p<0.05; 
**p<0.01; ****p<0.0001 by t-test; ns: not significant; horizontal lines: median.
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Another function reported for human pMPHs is 
the presentation of peptide antigens [42–46]. In view 
of the high expression of HLA genes in TAMs (Figure 
1) we therefore investigated the capacity of TAMs to 
trigger antigen-specific cytotoxic T cell activation. For 
this purpose, we exposed TAMs to a mixture of antigens 
(CEFT) derived from pathogens most individuals have 
previously been sensitized to and have developed 
antigen-specific memory T cells. Restimulation with 
these recall antigens results in the activation of this 
subset of antigen-specific T cells (1% of all T cells). 
Using intracellular IFNγ production as an activation 
marker, we found a clear stimulation of CD8+ T cells 
by TAMs within a range similar to the positive control 
(Figure 4C; non-stimulated cells served as negative 
controls for background substraction). Collectively, 
these data show that known immune functions of pMPHs 
are retained by TAMs in their pathophysiological 
environment.
Previous studies in mouse models have shown that 
pro-inflammatory signaling pathways are non-functional in 
TAMs in different tumor types [7, 20–23], and that ovarian 
cancer TAMs are refractory to pro-inflammatory stimuli 
[47]. In agreement with these observations we found that 
both expression of the pro-inflammatory mediator gene 
IL12B and secretion of its product p40 are not inducible 
by lipopolysaccharide (LPS) and interferon-γ (INFγ) in 
TAMs, whereas a strong induction was observed with the 
positive control (Figure 4D, 4E).
Genome-wide expression profiles of TAMs 
and pMPHs and delineation of a TAM-specific 
signature
We next sought to gain further insight into the specific 
phenotype of ovarian cancer TAMs by in-depth analysis 
of the transcriptomic data. Toward this end, we started 
out by analyzing the RNA-Seq data sets with edgeR, a 
Bioconductor package specifically developed for reliable 
gene-specific dispersion estimation in small samples by 
ranking genes that behave consistently across replicates 
more highly than genes that do not [48, 49]. The edgeR tool 
identified a group of 21 genes expressed at significantly 
different levels in TAMs versus pMPHs (Supplementary 
Table S1). We then searched for genes showing highly 
correlated expression pattern across all TAM samples 
(r >0.9) and a higher median expression in TAMs versus 
pMPH or vice versa (FC >3-fold). This resulted in the 
definition of an extended datasets of 30 genes upregulated in 
TAMs (Supplementary Dataset S2; Supplementary Figure 
S2; Figure 5A). PCA of TAM, pMPH and MDM samples 
for the upregulated gene set yielded clearly separable 
clusters for TAMs versus pMPHs or MDMs (Figure 5A), 
showing that the chosen strategy was successful.
We performed similar analyses with TAMs 
and MDMs (Supplementary Table S2) leading to an 
extended datasets of 497 upregulated genes (Figure 
5B). The majority of genes upregulated in TAMs 
versus pMPHs (20/30) were also upregulated relative to 
Figure 2: Similarity of TAMs and pMPH transcriptomes. A. Correlation heatmap (Pearson r) of the transcriptomes of TAM, 
pMPH and MDM samples. B. Pearson correlation (r) of the TAM transcriptome to that of pMPHs, MDMs, TATs and tumor cells (TU) for 
all individual samples. Bars: 95% CI; horizontal lines: median. C. Principle component analysis (PCA) of TAM, pMPH and MDM samples. 
Sample sizes were n=16 (TAM), n=4 (pMPH), n=3 (MDM), n=5 (TAT) and n=19 (TU), respectively, in all panels.
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MDMs (Figure 5B), thus providing a further validation 
of the upregulated gene set. Since only few genes 
were downregulated in TAMs versus pMPHs (n = 4; 
Supplementary Dataset S3; Supplementary Figure S3 and 
Supplementary Figure S4), we focused all further analyses 
on the upregulated gene set.
A TAM-specific ECM gene cluster
Gene Ontology (GO) term analysis showed 
a very strong association of the upregulated genes 
with extracellular matrix (ECM) and collagen fibril 
organization (Figure 5C; Supplementary Table S3). IPA 
Upstream Regulator Analysis identified these genes as 
targets mainly of TGFB and pro-inflammatory (LPS, TNF, 
INFG) signaling pathways (Figure 5D). This is intriguing 
in light of previous studies reporting the presence of 
TNFα and TGFβ1 in the ascites of the vast majority of 
ovarian cancer patients and their association with disease 
progression [2, 4, 50–53]. Hierarchial clustering using 
correlation as distance metric identified a group of 19 co-
regulated genes, which make up 63% of all upregulated 
genes identified (Figures 5E and Supplementary Figure 
S2). Intriguingly, this cluster harbors virtually all regulated 
genes associated with ECM remodeling. We subsequently 
refer to these genes as the “ECM cluster”.
Figure 3: Expression of genes coding for proteins with immune or pro-tumorigenic functions by TAMs and normal 
macrophages. A. Expression of genes coding for differentiation markers (resident/infiltrating macrophages), immune functions or “M1/
M2” polarization markers (RNA-Seq data). B. Expression of genes associated with pro-tumorigenic functions. Boxes show the upper and 
lower quartiles, whiskers the 95% confidence intervals amd horizontal lines the median. Sample sizes were n=16 (TAM), n=4 (pMPH), n=4 
(MDM), respectively. *p<0.05; **p<0.01; ****p<0.0001 by t-test; ns: not significant.
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The expression patterns of the ECM signature genes 
in TAMs and pMPHs shown in Figure 6A (red versus 
blue bars) clearly document their selective upregulation 
in TAMs. Similar results were obtained when expression 
in TAMs was compared to MDMs (red versus grey bars 
in Figure 6A) with only few exceptions, providing further 
evidence tor the robustness of the ECM signature and its 
association with tumor-triggered events. Comparison with 
tumor cells and TATs showed that most of these genes are 
mainly expressed by TAMs and tumor cells (Figure 6B). 
We also analyzed several genes of the ECM signature by 
RT-qPCR and could fully verify the RNA-Seq data in 
all for cases (Figure 6C). Finally, we also found readily 
detectable levels of PCOLCE2 protein by ELSIA in 
ovarian cancer ascites (Figure 6D), supporting a potential 
functional relevance of the upregulated ECM signature 
genes.
Contamination of TAM samples with tumor cells 
was very low in most samples, in several cases even 
undetectable (Supplementary Table S4). Furthermore, none 
of the ECM cluster genes were expressed at substantially 
higher levels by tumor cells relative to TAMs (Figure 6B), 
thus ruling out the possibility that the expression observed 
in TAM samples results from residual tumor cells. Another 
cell type present in ascites, albeit at low numbers, are 
carcinoma-associated fibroblasts (CAFs) [54]. Importantly, 
all CAF marker genes analyzed were either expressed at 
similar levels in both TAMs and pMPHs (Supplementary 
Figure S5) and/or did not show any appreciable correlation 
with expression of ECM cluster genes, as exemplified for 
Figure 4: Immune functions of ovarian carcinoma TAMs. A. Phagocytosis of E. coli particles conjugated to a pH-sensitive 
fluorochrome (pHrodo) by ovarian cancer TAMs in ascites. The plots show flow cytometry analysis of cells incubated at 37°C (active 
phagocytosis) and 4°C (background control). B. Quantification of 3 independent experiments as in panel A with TAMs in ascites. MDMs in 
RPMI medium were included as positive control. C. Antigen-specific CD8+ T cell stimulation. TAMs from the ascites of 5 ovarian cancer 
patients cultured in ascites were loaded with the recall antigen peptide mix CEFT and analyzed for their ability to stimulate INFγ production 
by co-cultured T cells. The fraction of CD8+IFNγ+ cells was determined by flow cytometry. MDMs established from 5 different donors were 
used as positive control. D. IL12B expression in TAMs (n=3) cultured in autologous ascites for 2 d. Cultures were stimulated with LPS (100 
ng/ml) and INFγ (20 ng/ml) or solvent only (none) for 24 h and RNA was analyzed by RT-qPCR. MDMs (n=3) in RPMI were included as 
positive control. E. p40 (IL-12B/IL-23) protein concentrations in the culture medium of the experiments in panel D. Each dot represents 
an independent sample in B-E. Horizontal lines: median; vertical bars: range. ***p<0.001 by t-test between unstimulated and INFγ/LPS-
stimulated cells in panels D and E; ns: not significant.
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Figure 5: Identification of a transcriptional ECM signature of genes upregulated in TAMs versus normal macrophages. 
A. PCA of TAM, pMPH and MDM samples for the upregulated gene set. TAM52 (x=3.4) is outside the range displayed. B. Venn diagram 
of genes upregulated in TAMs versus pMPHs or MDMs (FC >3; TPM>1.5). C. Functional annotation of upregulated genes by GO term 
analysis (Supplementary Table S3). The bar plot shows the top 5 terms (p< 0.001). D. Upstream regulator analysis (Ingenuity pathway 
database) of upregulated genes with a minimum overlap of gene sets of 30% (query gene set and genes targeted by indicated pathways). E. 
Correlation-based hierarchial clustering of upregulated genes. See Materials and Methods for details.
Figure 6: Expression of ECM signature genes. A. Expression of upregulated genes across TAM, pMPH and MDM samples. Data 
are represented as in Figure 2. Arrows point to genes with functions in ECM remodeling. B. Expression of upregulated genes (panel B) in 
different ovarian carcinoma-associated cell types, pMPHs and MDMs. The stacked boxes show the respective median expression values 
(TPM). C. Validation of RNA-Seq data by RT-qPCR. Each symbol represents a biological replicate (TAM: n=4; MDM: n=3). Horizontal 
lines: median. D. Concentrations of PCOLCE 2 in ascites from ovarian HGSC patients determined by ELISA (n=10).
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COL3A1 in Supplementary Figure S6. Similar results 
were obtained for markers of mesenchymal stem cells 
(MSCs) and mesothelial cells (Supplementary Figure 
S5 and Supplementary Figure S7), known to be present 
ovarian cancer ascites in ascites [54]. We therefore 
conclude that potential contaminations of TAM samples 
do are unlikely to make a significant contribution to the 
observed TAM-specific signature.
Importantly, proteins encoded by upregulated 
genes are also found in the ascites fluid from ovarian 
cancer patients, supporting potentially relevant 
functions. This is exemplified in Figure 5C for PCOLCE 
2 (upregulated in TAMs ~20-fold). Furthermore, 
previous proteomic profiling of ovarian cancer ascites 
identified several proteins relevant in this context, 
including multiple collagens and lumican [55]. In 
addition, collagen type I, III and IV fragments have been 
found at elevated levels in serum samples from ovarian 
cancer patients [56].
Taken together, these observations suggest that 
the upregulation of ECM remodeling genes is a hallmark 
of ovarian cancer TAMs. The coordinate regulation of 
the genes within this cluster is presumably caused by a 
tumor-triggered signaling pathway rather than merely a 
consequence of a genomic co-localization. The 5 COL genes 
of the ECM cluster, for instance, are localized on 4 different 
human chromosomes (2, 7, 9 and 17), LUM on chromosome 
12 and PCOLCE2 on chromosome 3 (Ensembl).
DISCUSSION
Activation state and immune functions of TAMs
Our flow cytometry and transcriptome data 
clearly show that markers are expressed in ovarian 
cancer TAMs in a way inconsistent with a directional 
inflammation-related polarization. On the other hand, 
these analyses revealed a surprisingly high similarity of 
TAMs and pMPHs, including their activation state and the 
expression of molecules with essential roles in immune 
functions. Thus, tissue resident macrophages, like TAMs, 
are characterized by a high expression of the alternative 
activation markers CD163 and CD206 [33]. and both 
TAMs and pMPHs express genes with essential functions 
in phagocytosis or antigen presentation at similarly high 
levels (Figures 1A–1C, Figure 3A).
Consistent with the high expression of scavenger 
receptors and other molecules involved in phagocytosis 
(Figure 3A), TAMs efficiently phagocytosed bacteria 
within their pathophysiological environment, i.e., ovarian 
cancer ascites (Figure 4A, 4B). TAMs share this function 
with pMPHs, known as major players in the clearance 
of pathogens and damaged cells [33]. Furthermore, 
in agreement with the strong expression of multiple 
HLA genes (Figure 3A), TAMs were able to trigger an 
antigen-specific cytotoxic T cell response (Figure 4C), 
which is also known as a function of pMPHs [42–45].
Previous work has shown that peritoneal 
macrophages in the mouse consist of two functionally 
and developmentally distinct subsets, with cells of fetal 
origin representing the vast majority [30]. In the mouse, 
these resident cells differ from infiltrating monocyte-
derived macrophages by the specific expression of 
several markers, including ADGRE1 (F4/80), GATA6 and 
TIMD4 [26–29, 31, 34–36]. Our data show that human 
pMPHs also express much higher levels of these marker 
genes than MDMs (Figure 1D, 1E), suggesting that these 
markers may also be applicable to human cells. TAMs 
and pMPHs showed very similar expression patterns of 
these markers, consistent with the hypothesis that pMPHs 
are a major origin of TAMs. However, it cannot be ruled 
out that infiltrating monocytes are converted to TAMs 
resembling pMPHs by tumor-borne mediators.
Previous work has identified TAMs as the major 
source of a number of pro-tumorigenic or immune 
suppressive protein mediators within the ovarian cancer 
microenvironment [38], The data presented here show that 
the corresponding genes are expressed at similar levels 
in TAMs and pMPHs, while their expression is lower in 
MDMs in most cases (Figure 2D). It is therefore likely 
that some pro-tumorigenic effects mediated by TAMs 
reflect functions of pMPHs rather than tumor-induced 
alterations.
Our data also confirm the previously described 
refractoriness of TAMs to inflammatory stimuli [7, 20–
23, 47], exemplified by the unresponsiveness of the IL12B 
gene to LPS and INFγ in ovarian cancer TAMs (Figure 
4D, 4E). Since pMPHs are principally inducible by pro-
inflammatory stimuli (Figure 4D, E) and the induction of 
proinflammatory genes in MDMs is repressed by ascites 
(as shown for IL12B in Supplementary Figure S8), it is 
likely that the observed lack of TAMs to LPS and INFγ 
is caused by the tumor microenvironment. This suggests 
that ovarian cancer ascites affects macrophage functions 
to varying degrees, with phagocytosis and antigen 
presentation remaining intact and inflammatory responses 
being suppressed. The molecular mechanisms underlying 
this repression remain obscure, as the comparative RNA-
Seq data did not provide insights into the transcriptional 
signaling pathways affected.
Upregulation of ECM remodeling genes in TAMs
Our study identified an ECM gene cluster as a 
specific feature of ovarian cancer TAMs (Figures 5 
and Figure 6), suggesting that TAMs figure in collagen 
deposition, fibrillogenesis and ECM remodeling. In this 
context it is noteworthy that fibrillar collagen has been 
shown to enhance the invasive properties of tumor cells 
by accelerating their movement along these fibers and 
macrophages clearly enhance cancer cell invasion [6, 24]. 
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Macrophages are also indispensable for mouse mammary 
gland development owing to their critical function in 
promoting collagen fibrillogenesis [57].
A number of published observations have linked 
the products of several of the ECM cluster genes to 
macrophage-mediated matrix remodeling and cancer cell 
invasion [24]. Apart from the collagens, other proteins 
encoded by the ECM cluster with instrumental functions 
in matrix deposition and remodeling include (i) lumican 
(LUM), which regulates collagen fibril organization 
and growth [58, 59], (ii) lysyl oxidase (LOX) with 
crucial functions in the cross-linking of ECM proteins 
[60] and (iii) procollagen C-endopeptidase enhancer 2 
(PCOLCE2), which promotes the enzymatic cleavage of 
type I procollagen to yield mature structured fibrils [61, 
62]. Importantly, PCOLCE2 protein was detectable at 
appreciable levels in the ascites of ovarian cancer patients 
(Figure 6D).
Clinical relevance of ECM remodelling
On the basis of our observations it is tempting to 
speculate that TAMs support tumor cell adherence and 
invasion by secreting ECM remodeling proteins. Such a 
scenario is indeed strongly supported by a mouse model 
of transcoelomic ovarian cancer dissemination, which 
showed a clear dependence of peritoneal colonization 
on macrophage-mediated effects on the ECM through 
metalloproteinase 9 [63]. Furthermore, other researchers 
showed that macrophage depletion in mice resulted in 
decreased ascites formation and peritoneal colonization 
[64–66].
Tumor cell spheroids from ovarian cancer 
ascites can adhere to, disintegrate and spread on ECM 
components [67, 68], suggesting that the macrophage-
triggered reorganization of collagen deposition may 
promote ovarian cancer cell invasion. This result is 
consistent with previous observations associating ECM 
remodeling genes with a poor clinical course of ovarian 
cancer [51, 69–73]. For example, Cheon et al [69]. 
described a relapse-associated signature that consists of 
genes coding for collagen/ECM remodeling proteins. 
Intriguingly, this signature is regulated by TGFβ1 
signaling as predicted for the ECM cluster identified in 
the present work (Figure 4D).
Busuttil and colleagues [71] identified a “stromal-
response” signature in ovarian cancer that is associated 
with poor survival and enriched for genes encoding 
inflammatory and extracellular matrix proteins expressed 
by the tumor-associated stroma. Furthermore, the 
mesenchymal subtype of ovarian HGSC, characterized by 
the upregulation of ECM remodeling genes, has the worst 
clinical outcome of all subtypes [72, 73]. Our observations 
extend these findings by providing compelling evidence that 
genes associated with ECM restructuring are coordinately 
upregulated in ovarian cancer TAMs. This may explain, 
at least in part, the critical role of macrophages in ovarian 
cancer progression [4, 74].
MATERIALS AND METHODS
Patient samples
Clinical samples (Supplementary Table S5) were 
obtained from untreated patients undergoing surgery 
for ovarian carcinoma (mostly HGSC) or hysterectomy 
for non-malignant diseases lacking peritoneal effusions. 
Informed consent was obtained from all patients according 
to the protocols approved by the local ethics committee. 
All experiments were conducted in agreement with the 
Helsinki declaration.
Isolation and culture of primary immune cells
Macrophages were isolated from ascites (TAMs) 
or peritoneal lavage fluids (pMPHs) by density gradient 
centrifugation (Lymphocyte Separation Medium 1077; 
PromoCell) and subsequent enrichment on magnetic 
CD14 microbeads (Miltenyi Biotech). Tumor cells and 
CD3+ T cells were isolated as described [38]. MDMs were 
generated from monocytes (6-day differentiation for RNA 
experiments, 10-day cultures for flow cytometry) from 
healthy donors as described [75] and in RPMI with human 
AB serum.
Flow cytometry analysis of macrophages
TAMs from malignant ascites or pMPHs from 
peritoneal lavage fluid were stained with FITC-labeled 
anti-CD14 (Miltenyi Biotech), APC-labeled anti-CD206 
(BioLegend), APC-labeled anti-HLA-DR or APC-labeled 
anti-CD206 (Biozol), PE-labeled anti-CD163, PE-labeled 
anti-CD64, PE-Cy7-labeled anti-CD16 and APC-labeled 
anti-CD32 (eBioscience) as described previously [4]. 
Intracellular staining was performed with PE-labeled 
anti-IL-10 (BD Biosciences) after permeabilization for 
20 min at 4 C using BD Cytofix Cytoperm Plus Fixation 
Permeabilization Kit (BD Biosciences). Additionally, 
APC-labeled anti-CD52 or APC-labeled anti-TIMD4 
(Biolegend) was used for surface staining of TAMs and 
MDMs from healthy donors. Isotype control antibodies 
were from BD Biosciences, Miltenyi Biotech and 
eBioscience. Cells were analyzed by flow cytometry and 
results were calculated as percentage of positive cells and 
mean fluorescence intensities (MFI).
ELISA of ascites
Concentrations of PCOLCE 2 in ascites from 
ovarian cancer patients were determined using an ELISA 
Kit from Biozol according to the instructions of the 
manufacturer.
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T cell activation
Antigen-specific T cell activation by macrophages 
was determined essentially as described [75]. In brief, 
MDMs or TAMs were loaded with 1μg/ml CEFT peptide 
pool (jpt Peptide Technologies, Berlin, Germany) as 
recall antigens and incubated with a 5-fold excess of 
lymphocytes for 18 h in the presence of Brefeldin A 
(Sigma Aldrich, Steinheim, Germany). Lymphocytes 
were harvested and stained with anti-CD8-APC 
(Miltenyi Biotec, Bergisch Gladbach, Germany) and 
after permeabilization with anti-IFNγ-FITC (eBioscience, 
Frankfurt, Germany). Flow cytometry (FACS Canto, BD 
Bioscience, Heidelberg, Germany) data were expressed as 
IFNγ+/CD8+ cells after subtracting background staining 
of non-stimulated controls.
Analysis of phagocytosis
Phagocytotic capacity was determined by incubating 
macrophages with pHrodo® Red E. coli BioParticles 
conjugate (Thermo Fisher) for 15 min in R10AB medium 
and subsequent quantification by flow cytometry.
RT-qPCR
Isolation of total RNA and RT-qPCR were carried 
out as described [76], using the following primers:
RPL27_fw: 5′ AAAGCTGTCATCGTGAAGAAC
RPL27_rv: 5′ GCTGTCACTTTGCGGGGGTAG
IL12B_fw: 5′ GCGAGGTTCTAAGCCATTCG
IL12B_rev: 5′ ACTCCTTGTTGTCCCCTCTG
 COL1A2_fw: 5′ AGCTCCAAGGACAAGAAAC 
ACGTCTGG
 COL1A2_rev: 5′ AGGCGCATGAAGGCAAG 
TTGGGTAG
COL3A1_fw: 5′ CTGGACCCCAGGGTCTTC
COL3A1_rev: 5′ CATCTGATCCAGGGTTTCCA
LOX_fw: 5′ TGGCACAGTTGTCATCAACA
 LOX_rev: 5′ TCTTCAAGACAGAAACTT 
GCTTT
LUM_fw: 5′ TGGAGGTCAATCAACTTGAGAA
LUM_rev: 5′ CCAAACGCAAATGCTTGAT.
RNA Sequencing (RNA-Seq)
RNA-Seq was performed as described [75]. 
Sequencing data were deposited at EBI ArrayExpress 
(E-MTAB-3167, E-MTAB-3398, E-MTAB-4162, 
E-MTAB-4764). Genome assembly and gene model 
data were retrieved from Ensembl release 81, hg38. 
RNA-Seq data were aligned using STAR (version 
STAR_2.3.1z13_r470) [77]. Gene read counts were 
established and TPM (transcripts per million) values were 
calculated as published [75]. Adjustment of RNA-Seq 
data for contaminating tumor and T cells was performed 
as describe [38]. Batch effects were removed using 
Bioconductor tool ComBat [78, 79] after filtering all genes 
with a variance <1.
Identification of regulated genes
RNA-Seq data (Supplementary Dataset S1) were 
filtered for genes with minimum TPM values of 3 and 
median TPM ratios TAM/TAT >0.1 and TAM/tumor 
cells >0.1. For the delineation of genes selectively up- or 
down-regulated in TAMs we applied the Bioconductor 
package edgeR [48, 49] and identified a group of 21 
genes expressed at significantly different levels in TAMs 
versus pMPHs (FDR = 0.2; Supplementary Table S1). 
We then used this gene set to identify additional genes 
showing highly correlated expression patterns across all 
TAM samples (r >0.9) and no overlaps of TAM and pMPH 
samples using the upper and lower quartiles, respectively, 
as thresholds. Upregulated genes were defined by 2-fold 
higher median TPM values in TAMs versus pMPH, or 
vice versa for down-regulated genes. This resulted in the 
definition of extended datasets of 30 genes upregulated and 
4 genes downregulated in TAMs (Supplementary Dataset 
S2 and Supplementary Dataset S3). Similar analyses 
performed for with TAMs and MDMs (Supplementary 
Table S2) lead to extended datasets of 497 upregulated 
genes.
Statistical and bioinformatic analyses
Flow cytometry, ELISA and RT-qPCR data were 
statistically analyzed by Student’s t-test (two-sided, 
equal variance). Results are shown as follows: *p<0.05; 
**p<0.01; ***p<0.001; ****p<0.0001. Quantiles, 
confidence intervals and correlation coefficients were 
calculated using the Python functions pandas.DataFrame.
boxplot () and scipy.stats.pearsonr (), respectively. 
Hierarchical cluster analysis was performed using the scipy.
cluster.hierarchy functions linkage (method=“weighted”, 
metric=“correlation”) and dendrogram (). Gene sets were 
analyzed for Upstream Regulators using the Ingenuity 
Pathway Analysis (IPA) database (Qiagen Redwood City, 
CA, USA) as described [75]. Functional annotations were 
performed by gene ontology (GO) enrichment analysis 
(http://geneontology.org).
Abbreviations
CI, confidence interval; ELISA, enzyme-linked 
immunosorbent assay; HGSC, high-grade serous 
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